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The Al-triamine complex catalyzed acyl halide-aldehyde cyclocondensation (AAC) 
reactions, developed previously by the Nelson group, have been extended to asymmetric 
AAC reactions of alkyl-substituted ketenes with structurally diverse aldehydes. By using 
of 2nd generation Al-triamine complex as catalyst, benzotrifluoride as solvent, the 
disubstituted β-lactones were synthesized in high yields and excellent enantioselectivities 
from readily available starting materials. 
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Another conceptionally different methodology has also been developed to 
synthesize enantioenriched β-lactones. The concept of double activation has been applied 
in this reaction technology to accelerate the β-lactones formation. By using of cinchona 
alkaloids to activate ketenes, and at the same time utilizing of lithium salts to activate 
aldehydes, Wynberg’s [2+2] cycloaddition protocol has been greatly expanded to a 
variety of aldehydes.  
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Stereoenriched β-lactones derived from either Al-triamine or cinchona alkaloids 
catalyzed asymmetric acyl halide-aldehyde cyclocondensation (AAC) have been untilized 
in natural product synthesis. An asymmetric total synthesis of the antitumor agent 
pironetin was pursued using β-lactone templates for establishing all the requisite 
stereochemical relationships. 
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1.0  INTRODUCTION 
1.1 β-LACTONES 
Enantioenriched β-lactones (2-oxetanones) are important targets for asymmetric catalysis.1-3 β-
Lactones can be viewed as ‘activated aldol products’ since they have an identical β-hydroxy 
carbonyl relation as that found in aldol products, while also having increased reactivity due to 
ring strain (Figure 1).4 
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Figure 1. Comparison of β-lactones with aldol products 
 
β-Lactones undergo reactions with nucleophiles involving either C1-O4 or C3-O4 bond cleavage. 
As a result, they are direct progenitors of many useful synthetic building blocks, such as 
enantioenriched β-amino acids,5 allenes6 and β,β-disubstituted carboxylic acids.7 
Due to the important synthetic value of β-lactones, chemists have attempted to develop 
general methods to synthesize enantioenriched β-lactones efficiently and selectively.3,8 There are 
several good reviews describing this area.1-3 In this introduction, I will focus on the catalytic 
asymmetric synthesis of β-lactones and some closely related methodologies. 
 1 
1.2 LEWIS BASE-CATALYZED β-LACTONE FORMATION 
In 1982, Wynberg reported a remarkable example of asymmetric quinidine-catalyzed ketene-
chloral cycloaddition, affording the β-lactone in 98% ee.9 Substoichiometric amounts of a chiral 
Lewis base, quinidine 1, were used as a nucleophile to attack pregenerated ketene (in toluene 
solution) to form a chiral acyl ammonium enolate 2 (Figure 2).  
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R3N
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2  
Figure 2. Wynberg [2+2] cycloaddition 
 
The enolate 2 was subsequently trapped by highly electrophilic aldehydes or ketones to form β-
lactones in good yield and high enantioselectivity (eq 1). The success of Wynberg’s system was 
limited to the use of highly reactive non-enolizable carbonyl electrophiles.10   
R CCl3
O O
O
R
CCl3
+
2 mol% 1
R = H, 98% ee
R = pC6H4Cl, 90% ee
(1)
O
HH
 
In 1996, Calter reported a catalytic, asymmetric dimerization of methyl ketene catalyzed 
by cinchona alkaloids.11 In the presence of 1 mol% quinidine 1, pregenerated methyl ketene 
dimerized to give β-methylene β-lactone, which was directly reduced to the corresponding 
alcohol due to its volatility and instability (eq 2).  Either enantiomer of the product can be 
 2 
produced in high enantioselectivity by judicious choice of the readily available catalysts (quinine 
or quinidine).  
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More recently, the Calter group has dramatically expanded the ketene dimerization 
reaction scope by utilizing in situ generated ketenes from acid chlorides and N,N-
diisopropylethylamine. Under these new reaction conditions, the dimerization tolerates a variety 
of highly functionalized substituted ketenes not available from pyrolytic methods of ketene 
generation used previously.12 Due to the instability, the ketene dimers were converted into the 
corresponding β-ketoamides without isolation (eq 3). 
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Based on Calter’s cinchona alkaloid catalyzed ketene dimerization, very recently Romo 
reported the asymmetric synthesis of β-lactones via a sequential ketene dimerization/ 
 3 
hydrogenation process.13 A variety of β-lactones were formed in good yield and high 
enantioselectivity (eq 4). 
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In 2001, Romo and co-workers reported an intramolecular nucleophile-catalyzed aldol-
lactonization process that leads to a variety of β-lactone-fused bicyclic systems in moderate 
yields and very good enantioselectivities (eq 5).14,15  They were able to generate ketene in situ by 
treating various aldehyde acids with 2-chloro-1-methylpyridinium iodide and triethylamine. The 
intramolecular cycloaddition allowed for the employment of unactivated aldehydes.  
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In 2004, Fu reported asymmetric synthesis of highly substituted β-lactones by planar-
chiral PPY derivative 5 catalyzed [2+2] cycloadditions of disubstituted ketenes with aromatic 
 4 
aldehydes (eq 6).16 This is the first catalyst reported that is effective for enantioselective 
cycloadditions of disubstituted ketenes, which generate α,α-disubstituted β-lactones.   
O
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76-91% ee
48-92% yield
THFH R
3
O
+
O
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R2 R
3
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R1 = iPr,  R2 = Et
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Me
MeMe
N
N
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5
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In 2005, Calter reported asymmetric synthesis of trans β-lactones by cinchona alkaloids 
and Sc(OTf)3 catalyzed [2+2] cycloadditions of ketenes with aromatic aldehydes (eq 7).17 The 
sense of diastereoselectivity depends on the substitution of the acid chloride, with the reactions 
of aliphatic acid chlorides giving predominantly trans isomer and those of alkoxyacetyl chlorides 
favoring formation of cis isomer.  
 
15 mol% 3
99% ee
75-82% yield
H Ar
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R
O
R15 mol% Sc(OTf)3
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1.3 LEWIS ACID-CATALYZED β-LACTONE FORMATION 
In the aforementioned methods, chiral amines were employed as nucleophiles to activate ketenes 
by forming chiral acyl ammonium enolates; the resulting enolates subsequently cyclize with 
 5 
aldehydes to give β-lactones (Figure 3, right). There is a conceptionally different method to 
synthesize β-lactones. This reaction technology utilizes chiral Lewis acids to activate 
electrophiles, instead of employing chiral Lewis bases to activate ketenes (Figure 3, left). And 
the nucleophilic ketenes react with the Lewis acid-activated aldehydes, forming the β-lactones 
and regenerating the Lewis acid. 
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Figure 3. Comparison of Lewis acid and Lewis base-catalyzed β-lactone formation 
 
In 1994, Miyano documented the first asymmetric synthesis of β-lactones via [2+2] 
cycloaddition of ketene with aldehydes catalyzed by a stoichiometric amount of chiral 
aluminum-binaphthol complexes 6 (eq 8).18 While moderate yields and enantioselectivities were 
reported for these stoichiometric reactions, yields and enantioselectivities greatly decreased 
when a substoichiometric amount of the chiral Lewis acid was employed. It was suggested that 
the catalyst was deactivated via acylation of the BINOL ligand by ketene. Catalyst deactivation 
by acylation could be avoided by using chiral bis-sulfonamides as ligands. Subsequently, the 
Miyano group reported the first catalytic, asymmetric [2+2] cycloaddition catalyzed by 10 mol% 
 6 
Al(III)-bissulfonamide complexes 7 (eq 8).19 A variety of β-lactones were obtained in good 
yields and moderate enantioselectivities.     
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17-56% ee
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30-74% ee6 7
(8)
O
HH
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Because the generation of the ketene gas by pyrolysis of acetone is laborious, commercial 
trimethylsilyl ketene has been used in enantioselective ketene-aldehyde cycloaddition as an 
alternative to gaseous ketene. In 1996, Kocienski20 and Romo21 independently reported catalytic, 
enantioselective [2+2] cycloadditions of aldehydes with stable trimethylsilyl ketene using 
aluminium-based chiral Lewis acids (8 and 9) as catalysts (eq 9). Moderate to good yields and 
selectivities were obtained. 
 7 
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Me
Me
MeMe
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Romo also studied the [2+2] cycloaddition of trimethylsilyl ketene with various 
aldehydes by employing Seebach’s dichlorotitanium-TADDOL catalysts 10.22 After desilylation, 
the desired β-lactones were obtained in moderate to good yield and enantioselectivity (eq 10). 
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 8 
Evans utilized C2-symmetric copper(II)-bisoxazoline complex (11) as chiral catalyst for 
the [2+2] cycloaddition reaction of nucleophilic silyl ketenes and chelating carbonyl substrates, 
which afford the enantioenriched β-lactones in excellent yield and enantioselectivity (eq 11).23 
The observed enantioselectivity is proposed to be derived from a chelation of the chiral metal 
complex to the both carbonyl groups of electrophiles in a square-planar geometry around the 
copper ion. 
 
R
O
+
O
O
OR1
O
R
CO2R1
2+
1. 1 mol% 11, CH2Cl2
2. KF, CH3CN
R = H, Me, Et, iPr, iBu, BrCH2, Ph 11
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_
2 SbF6
O
TMSH N Cu
N
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Me Me
 
 
The Corey group very recently developed an enantioselective β-lactone formation from 
ketene and aldehydes catalyzed by the combination of a chiral oxazaborolidine and tributyltin 
triflate (eq 12).24 The β-lactones were formed in fair yields (60-78%) and moderately good 
enantioselectivity (65-81% ee). In the proposed mechanism, activation of precatalyst 12 by tri-n-
butyltin triflate produced the ion pair 13, which by reaction with ketene formed the ketene acetal 
intermediate 14, which coordinates with aldehyde generate transient species 15, upon ejecting 
the β-lactone, completes the catalytic cycle (Figure 4). 
+
O
O
 10 mol% 12
10 mol% Bu3SnOTf
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O
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Figure 4. Corey’s Sn-oxazaborolidine complex catalyzed β-lactone formation 
 
There are several catalytic enantioselective routes to β-lactones other than ketene-
aldehyde [2+2] cycloaddition. These methods include asymmetric hydrogenation of diketene (eq 
13)25 and lipase-catalyzed kinetic resolution of racemic β-lactones (eq 14).26 
 
O
O
O
O
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85% yield
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O
O
O
O
R
R OBn
OOH
+
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36-42% yield
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R
 
 
Recently, Coates developed a general method to synthesize β-lactones by carbonylation 
of epoxides catalyzed by cationic aluminium complexes (16);27 however, enantioenriched 
 10 
epoxides were used as starting materials to form enantioenriched lactones (eq 15). In the 
proposed mechanism, epoxides were activated by the coordination of the aluminium, backside 
attack by Co(CO)4− on the less hindered carbon giving the ring-opened aluminium oxide species, 
insertion of CO, β-lactone extrusion and recoordination of CO to cobalt complete the catalytic 
cycle (Figure 5). 
O
Me
CO
O
O
Me
2 mol% 16
+
95%
(15)
 
N N
O O
Al
+
(THF)2
O
O
O
R
Co(CO)xLn
O
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R
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CO
R
16
_
_
Co(CO)4
 
 
Figure 5. Coates’ carbonylation approach to β-lactones 
 
While several routes for the asymmetric synthesis of β-lactones have been developed, 
many of them suffer from either limited substrate compatibility or modest enantioselectivity and 
yields. Our goals were to develop general and convenient methods to make enantioenriched β-
lactones by merging in situ ketene generation with asymmetric Lewis base- or Lewis acid-
catalyzed [2+2] cycloaddition, and apply these methodologies to complex molecule synthesis. 
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2.0  AL(III)-TRIAMINE-CATALYZED AAC OF SUBSTITUTED KETENES 
2.1 INITIAL STUDIES ON AL(III)-TRIAMINE-CATALYZED AAC 
In 1999, the Nelson group reported the 1st generation asymmetric acyl halide aldehyde 
cyclocondensation (AAC) reactions (eq 14).28 Under the influence of Al-triamine catalysts 17, in 
situ generated ketene reacted with a variety of aldehydes to afford the β-lactones in good yields 
and high enantioselectivities. The 1st generation Al-triamine catalyst 17 proved to be generally 
useful for AAC reactions involving unsubstituted ketene. However, for substituted ketene AAC 
reactions, 17 was effective only for a very limited subset of activated aldehydes (such as 4-nitro 
benzaldehyde).29 For example, applying 17 to the cyclocondensation of methylketene and 
hydrocinnamaldehyde resulted in less than 10% conversion of starting aldehyde to desired β-
lactone (eq 15). Due to this limitation of 1st generation AAC reaction, the goal of this project was 
to develop a general solution to Lewis acid-catalyzed asymmetric AAC reactions of substituted 
ketenes with structurally diverse aldehydes. 
 
 
 12 
Br Me
O
H R
O
O
O
R
10 mol% 17
iPr2NEt
CH2Cl2, −50 °C
+
74-93% yield
85-95% ee
(14)
Br Et
O
H CH2CH2Ph
O
O
O
CH2CH2Ph
20 mol% 17
iPr2NEt
CH2Cl2, −50 °C
+
Me
< 10% conversion
(15)
N
iPr
Ph
N N
SO2CF3F3CO2S
1st generation catalyst
17
iPr
Al
Me
 
 
The Lewis acid-catalyzed AAC reactions are complex processes.30 There are various 
other reaction pathways competing with the β-lactones formation during the AAC reaction 
(Figure 6). 
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Figure 6. Competing reaction pathways in Lewis-acid-catalyzed AAC reactions 
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For AAC reactions with unsubstituted ketene, the desired [2+2] cyclocondensation is much faster 
than ketene trimerization, so the Al-triamine catalyst 17 works very well for unsubstituted ketene 
AAC. However, for AAC reactions with substituted ketene, the desired [2+2] cyclocondensation 
turns out to be much slower than ketene trimerization. Under Lewis acidic conditions, the 
aldehyde component may undergo the Tischenko or aldol reaction, affording the corresponding 
ester 18 or β-hydroxy aldehyde 19 as side products, respectively. Therefore, it was necessary to 
alter the reaction conditions and modify the AAC catalyst to retard the rate of unwanted 
pathways while facilitating the desired [2+2] cycloadditions.  
Ketene trimerization is accelerated by ammonium halide salts.31 The halide ion could add 
to the methyl ketene to form a halide enolate 20, which is sufficiently nucleophilic to add to 
another ketene molecule resulting in the formation of the ketene dimer, this dimer reacts with 
another ketene eventually forming the ketene trimer 21 (Figure 7).  
 
O
Br
Me
O
OHH
NR3
Me
Br
Me
O
R3NH
+
Me O
OCOEtMe
Me
21
O
Me
H
O
Me
H
_
20  
Figure 7. Halide ion-catalyzed ketene trimerization 
 
So removal of ammonium halide salts would slow unproductive methylketene trimerization. 
Hence, one of the essential criteria for choosing a solvent for the propionate-AAC reaction was 
based on how well the hydrohalide salt precipitated in that medium. An effective solvent for the 
AAC reactions with methyl ketene requires sufficient polarity to allow the ketene-aldehyde 
cycloaddition to proceed via a polar transition state.32 Based on these considerations, we 
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screened several solvents for methylketene-hydrocinnamaldehyde cycloaddition. The standard 
test reactions employed hydrocinnamaldehyde (1.0 mmol) as the electrophile, propionyl bromide 
(4.0 mmol) as the ketene source, diisopropylethylamine (2.0 mmol) as the base, in situ generated 
Al(III)-triamine complex 17 (0.2 mmol) from trimethylaluminium and triamine ligand as the 
catalyst, under a N2 atmosphere the reaction was stirred for 14 h at −25 °C.  The reaction was 
quenched at −25 °C by adding 10 mL of Et2O and the resulting mixture was filtered through 
silica gel eluting with 60 mL of Et2O.  The filtrate was concentrated in vacuo and the crude 
product mixture was used to determine the aldehyde conversion by 1H NMR (the relative 
integration ratio of the characteristic 1H NMR resonance of starting material aldehyde and 
product β-lactone was used to determine the percentage conversion of aldehyde to β-lactone).  
From these results (Table 1), we discovered that pseudo salt-free conditions could be achieved 
by using BTF (benzotrifluoride) as the reaction solvent.33 In BTF, iPr2NEt·HBr salt generated 
from iPr2NEt and acid bromide is insoluble and the reaction mixture is heterogeneous, AAC 
reaction conversion was improved considerably in the standard propionyl bromide-
hydrocinnamaldehyde reaction (from <10% to 47%) due to extended ketene lifetime (Table 1, 
entry a vs d).  In the relatively non-polar solvent toluene, the reaction is also heterogeneous; 
however, the AAC reaction conversion is very low (<5 %, entry b). 
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Table 1. Effect of solvent on the first generation AAC reaction 
H CH2CH2Ph
O
Br
O
20 mol% catalyst O
O
CH2CH2Ph
Me
Me
% conversiona
<10
iPr2NEt
+
% eeb
47
<5
48
catalyst solvent
N
iPr
Ph
N N
SO2CF3F3CO2S
(S, S)-Catalyst 17
17 CH2Cl2
17
17
BTF
toluene
NDc
entry
a
d
b
iPr
<517 CHCl3c ND
ND
a Conversion determined by 1H NMR of crude product mixture.
b Enantiomer ratio assayed by chiral HPLC (Chiralcel OD-H).
c Not determined.
Al
Me
(3R, 4S)
 
In order to further improve the conversion and obtain higher enantioselectivities for the 
propionyl bromide AAC, we decided to modify the ligand structures to discover more reactive 
and/or more selective catalysts (Figure 8). Since the ketene aldehyde cycloaddition is Lewis acid 
dependent, more electrophilic catalysts would make aldehydes more reactive by lowering the 
energy of the LUMO orbital of aldehyde after forming RCHO-Lewis acid complex.   
N
iPr
Ph
N N
SO2CF3F3CO2S
17
N
iPr
N N
SO2CF3F3CO2S
EWG
iPr iPr
22
δ-
δ+
Al Al
Me Me
 
Figure 8. Concept for more reactive catalyst design 
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Thus, introduction of an electron-withdrawing substituent to the 1st generation catalyst 17 would 
render the metal center more electrophilic, enabling an accelerated AAC reaction of methyl 
ketene. We speculated that inductive electron withdrawal from the central nitrogen would 
decrease electron density at aluminum, thereby enhancing Lewis acidity of the catalyst (17 vs 22). 
 
N
iPr
CF3
N N
SO2CF3F3CO2S
N
iPr
N N
SO2CF3F3CO2S
iPr iPr
F5
N
iPr
N N
SO2CF3F3CO2S
iPr CF3
CF3
1
2
3
Al
Al
AlMe
Me
Me
(S, S)-23 (S, S)-25(S, S)-24  
Figure 9. New catalysts with electron-withdrawing group on nitrogen 
 
Accordingly, some modified 1st generation catalysts (23, 24 and 25, Figure 9) were prepared by 
Cheng Zhu, in these catalysts fluorinated alkyl and aryl substituents were included at the central 
nitrogen of the catalyst. When evaluated in the AAC reactions, these modified catalysts exhibited 
improved substrate conversion in reactions involving unactivated aldehydes. For example, 
replacing benzyl group on the central nitrogen by trifluoroethyl group dramatically increased the 
reaction conversion (from 47% to 100%, Table 2, entry a vs b).  
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Table 2. Reactivity and selectivity for new catalysts 
H CH2CH2Ph
O
Br
O catalyst O
O
CH2CH2Ph
Me
Me
% conversiona
iPr2NEt
+
% eeb
47
100
48
56
catalyst solvent
17
23
BTF
BTF
entry
a
b
51 5824 BTFc
100 5425 BTFd
cat. loading
mol %
20
20
10c
20
a Conversion determined by 1H NMR of crude product mixture.
b Enantiomer ratio assayed by chiral HPLC (Chiralcel OD-H).
c Because of low solubility of 24 in BTF, 10 mol% of 24 used.
(3R, 4S)
 
 
The combination of BTF precipitation of ammonium bromide salts and enhancement of 
catalyst electrophilicity largely solved the unactivated aldehyde conversion problem in the 
methyl ketene AAC (Table 2, entry b and d). However, enantioselectivity of the substituted AAC 
reaction remained relatively low (56% ee, Table 2, entry b). Our investigation then focused on 
identifying modified triamine ligands that would provide the requisite levels of enantioselectivity 
at reaction temperatures above the freezing point of BTF (−29 oC). 
2.2 DEVELOPMENT OF A 2ND GENERATION CATALYST FOR AAC 
In order to design more enantioselective catalysts for substituted ketene AAC reactions, we 
studied the crystal structure of 1st generation catalyst (17). Crystallographic studies by Nelson 
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revealed that complex 17 adopts a four-coordinate, trigonal monopyramidal geometry with the 
methyl and triflamide ligands defining the equatorial plane of the bipyramidal structure.34 The 
crystal structure data suggested that the distorted trigonal monopyramidal coordination geometry 
defined in 17 by the tridentate ligand was responsible for the observed Lewis acidity by 
providing a vacant apical coordination site disposed ideally to accept a fifth ligand. As shown in 
Figure 10, aldehydes were activated by coordination to the apical vacant orbital, nucleophilic 
ketene then attacked the aldehyde selectively from one face over another, forming 
enantioenriched β-lactones. 
 
N Al
Me
N
N
R
Tf
Tf
R
OH
N Al
Me
N
N
R
Tf
R
OH
NuNu
blocked
 
 
Figure 10. First generation AAC catalyst structure (from X-ray 12) 
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Altering sterics or electronics of the trifluoromethanesulfonyl group in the 1st generation 
catalyst would be expected to have an impact on the geometry as well as the electrophilicity of 
the newly formed catalysts 23, 26-29 (Figure 11). Likewise, changing the isopropyl side chain to 
other alkyl groups would have some effect on the orientation of the sulfonyl group (23, 30-33, 
Figure 11), and therefore enable an effective facial bias of the aldehyde during the AAC reaction 
with substituted ketenes. Unfortunately, various Al(III) catalysts derived from C2-symmetric 
triamine ligands differing in sulfonamide structure and backbone alkyl groups provided little 
improvement in enantioselectivity compared to 1st generation catalyst 17.  
N
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N N
SO2YYO2S
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iPr
N
R
CF3
N N
SO2CF3F3CO2S
NO2
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F F
FF
F
CF3
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CF3 R = iPr
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29
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31
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Al Al
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Figure 11. Modification of 1st generation AAC catalyst 
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We noticed that one trifluoromethane sulfonyl group blocked one face of the aldehyde 
after we analyzed the crystal structure of complex 17, we speculated that a large sulfonyl group 
would further increase the facial bias (Figure 10).  Indeed, the catalyst derived from unsymmetric 
triamine provide an Al(III)-derived complex 34 exhibiting substantially improved 
enantioselectivity in the substituted ketene AAC (Table 3, entry a vs b).  
 
Table 3. Comparison of catalysts derived from unsymmetric and symmetric ligands 
Me
Br
O
H CH2CH2Ph
O O
Me CH2CH2Ph
O
N
Al
CF3
N
iPr
N
iPr
Me
SO2CF3YO2S
Catalyst (S, S)-23   Y = CF3
(S, S)-34   Y = pNO2C6H4
20 mol% catalyst
iPr2NEt, BTF
+
entry        catalyst         % conversiona        % eeb
a
b
23
34
100
100
56
80
a Conversion determined by 1H NMR of crude product mixture.
b Enantiomer ratio assayed by chiral HPLC (Chiralcel OD-H)
(3R, 4S)
 
Based on this result, we then turned our attention to unsymmetric ligands. We 
synthesized a series of unsymmetric triamine ligands 35-38 (Figure 12).     
                                                                                                                             
N
iPr
CF3
NH HN
SO2CF3ArO2S
N
CF3
NH HN
SO2CF3O2S
NO2
N
iPrEt
CF3
NH HN
SO2CF3O2S
NO2
Ar = pNO2C6H4  (S, S)-35
Ar = 3,5-(CF3)2C6H3  (S, S)-38 (S, S)-36 (S, S)-37
iPr
 
Figure 12. Unsymmetric triamine ligands 
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These unsymmetric ligands were easily prepared from different α-amino alcohols along a route 
very similar to that used in preparing the symmetric triamine ligands. For example, ligand 38 
was synthesized from (S)-valinol (Scheme 1). Valinol was treated with 1 equiv of 3,5-
bis(trifluoromethyl)benzenesulfonyl chloride and MsCl in the presence of 4 equiv of triethyl 
amine at 0 oC to form corresponding aziridine 39 in 69% yield. Ring-opening reactions of the 
aziridine employing 2,2,2-trifluoroethylamine resulted in the formation of the corresponding 
half-ligand 40. Without purification, the half-ligand 40 reacted with the N-triflic aziridine to 
form unsymmetrical ligand 38. After recrystallization, this ligand was used for in situ generation 
of the catalyst 41 with trimethylaluminium. Other unsymmetric ligands 35-37 were synthesized 
by similar method.    
Scheme 1. Synthesis of unsymmetric ligand 38 and catalyst 41 
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These Al(III)-triamine catalysts derived from unsymmetric ligands were screened for 
ethyl ketene-hydrocinnamaldehyde cycloaddition. A representative procedure consisted of 
following steps: a solution of triamine ligand 35-38 (0.10 mmol) in 2.0 mL of BTF at ambient 
temperature was slowly added 0.050 mL of a 2.0 M hexane solution of AlMe3 (0.10 mmol).  
After stirring for 2 hours, the resulting catalyst solution was cooled to −25 °C and 0.35 mL of 
N,N-diisopropylethylamine (2.0 mmol) and 4 equiv of butyryl bromide were added consecutively.  
The resulting heterogeneous mixture was stirred 15 min at −25 °C whereupon 
hydrocinnamaldehyde (1.0 mmol) was added dropwise and the reaction was stirred for 15 hours 
at −25 °C.  The reaction was workup at −25 °C by adding 10 mL of Et2O and the resulting 
mixture was filtered through silica gel eluting with 60 mL of Et2O.  The filtrate was concentrated 
in vacuo and the crude product mixture was purified by flash chromatography. From the results 
(Table 4), we discovered catalysts 42-44 derived from ligand 35-37 giving similar selectivity 
(80-85% ee, entry a-c). Catalyst 41 (2nd generation catalyst) derived from 38 gave the best 
enantioselectivity (91% ee, entry d).  
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Table 4. Evalution of unsymmetric ligands by the ethyl ketene-hydrocinnamaldehyde cyclocondensation 
H CH2CH2Ph
O
Br
O 20 mol% catalyst O
O
CH2CH2Ph
Et
EtBTF, −25 °C
% eeaentry
a
b
c
d
42 85
iPr2NEt
+
% yieldb
44
41
83
80
91
43
73
75
79
77
catalyst
N
iPr
CF3
N N
SO2CF3ArO2S
N
CF3
N N
SO2CF3O2S
NO2
N
iPrEt
CF3
N N
SO2CF3O2S
NO2
Ar = pNO2C6H4, (S, S)-42
Ar = 3,5-(CF3)2C6H3, (S, S)-41
(S, S)-43 (S, S)-44
Al
Me
Al
Me
Al
Me
iPr
a Enantiomeric ratios assayed by chiral HPLC. b Isolated yield for diastereomerically pure material.
(3R, 4S)
 
2.3 SECOND GENERATION AAC REACTIONS 
For the substituted ketene AAC reactions, the 2nd generation catalyst 41 in conjunction with 
pseudo-salt-free reaction conditions (BTF, –25 oC) afforded a variety of β-lactones in high 
diastereo and enantioselectivity.35 Methylketene seems uniquely disposed toward trimerization; 
as a result, slow-reacting aliphatic aldehydes require 20 mol% 41 to ensure ketene-aldehyde 
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cycloaddition (Table 5, entry a), unsaturated aldehydes provide sufficiently accelerated [2+2] 
reaction rates such that efficient AAC cross coupling is achieved with 10 mol% 41 (Table 5, 
entry c).  Similarly, ethylketene trimerization is sufficiently retarded relative to the AAC process 
that 10 mol% 41 affords efficient cross coupling for both enolizable aliphatic and unsaturated 
aldehydes (Table 5, entries d-g).  Propylketene and isopropylketene, derived from valeryl 
bromide and isovaleryl bromide, respectively, also participate in highly stereoselective AAC 
reactions under the 2nd generation reaction conditions, although isopropylketene reactions are 
currently limited to electron-deficient, non-enolizable aldehydes (Table 5, entries k-l).  
Asymmetric catalytic acid bromide-aldehyde cyclocondensation reactions afforded a 
convenient method for preparing highly enantiomerically enriched β-lactones (45a-l) as masked 
propionate aldol products. This methodology provides an effective strategy for executing 
enantioselective C-C bond constructions that constitute surrogates for typical cross ester aldol 
addition reactions. These catalyzed aldol variants are characterized by their operational 
simplicity and their use of inexpensive, commercially available reaction components. 
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Table 5. Catalytic asymmetric substituted ketene-aldehyde cyclocondensation* 
H R2
O
Br
O 10-20 mol%  41 O
O
R2
R1
R1
BTF, −25 °C
% ee a syn:antib, centry
b
c
d
e
f
g
Me 91 86:14
i
iPr2NEt
+
% yield d
j
k
l
Et
Et
Et
Et
Ph
Ph
96
91
93
91
94
98:2
95:5
89:11
88:12
98:2
Me
75
80
81
78
83
83
R1 R2
nPr
nPr
iPr
iPr Ph
91
96
94
96
91:9
98:2
98:2
98:2
88
85
71e
84
C CSiMe3
45
h nPr 80 95:5 91
a Me 90 95:5 71
catalyst loading
mol%
20
20
10
10
10
10
10
10
10
10
10
10
CH2CH2OBn
CH2CH2Ph
CH2OBn
CH2CH2OBn
CH2CH2OBn
Ph
CH2CH2Ph
CH2CH2Ph
 
    a Enantiomeric ratios assayed by chiral HPLC. b Diastereomeric ratios determined by 1H NMR of crude product 
mixtures. c Relative and absolute stereochemical assignments based on prior literature precedent; see reference 24. 
Absolute stereochemistry of compound 45 shown here. d Yields for diastereomerically pure materials except entries f 
and i (diastereomers were inseparable). e Yield for the amide derived from amine-mediated ring opening of the crude 
β-lactone. see experimental for details. * Investigation performed in collaboration with Dr. Cheng Zhu. 
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2.4 NUCLEAR MAGNETIC RESONANCE STUDIES OF 2ND GENERATION 
CATALYST 41 
Given the trigonal monopyramidal catalyst structure, unsymmetric ligands potentially generate 
two diastereomeric Al complexes (Figure 13).  
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Figure 13. Diastereomers from unsymmetric ligand 
 
To probe the diastereomeric ratio of 2nd generation catalyst, the Al-triamine complex 41 was 
examined by 1H NMR. The catalyst 41 was prepared by treating unsymmetric ligand 38 with 
AlMe3 in CH2Cl2 at ambient temperature. After stirring 2 h, the solvent was removed in vacuo 
and the crude product was washed with pentane once, and the Al-triamine complex 41 was 
obtained as a white solid (eq 16), this white solid was stored in the glovebox and was used for 1H 
NMR analysis (Figure 14). 
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Ar = 3,5-(CF3)2C6H3
N
CF3
N NAl
Me
SO2O2S
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N
CF3
N NAl
Me
SO2O2S
CF3 Ar
Me
Me
Me
Me
Me Me
Me Me
41 CD2Cl2
Peak A: one of the observed methyl group
              in the major diastereomer
Peak B: one of the observed methyl group
              in the minor diastereomer
The integrations of peak A and B by 1H NMR were used to determine diastereomer ratio.
23 °C
 
Figure 14. 1H NMR spectra analysis of diastereomers 
 
 
1H NMR spectrum of the catalyst 41 solution in CD2Cl2 was taken after 25, 75 and 900 
min at ambient temperature, giving about 2:1 (Figure 15), 2.5:1 (Figure 16) and 7:1 (Figure 17) 
diastereomeric complexes ratios respectively, and after 900 min, the diastereomeric ratio 
remained about 7:1. 
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 Figure 15. 1H NMR spectrum of 2nd generation catalyst 41 in CD2Cl2, 25 min (dr = 2:1)
 
 
 
 
Figure 16. 1H NMR spectrum of 2nd generation catalyst 41 in CD2Cl2, 75 min (dr = 2.5:1) 
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 Figure 17. 1H NMR spectrum of 2nd generation catalyst 41 in CD2Cl2, 900 min (dr = 7:1) 
 
 
 
In order to further understand the diastereomeric Al-triamine complex, we prepared 
diastereomerically pure 41 by recrystallizing 41 from CH2Cl2 and pentane. 1H NMR analysis of 
the recrystallized 2nd generation catalyst in CD2Cl2 at 5 min revealed a 30:1 bias favoring one 
diastereomer (Figure 18), however, after 2 h in the CD2Cl2, the ratio of  two diastereomers went 
down to about 10:1 (Figure 19), and after 24 h, the diastereomeric ratio went back to 7:1. These 
NMR analyses of 2nd generation catalyst revealed a 7:1 bias favoring one diastereomer in CD2Cl2 
(Figure 20). 
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 Figure 18. 1H NMR spectrum of crystallized 2nd generation catalyst in CD2Cl2 5 min (dr = 30:1) 
 
 
 
Figure 19. 1H NMR spectrum of crystallized 2nd generation catalyst in CD2Cl2 120 min (dr = 10:1) 
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Figure 20. Equilibrium between two diastereomers 
 
 
Later, crystallographic analysis of a closely related complex 46 by single crystal revealed 
that the major diastereomer to orient the large aryl sulfonamide group in the sterically less 
congested outside position relative to the [3.3.0] ring system defined by the Al-coordinated 
triamine ligand (Figure 21).* This indicated the major diastereomer was the active catalyst for 
AAC reactions.  
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Figure 21. X-ray crystal structure 46 
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2.5 EXPERIMENTALS 
 
General Information:  Optical rotations were measured on a Perkin-Elmer 241 digital 
polarimeter with a sodium lamp at ambient temperature and are reported as follows: [α]λ (c 
g/100mL).  Infrared spectra were recorded on a Nicolet Avatar 360 FT-IR spectrometer.  NMR 
spectra were recorded on a Bruker Avance-300 (300 MHz) spectrometer with chemical shifts 
reported relative to residual CHCl3 (7.27 ppm) for 1H and CDCl3 (77.0 ppm) for 13C NMR 
spectra.  Analytical high performance liquid chromatography (HPLC) was performed on a 
Hewlett Packard 1100 liquid chromatograph equipped with a variable wavelength UV detector 
(deuterium lamp, 190-600 nm) using a Daicel ChiracelTM OD-H column (250 x 4.6 mm) (Daicel 
Inc.) or Daicel ChiralpakTM AD column (250 x 4.6 mm) (Daicel Inc.) and HPLC-grade 
isopropanol and hexanes as the eluting solvents.  Analytical gas-liquid chromatography (GLC) 
was performed on a Varian 3900 gas chromatography equipped with a flame ionization detector 
and split mode capillary injection system using a Chiraldex™ G-TA column (20 m x 0.25 mm) 
(Advanced Separation Technologies Inc.).  Helium was used as the carrier gas at the indicated 
pressures.  
Unless otherwise stated, all reactions were carried out in dry glassware under a nitrogen 
atmosphere using standard inert atmosphere techniques for the manipulation of solvents and 
reagents.  Anhydrous solvents (CH2Cl2, THF, DMF, diethyl ether, pentane and toluene) were 
obtained by passage through successive alumina and Q5 reactant-packed columns on a solvent 
purification system.  N, N-Diisopropylethylamine and triethylamine were distilled under nitrogen 
from CaH2.  Trimethylaluminum (2.0M in hexane) and benzotrifluoride (BTF) were purchased 
from Aldrich in Sure/SealTM bottles.  [(cC8H14)2IrCl]2,36 3-Benzyloxypropionaldehyde37 and 
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trimethylsilanylpropynal38 were prepared according to published procedures. All commercially 
available aldehydes were redistilled under N2.  Anhydrous LiClO4 (ReagentPlus) and LiI were 
purchased from Aldrich. O-trimethylsilyl quinidine (TMS-QD) and O-trimethylsilyl quinine 
(TMS-QN) was prepared according to the literature procedure11(TMSCl was added at 0°C for 
large scale). Commercially available acetyl chloride, propionyl chloride, butyryl chloride and 
valeryl chloride were redistilled under N2. Commercially available propionyl bromide and 
valeryl bromide were distilled from P2O5.  Butyryl bromide and isovaleryl bromide were 
prepared according to literature procedures and were distilled from P2O5.39  Flash 
chromatography was performed as previously described on EM silica gel 60 (230-240 mesh).40 
 
(S)-2-Cyclohexyl-1-(4-nitrobenzenesulfonyl)aziridine (47):  To a 
solution of 1.00 g of (S)-2-amino-2-cyclohexylethanol (7.00 mmol, 1.00 eq) and 
43.0 mg of DMAP (0.35 mmol, 0.05 equiv) in 25 mL of CH2Cl2 at 0 °C was 
added 3.90 mL of Et3N (28.0 mmol, 4.00 equiv).  To the resulting solution was 
added 3.41 g of 4-nitrobenzenesulfonyl chloride (15.4 mmol, 2.20 equiv) in 
portions.  After addition was complete, the reaction mixture was warmed to ambient temperature 
and stirred for 5 h.  The reaction mixture was poured into brine (50 mL) and extrated with 50 mL 
CH2Cl2 twice. The organic portion was washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo.  The crude product was purified by flash chromatography (9% ethyl 
acetate in hexane) to afford 1.50 g (69%) of the title compound as slightly yellow solid.  [α]D 
+15.7 (c 1.66, CHCl3); IR (KBr Plate): 2925, 2851, 1532, 1349, 1312, 1169, 944, 887 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 8.40 (d, J = 8.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H), 2.74-2.70 (m, 2H), 
2.21 (d, J = 4.0 Hz, 1H), 1.74-1.64 (m, 4H), 1.54-1.50 (m, 1H), 1.20-1.10 (m, 4H), 1.05-0.93 (m, 
N
SO2
NO2
47
 34 
2H); 13C NMR (75 MHz, CDCl3) δ 150.5, 144.0, 129.3, 124.2, 45.9, 39.2, 33.4, 30.1, 29.5, 25.8, 
25.4, 25.2; HRMS (ESI) calcd for (M++Na) C14H18N2O4SNa : 333.0885; found: 333.0893. 
 
(S)-N-1-Cyclohexyl-2-(2’,2’,2’-trifluoroethylamino)ethyl-4-
nitrobenzenesulfonamide (48): A mixture of 1.41 g of (S)-2-
cyclohexyl-1-(4-nitrobenzenesulfonyl)aziridine 47 (4.55 mmol, 1.00 
equiv) and 1.10 mL of 2,2,2-trifluoroethylamine (13.7 mmol, 3.00 equiv) 
was placed in a sealed Pyrex® tube and the mixture stirred at ambient 
temperature for 1 h, then heated at 50 °C for 15 h and finally heated at 70 
°C for 4 h .  The reaction mixture was then cooled to ambient temperature and the remaining 2, 2, 
2-trifluoroethylamine was evaporated in vacuo.  The resulting crude product was used directly 
for next step. [α]D +8.90 (c 1.85, CHCl3); IR (KBr Plate): 3413, 3252, 2930, 2855, 1528, 1351, 
1336, 1310, 1263, 1155, 1110, 854, 737 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.37 (d,  J = 8.8 Hz, 
2H), 8.07 (d, J = 8.8 Hz, 2H), 5.05 (d, J = 8.2 Hz, 1H), 3.17-3.14 (m, 1H), 3.07 (q, J = 9.3 Hz, 
2H), 2.84 (dd, J = 12.6, 5.9 Hz, 1H), 2.60 (dd, J = 12.6, 4.2 Hz, 1H), 1.69-1.40 (m, 8H), 1.17-
1.04 (m, 2H), 0.93-0.75 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 149.8, 146.7, 128.2 (2C), 125.2 
(q, J = 278.2 Hz), 124.2 (2C), 59.0, 50.4 (q, J = 31.4 Hz), 49.8, 39.8, 29.0 (2C), 25.9 (3C); 
HRMS (ESI)  calcd for (M++H) C16H23F3N3O4S: 410.1361; found: 410.1380. 
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(1S,2’S)-N-(1-Cyclohexyl-2-[(2’-cyclohexyl-2’-trifluoro-
methanesulfonylaminoethyl)-(2,2,2-trifluoroethyl)amino]ethyl)-
4-nitrobenzenesulfonamide (49):(S)-N-[1-Cyclohexyl-2-(2,2,2-
trifluoroethyl-amino)ethyl]-4-nitrobenzenesulfonamide 48 1.75g 
NH
N
O2S
NO2
CF3
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(4.28 mmol, 1.00 equiv) was combined with 1.10 g of (S)-2-Cyclohexyl-1-
trifluoromethanesulfonyl-aziridine (4.28 mmol, 1.00 equiv)40 and the mixture stirred at ambient 
temperature for 10 min then heated at 80 °C for 16 h.  After cooling to ambient temperature, the 
crude product mixture was purified by flash chromatography (20% ethyl acetate in hexane) to 
afford 2.65 g (93%) of the title compound. [α]D −7.10 (c 2.11, CHCl3); IR (KBr Plate): 3309, 
2931, 2857, 1534, 1451, 1351, 1229, 1197, 1148, 1093, 737 cm-1; 1H NMR (300 MHz, CDCl3) δ 
8.38 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 6.20 (d, J = 8.9 Hz, 1H), 5.28 (d, J = 7.7 Hz, 
1H), 3.73-3.58 (m, 1H), 3.55-3.44 (m, 2H), 3.16-2.93 (m, 4H), 2.81 (dd, J = 14.0, 8.3 Hz, 1H), 
1.93-1.50 (m, 12H), 1.32-0.93 (m, 8H), 0.88-0.70 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 149.9, 
146.8, 128.0 (2C), 125.9 (q, J = 284.2 Hz), 124.3 (2C),  119.3 (q, J = 318.4 Hz), 58.8, 57.0, 55.4, 
55.3, 53.5 (q, J = 28.7 Hz), 39.6 (2C), 29.2(2C), 28.0, 27.9, 26.0 (6C); HRMS (ESI)  calcd for 
(M++Na) C25H36N4O6F6S2Na: 689.1878; found: 689.1853. 
 
(S)-N-[3,5-(Bistrifluoromethyl)benzenesulfonyl]-2-isopropylaziri- 
dine (50):  To a solution of 2.05 g of (S)-valinol (19.9 mmol, 1.00 eq)  and 
122 mg of DMAP (1.00 mmol, 0.05 equiv) in 40 mL of CH2Cl2 at –25 °C 
was added 11.0 mL of Et3N (80.0 mmol, 4.00 equiv).  To the resulting 
 6.84 g of 3, 5-bis(trifluoromethyl)benzenesulfonyl chloride (21.9 mmol, 1.10 
equiv) in portions.  After addition was complete, the reaction mixture was warmed to 0 °C and 
stirred for 2 h whereupon 1.85 mL of MsCl (23.9 mmol, 1.20 equiv) was added dropwise and the 
resulting reaction mixture was stirred an additional 2 h at 0 °C.  The reaction mixture was poured 
into saturated aqueous NaHCO
solution was added
3 (50 mL) and the layers were shaken and separated.  The organic 
portion was washed with brine (50 mL), dried over Na2SO4 and concentrated in vacuo.  The 
N
Me
Me
SO2
CF3F3C
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crude product mixture was purified by flash chromatography (9% ethyl acetate in hexanes) to 
afford 4.96 g (69%) of the title compound as a colorless oil.  [α]D +14.8 (c 2.24, CHCl3); IR (thin 
film):  2968, 1626, 1470, 1362, 1274, 1166 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.43 (s, 2H), 
8.15 (s, 1H), 3.03-2.71 (m, 2H), 2.25 (d, J = 4.2 Hz, 1H), 1.51 (m, 1H), 0.96 (d, J = 6.8 Hz, 3H), 
0.86 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 141.5, 133.0 (q, J = 34.4 Hz), 128.3, 
126.9 (m), 122.4 (q, J = 271.7 Hz), 47.3, 33.8, 30.1, 19.4, 18.9; HRMS (EI) calcd for (M+ + H) 
C13H14NO2F6S: 362.0649; found: 362.0640. 
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N-[(S)-N'-Trifluoromethylsulfonyl-2-amino-3-methylbutyl]-N-[(S)-N''-[3,5-
bis(trifluoromethyl)benzenesulfonyl]-2’-amino-3’-methylbutyl]-2,2,2-trifluoroethyl amine 
(38): A mixture of 4.96 g of (S)-[3,5-bis(trifluoromethyl)benzenesulfonyl]-2-iso-propylaziridine 
50 (13.7 mmol, 1.00 equiv) and 3.30 mL of 2,2,2-trifluoroethylamine (41.2 mmol, 3.00 equiv) 
was placed in a sealed Pyrex® tube and heated at 50 °C for 12 h.  The reaction was then cooled to 
ambient temperature and the remaining 2,2,2-trifluoroethylamine was evaporated in vacuo.  The 
resulting crude (S)-N-[3,5-bis(trifluoromethyl)benzenesulfonyl]-N'-(2',2',2'-trifluoroethyl)-2-
isopropylethylene diamine was combined with 3.43 g of (S)-N-trifluoromethylsulfonyl-2-
isopropylaziridine40 (15.8 mmol, 1.20 equiv) and the mixture stirred at ambient temperature for 1 
h then heated at 80 °C for 3 h.  After cooling to ambient temperature, the crude product mixture 
was purified by flash chromatography (25% to 33% ethyl acetate in hexane) to afford 9.00 g 
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(97%) of the title compound; crystallization of purified 38 from CH2Cl2/hexane afforded 7.68 g 
of 38 (83 %) as colorless needles: mp 99-100 °C.  [α]D –8.50 (c 2.02, CHCl3); IR (thin film): 
3302, 1361, 1281 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.32 (s, 2H), 8.08 (s, 1H), 6.08 (d, J = 8.9 
Hz, 1H), 5.35 (d, J = 7.4 Hz, 1H), 3.73-3.48 (m, 3H), 3.21-2.99 (m, 3H), 2.93 (dd, J = 14.3, 8.0 
Hz, 1H), 2.79 (dd, J = 14.0. 8.6 Hz, 1H), 2.07-1.87 (m, 2H), 1.05 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 
6.9 Hz, 3H), 0.81 (d, J = 6.9 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 144.0, 133.0 (q, J = 34.4 
Hz), 127.2 (m), 126.2 (m), 126.0 (q, J = 284.0 Hz), 122.5 (q, J = 271.7 Hz), 119.4 (q, J = 318.1 
Hz), 59.3, 57.6, 55.5, 55.2, 53.7 (q, J = 29.0 Hz), 29.9, 29.7, 18.43, 18.39, 17.6, 17.3; HRMS (EI) 
m/z calcd for (M++H) C21H28N3O4F12S2: 678.1330; found: 678.1339. 
 
(S,S)-N-(2-Methyl-1-([(3-methyl-2-
trifluoromethanesulfonylaminobutyl)-(2,2,2-
trifluoroethyl)amino]methyl)propyl)trifluoromethanesulfona
mide (51) :  To the (S)-N-triflic-2-isopropylaziridine 6.05g (50% purity, 13.9 mmol) was added 
0.69 g of 2,2,2-trifluoroethylamine (6.96 mmol, 0.50 eq) dropwise at ambient temperature, the 
mixture was stirred for 4.5 h at ambient temperature, then heated at 80 ºC for 4 h. After cooling 
to ambient temperature, flash chromatography of the mixture (10% ethyl acetate in hexanes) and 
recrystallization from CH2Cl2/hexane gave 2.99 g of the title compound (80%) as colorless solid:  
[α]D –9.50 (c 1.59, CHCl3); IR (KBr Plate): 3366, 3289, 2970, 1381, 1360, 1233, 1192, 1149 cm-
1; 1H NMR (300 MHz, CDCl3) δ 5.48 (d, J = 8.9 Hz, 2H), 3.56 (dq, J = 16.4, 9.3 Hz, 1H), 3.49-
3.40 (m, 2H), 3.21-3.09 (m, 1H), 3.05 (dd, J = 14.3, 4.9 Hz, 2H), 2.90 (dd, J = 14.3, 7.1 Hz, 2H), 
2.05-1.89 (m, 2H), 1.02 (d, J = 6.8 Hz, 6H), 0.96 (d, J = 6.9 Hz, 6H). 13C NMR (75 MHz, CDCl3) 
51
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δ 125.8 (q, J = 283.3 Hz ), 119.3 (q, J = 318.2 Hz), 59.4, 56.2, 53.8 (q, J = 29.2 Hz), 29.3, 18.6, 
17.0; HRMS (ESI) calcd for (M++Na) C14H24F9N3O4S2Na:  556.0962;  found:  556.0967. 
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(S,S)-N-(2-Methyl-1-([(3-methyl-2-trifluoromethanesulfonylaminobutyl)-(2,2,2-
trifluoroethyl)amino]methyl)propyl)-4-nitrobenzenesulfonamide (35): A mixture of (S)- 2-
isopropyl-1-(4-nitrobenzenesulfonyl)aziridine41 1.62 g (6.00 mmol) and 1.78 g of 2,2,2-
trifluoroethylamine (18.0 mmol, 3.00 eq) was placed in a sealed Pyrex® tube and heated at 50 °C 
for 12 h.  The reaction was then cooled to ambient temperature and the remaining 2,2,2-
trifluoroethylamine was evaporated in vacuo.  The resulting crude (S)- N-(2-methyl-1-[(2,2,2-
trifluoroethylamino)methyl]propyl)-4-nitrobenzenesulfonamide was combined with 4.23 g of 
(S)-N-triflic-2-isopropylaziridine (50% purity, approx. 9 mmol, 1.5 equiv) and the mixture stirred 
at ambient temperature for 1 h then heated at 80 °C for 3 h.  After cooling to ambient temperature, 
the crude product mixture was purified by flash chromatography (10% ethyl acetate in hexane) to 
afford 2.01 g (57%, two steps) of the title compound. [α]D –20.5 (c 1.85, CHCl3); IR (KBr Plate): 
3301, 3220, 2968, 1536, 1469, 1379, 1352, 1198, 1170, 1144, 1098 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 8.37 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 6.25 (d, J = 8.9 Hz, 1H), 5.31 (d, J = 
7.6 Hz, 1H), 3.75-3.59 (m, 1H), 3.55-3.46 (m, 2H), 3.21-2.92 (m, 4H), 2.80 (dd, J = 13.9, 8.5 Hz, 
1H), 1.99 (sextet, J = 6.8 Hz, 1H), 1.89-1.78 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.9 
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Hz, 3H), 0.77 (d, J = 6.9 Hz, 3H), 0.75 (d,  J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 149.9, 
146.8, 128.0, 126.0 (q, J = 288.4 Hz), 124.3, 119.3 (q, J = 318.2 Hz), 59.3, 57.4, 55.4, 55.0, 53.4 
(q, J = 28.9 Hz), 29.81, 29.78, 18.50, 18.48, 17.7, 17.4; HRMS (ESI) calcd for (M++Na) 
C19H28F6N4O6S2Na : 609.1252; found: 609.1238. 
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(S,S)-N-[1-Ethyl-6-methyl-3-(2,2,2-trifluoroethyl)-5-trifluoromethanesulfonylamino 
heptyl]-4-nitrobenzenesulfonamide (37): A mixture of (S)-2-Ethyl-1-(4-
nitrobenzenesulfonyl)aziridine41 200 mg (0.78 mmol) and 249 mg of 2,2,2-trifluoroethylamine 
(2.34 mmol, 3.00 eq) was placed in a sealed Pyrex® tube and stirred at ambient temperature for 2 
h, then heated at 50 °C for 17 h.  The reaction was then cooled to ambient temperature and the 
remaining 2,2,2-trifluoroethylamine was evaporated in vacuo.  The resulting crude (S)-4-nitro-N-
(1-[(2,2,2-trifluoroethylamino)methyl]propyl)-benzenesulfonamide was combined with 170 mg 
of (S)-N-triflic-2-isopropylaziridine (0.78 mmol, 1.0 equiv) and the mixture stirred at ambient 
temperature for 1 h and heated at 45 °C for 1 h, then heated at 80 °C for 15h.  After cooling to 
ambient temperature, the crude product mixture was purified by flash chromatography (10% 
ethyl acetate in hexane) to afford 410 mg (91%, two steps) of the title compound. [α]D –18.2 (c 
1.73, CHCl3); IR (KBr Plate): 3328, 2973, 1542, 1351, 1195, 1167, 1092 cm-1; 1H NMR (300 
MHz, CDCl3) δ 8.37 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 5.99 (d, J = 9.0 Hz, 1H), 5.39 
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(d, J = 6.8 Hz, 1H), 3.68-3.46 (m, 3H), 3.18-3.03 (m, 3H), 2.88 (d, J = 9.5 Hz, 1H), 2.81 (dd, J = 
14.5, 7.8 Hz, 1H), 2.01-1.93 (m, 1H), 1.55-1.45 (m, 2H), 1.03 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 
6.9 Hz, 3H), 0.74 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 149.9, 146.7, 128.1, 125.8 (q, 
J = 283.4 Hz), 124.3, 119.3 (q, J = 318.2 Hz), 59.0, 58.1, 55.6, 53.9, 53.8 (q, J = 29.4 Hz), 29.8, 
25.8, 18.4, 17.1, 9.6; HRMS (ESI) calcd for (M++H) C18H27F6N4O6S2  573.1276; found: 
573.1257. 
 
General procedure A: Al-triamine catalyzed asymmetric AAC reaction  
To a solution of triamine ligand (0.10 mmol) in 2.0 mL of BTF at ambient temperature 
was slowly added 0.050 mL of a 2.0 M hexane solution of AlMe3 (0.10 mmol).  After stirring for 
2 hours, the resulting catalyst solution was cooled to −25 °C and 0.35 mL of N, N-
diisopropylethylamine (2.0 mmol) and 2-4 equiv of acid bromide were added consecutively (see 
table below).  The resulting heterogeneous mixture was stirred 10-30 min at −25 °C (10 min: 
propionyl bromide; 15 min: butyryl bromide; 20 min: isovaleryl bromide; 30 min: valeryl 
bromide) whereupon aldehyde (1.0 mmol) was added dropwise and the reaction was stirred 14 h 
at −25 °C.  The reaction was quenched at −25 °C by adding 10 mL of a 3% Et3N-Et2O solution 
(v/v) and the resulting mixture was filtered through silica gel (pretreated with 3% Et3N-Et2O) 
eluting with 60 mL of Et2O.  The filtrate was concentrated in vacuo and the crude product 
mixture was purified by flash chromatography (for benzaldehyde-derived lactones, the silica gel 
was pretreated with 2% Et3N-hexanes). 
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Table 6. Acid bromide and catalyst stoichiometry used for enolizable and non-enolizable aldehydes 
 
Aldehyde       
Ketene 
Enolizable 
(catalyst, acid bromide) 
Non-enolizable 
(catalyst, acid bromide) 
Methyl ketene 20 mol %, 4 equiv 10 mol %, 2 equiv 
Ethyl ketene 10 mol %, 4 equiv 10 mol %, 2 equiv 
nPropyl ketene 10 mol %, 4 equiv 10 mol %, 2 equiv 
iPropyl ketene NA 10 mol %, 2 equiv 
 
 
 (3R, 4S)-3-Methyl-4-phenethyloxetan-2-one (45a): General 
procedure A was followed employing 136 mg of ligand 38 (0.20 mmol, 20 
mol%) and 132 µL of hydrocinnamaldehyde (1.0 mmol). Purification by 
flash chromatography (10% ethyl acetate in hexane) gave 135 mg (71%) of the title compound as 
colorless oil. Separation of enantiomers by Chiral HPLC [Daicel ChiracelTM OD-H column, flow 
rate 1.0 mL/min, 5% iPrOH, 95% hexane Tr: 13.7 min (3S, 4R), 14.5 min (3R, 4S)] provided the 
enantiomer ratio (3R, 4S): (3S, 4R) = 94.5:5.5 (89% ee).  [α]D –42.3 (c 1.89, CHCl3); IR (thin 
film):  1821, 1455 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.34-7.21 (m, 5H), 4.59 (ddd, J = 10.5, 
6.4, 4.1 Hz, 1H), 3.76 (qd, J = 7.8, 6.5 Hz, 1H), 2.90 (ddd, J = 13.8, 9.4, 5.3 Hz, 1H), 2.72 (ddd, 
J = 13.8, 8.8, 7.5 Hz, 1H), 2.13-1.97 (m, 2H), 1.29 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 172.4, 140.2, 128.4, 128.3, 126.1, 74.5, 47.0, 31.7, 31.3, 7.9; HRMS (EI) m/z calcd for 
(M+) C12H14O2: 190.0994; found: 190.0990. 
O
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 (3R, 4S)-4-(2-Benzyloxyethyl)-3-methyloxetan-2-one (45b): 
General procedure A was followed employing 136 mg of ligand 38 (0.20 
mmol, 20 mol%) and 164 mg (1.0 mmol) of  3-benzyloxypropionaldehyde.  
Purification by flash chromatography (15% ethyl acetate in hexane) gave 165 mg (75%) of the 
title compound.  Separation of the enantiomers by chiral HPLC (Daicel Chiracel™ OD-H 
column, flow rate 1.0 mL/min, 10% iPrOH, 90% hexane, Tr 10.6 (4S, 3R) and 15.7 (4R, 3S) min) 
provided the enantiomer ratio: (4S, 3R):(4R, 3S) = 95.5:4.5 (91% ee).  [α]D –40.4 (c 1.88, CHCl3); 
IR (thin film): 2866, 1824, 1455, 1111 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.39-7.30 (m, 5H), 
4.81 (ddd, J = 8.4, 6.5, 5.1 Hz, 1H), 4.54 (s, 2H), 3.78 (qd, J = 7.7, 6.7 Hz, 1H), 3.67-3.62 (m, 
2H), 2.10-2.00 (m, 2H), 1.29 (d, J = 7.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.4, 137.8, 
128.3, 127.6, 127.5, 73.1, 72.7, 65.7, 47.2, 30.3, 8.1; HRMS (EI) m/z calcd for (M+-CO) 
C12H16O2: 192.1150; found: 192.1156. 
O
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 (3R, 4R)-3-Methyl-4-phenyloxetan-2-one (45c): General procedure A 
was followed employing 68 mg of ligand 38 (0.10 mmol, 10 mol%) and 102 µL 
(1.0 mmol) of benzaldehyde.  Purification by flash chromatography (10% ethyl acetate in hexane) 
gave 130 mg (80%) of the title compound.  Separation of the enantiomers by chiral HPLC 
(Daicel Chiracel™ OD-H column, flow rate 1.0 mL/min, 3% iPrOH, 97% hexane, Tr 9.8 (3R, 4R) 
and 10.8 (3S, 4S) min) provided the enantiomeric ratio: (3R, 4R):(3S, 4S) = 98:2 (96% ee).  [α]D 
+138 (c 1.44, CHCl3); IR (thin film): 2979, 1830, 1497, 1455, 1143, 1108 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.46-7.38 (m, 3H), 7.32-7.29 (m, 2H), 5.66 (d, J = 6.5 Hz, 1H), 4.06 (qd, J = 7.8, 
O
Me Ph
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6.5 Hz, 1H), 0.94 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.2, 134.6, 128.6, 128.5, 
125.7, 75.2, 50.1, 9.5; HRMS (EI)  m/z calcd for (M+) C10H10O2:  162.0681; found: 162.0677.  
 
 (3R, 4S)-3-Ethyl-4-phenethyloxetan-2-one (45d): General 
procedure A was followed employing 68 mg of ligand 38 (0.10 mmol, 10 
mol%) and 132 µL (1.0 mmol) of hydrocinnamaldehyde.  Purification by 
flash chromatography (9% ethyl acetate in hexane) gave 165 mg (81%) of the title compound.  
Separation of the enantiomers by chiral HPLC (Daicel Chirapak™ AD column, flow rate 0.7 
mL/min, 10% iPrOH, 90% hexane, Tr 8.4 (3S, 4R) and 9.1(3R, 4S) min) provided the enantiomer 
ratio: (3S, 4R):(3R, 4S)  = 4.5:95.5 (91% ee).  [α]D –48.8 (c 1.37, CHCl3); IR (thin film): 2969, 
1821, 1497, 1455, 1106 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.20 (m, 5H), 4.56 (ddd, J = 
10.1, 6.4, 3.6 Hz, 1H), 3.55 (ddd, J = 8.8, 7.7, 6.4 Hz, 1H), 2.91 (ddd, J = 14.0, 9.4, 5.1 Hz, 1H), 
2.71 (ddd, J = 14.1, 8.7, 7.7 Hz, 1H), 2.16-1.78 (m, 3H), 1.74-1.60 (m, 1H), 1.07 (t, J = 7.4 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 171.7, 140.4, 128.5, 128.4, 126.2, 74.4, 54.1, 31.9, 31.5, 17.3, 
12.0; HRMS (EI) m/z calcd for (M+) C13H16O2: 204.1150; found: 204.1158.  
O
Et CH2CH2Ph
O
45d
 
 (3R, 4R)-4-(Benzyloxymethyl)-3-ethyloxetan-2-one (45e): General 
procedure A was followed employing 68 mg of ligand 38 (0.10 mmol, 10 mol%) 
and 140 µL (1.0 mmol) of benzyloxyacetaldehyde.  Purification by flash 
chromatography (10% ethyl acetate in hexane) gave 172mg (78%) of the title compound.  
Separation of the enantiomers by chiral HPLC (Daicel Chiracel™ OD-H column, flow rate 1.0 
mL/min, 10% iPrOH, 90% hexane, Tr 11.2 (3R, 4R) and 22.8 (3S, 4S) min) provided the 
enantiomeric ratio: (3R, 4R):(3S, 4S) = 96.5:3.5 (93% ee).  [α]D –8.00 (c 2.01, CHCl3); IR (thin 
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film): 2970, 2878, 1828, 1455, 1372, 1112 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.40-7.29 (m, 
5H), 4.71 (q, J = 5.5 Hz, 1H), 4.60 (s, 2H), 3.78 (d, J = 5.5 Hz, 2H), 3.64 (dt, J = 8.8, 6.9 Hz, 
1H), 1.94-1.65 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.2, 137.3, 
128.4, 127.8, 127.6, 73.6, 72.9, 68.0, 54.2, 17.3, 12.1; HRMS (EI) m/z calcd for (M+) C13H16O3: 
220.1099; found: 220.1109.  
 
 (3R, 4S)-4-(2-Benzyloxyethyl)-3-ethyloxetan-2-one (45f): General 
procedure A was followed employing 68 mg of ligand 38 (0.10 mmol, 10 
mol%) and 164 mg (1.0 mmol) of 3-benzyloxypropionaldehyde.  Purification 
by flash chromatography (14% ethyl acetate in hexane) gave 194 mg (83%) of the title 
compound as an 88:12 syn:anti mixture.  Separation of the enantiomers by chiral HPLC (Daicel 
Chiracel™ OD-H column, flow rate 1.0 mL/min, 10% iPrOH, 90% hexane, Tr 8.5 (3R, 4S) and 
13.3 (3S, 4R) min) provided the enantiomeric ratio: (3R, 4S):(3S, 4R) = 95.5:4.5 (91% ee).  [α]D 
–41.7 (c 2.06, CHCl3); IR (thin film): 2969, 2877, 1824, 1496, 1455, 1116 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.39-7.29 (m, 5H), 4.80 (ddd, J = 9.8, 6.5, 4.0 Hz, 1H), 4.54 (s, 2H), 3.69-3.55 
(m, 3H), 2.14-1.95 (m, 2H), 1.87-1.77 (m, 1H), 1.73-1.63 (m, 1H), 1.07 (t, J = 7.4 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 171.7, 137.8, 128.2, 127.5, 127.4, 73.0, 72.4, 65.7, 54.0, 30.3, 17.3, 
11.8; HRMS (EI) calcd for (M++H) C14H19O3: 235.1334; found: 235.1329.  
O
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 (3R, 4R-)-3-Ethyl-4-phenyloxetan-2-one (45g): General procedure A was 
followed employing 68 mg of ligand 38 (0.10 mmol, 10 mol%) and 102 µL (1.0 
mmol) of benzaldehyde.  Purification by flash chromatography (9% ethyl acetate in 
hexane) gave 146 mg (83%) of the title compound.  Separation of the enantiomers by chiral 
O
Et Ph
O
45g
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HPLC (Daicel Chiracel™ OD-H column, flow rate 0.5 mL/min, 10% iPrOH, 90% hexane, Tr 
13.3 (3R, 4R) and 16.1 (3S, 4S) min) provided the enantiomeric ratio: (3R, 4R):(3S, 4S) = 97:3 
(94% ee).  [α]D +128 (c 2.08, CHCl3); IR (thin film): 2970, 2938, 1825, 1497, 1455, 1111 cm-1; 
1H NMR (300 MHz, CDCl3) δ 7.45-7.32 (m, 5H), 5.64 (d, J = 6.4 Hz, 1H), 3.85 (ddd, J = 8.3, 
8.3, 6.4 Hz, 1H), 1.57-1.41 (m, 1H), 1.35-1.21 (m, 1H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 171.6, 134.7, 128.6, 128.4, 125.8, 75.1, 56.8, 18.6, 11.1; HRMS (EI) m/z calcd 
for (M+) C11H12O2:  176.0837; found: 176.0837.  
 
 (3R, 4S)- 4-Phenethyl-3-propyloxetan-2-one (45h): General 
procedure A was followed employing 68 mg of ligand 38 (0.10 mmol, 10 
mol%) and 132 µL (1.0 mmol) of hydrocinnamaldehyde.  Purification by 
flash chromatography (8% ethyl acetate in hexane) gave 200 mg (91%) of the title compound.  
Separation of the enantiomers by chiral HPLC (Daicel Chirapak™ AD column, flow rate 1.0 
mL/min, 10% iPrOH, 90% hexane, Tr 5.4 (3S, 4R) and 5.9 (3R, 4S) min) provided the 
enantiomeric ratio: (3S, 4R):(3R, 4S)  = 10:90 (80% ee).  [α]D –37.1 (c 1.48, CHCl3); IR (thin 
film): 2960, 1817, 1497, 1455, 1107 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.20 (m, 5H), 
4.56 (ddd, J = 10.0, 6.4, 3.5 Hz, 1H), 3.63 (dt, J = 8.7, 6.7 Hz, 1H), 2.91 (ddd, J = 13.9, 9.4, 5.0 
Hz, 1H), 2.71 (ddd, J = 14.1, 8.7, 7.7 Hz, 1H), 2.10-1.99 (m, 2H), 1.80-1.70 (m, 1H), 1.62-1.41 
(m, 3H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.9, 140.3, 128.4, 128.3, 
126.1, 74.4, 52.1, 32.0, 31.4, 25.8, 20.6, 13.6; HRMS (EI) m/z calcd for (M+) C14H18O2: 
218.1307; found: 218.1306.  
O
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 (3R, 4S)-4-(2-Benzyloxyethyl)-3-propyloxetan-2-one (45i): 
General procedure A was followed employing 68 mg of ligand 38 (0.10 
d 164 mg (1.0 mmol) of  3-benzyloxypropionaldehyde.  Purification by flash 
chromatography (12% ethyl acetate in hexane) gave 218 mg (88%) of the title compound as a 
91:9 syn:anti mixture.  Separation of the enantiomers by chiral HPLC (Daicel Chiracel™ OD-H 
column, flow rate 1.0 mL/min, 10% 
mmol, 10 mol%) an
iPrOH, 90% hexane, Tr 8.0 (3R, 4S) and 12.4 (3S, 4R) min) 
provided the enantiomeric ratio: (3R, 4S):(3S, 4R) = 95.5:4.5 (91% ee).  [α]D –37.5 (c 1.78, 
CHCl3); IR (thin film): 2961, 2873, 1817, 1455, 1115 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.39-
7.29 (m, 5H), 4.80 (ddd, J = 9.5, 6.4, 4.0 Hz, 1H), 4.54 (s, 2H), 3.71-3.60 (m, 3H), 2.13-1.96 (m, 
2H), 1.84-1.33 (m, 4H), 0.95 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.7, 137.8, 
128.1, 127.4, 127.3, 72.9, 72.3, 65.6, 52.1, 30.4, 25.7, 20.4, 13.5; HRMS (EI) m/z calcd for (M+-
CO) C14H20O2: 220.1463; found: 220.1466. 
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 (3R, 4R)-4-Phenyl-3-propyloxetan-2-one (45j): General procedure A 
was followed employing 68 mg of ligand 38 (0.10 mmol, 10 mol%) and 102 µL 
(1.0 mmol) of benzaldehyde.  Purification by flash chromatography (8% ethyl 
acetate in hexane) gave 161 mg (85%) of the title compound.  Separation of the enantiomers by 
chiral HPLC (Daicel Chiracel™ OD-H column, flow rate 0.5 mL/min, 10% iPrOH, 90% hexane, 
Tr 11.8 (3R, 4R) and 13.8 (3S, 4S) min) provided the enantiomeric ratio: (3R, 4R): (3S, 4S) = 98:2 
(96% ee).  [α]D +116 (c 1.73, CHCl3); IR (thin film): 2961, 2874, 1825, 1455, 1114 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.45-7.31 (m, 5H), 5.63 (d, J = 6.5 Hz, 1H), 3.93 (ddd, J = 8.5, 8.5, 
6.5 Hz, 1H), 1.43-1.34 (m, 2H), 1.25-1.18 (m, 2H), 0.77 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
O
Ph
O
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CDCl3) δ 171.7, 134.7, 128.6, 128.4, 125.8, 75.1, 55.1, 27.0, 19.9, 13.5; HRMS (EI) m/z calcd 
for (M+) C12H14O2: 190.0994; found: 190.0998.  
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(2R, 3R)-3-Hydroxy-2-isopropyl-5-trimethylsilanylpent-4-ynoic acid, benzylamide 
(52) [from (3R, 4R)-3-isopropyl-4-trimethylsilanylethynyloxetan-2-one (45k)]: General 
procedure A was followed employing 68 mg of ligand 38 (0.10 mmol, 10 mol%) and 134 µL 
(1.0 mmol) of trimethylsilanylpropynal.  Due to the volatility of the β-lactone, the crude product 
mixture was dissolved in 1 mL of CH3CN and 109 µL of benzylamine (1.0 mmol) and DMAP 
(~1 mg) were added at ambient temperature.  The resulting solution was stirred at ambient 
temperature for 15 h prior to evaoparting the volatiles in vacuo.  The crude product mixture was 
purified by flash chromatography (20% ethyl acetate in hexane) to afford 225mg of (2R, 3R)-3-
hydroxy-2-isopropyl-5-trimethylsilanylpent-4-ynoic acid, benzylamide (71%).  Separation of the 
enantiomers by chiral HPLC (Daicel Chiracel™ OD-H column, flow rate 1.0 mL/min, 5% iPrOH, 
95% hexane, Tr 7.4 (2S, 3S) and 8.9 (2R, 3R) min) provided the enantiomeric ratio: (2R, 3R):(2S, 
3S) = 97:3 (94% ee).  [α]D +50.4 (c 1.58, CHCl3); IR (thin film):  3379, 3312, 2960, 2932, 2171, 
1650, 1539, 1250, 1045, 845 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36-7.30 (m, 5H), 6.38 (br, 
1H), 4.73 (t, J = 4.9 Hz, 1H), 4.48 (d, J = 5.5 Hz, 2H), 3.19 (d, J = 4.6 Hz, 1H), 2.32 (dd, J = 8.5, 
5.4 Hz, 1H), 2.15 (m, 1H), 1.04 (t, J = 7.0 Hz, 6H), 0.10 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
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172.7, 138.0, 128.5, 127.7, 127.3, 104.4, 91.6, 62.3, 59.1, 43.4, 28.1, 21.1, 20.6, –0.5; HRMS (EI) 
m/z calcd for (M+) C18H27NO2Si: 317.1811; found: 317.1808.  
 
 (3R, 4R)-3-Isopropyl-4-phenyloxetan-2-one (45l): General procedure A 
was followed employing 68 mg of ligand 38 (0.10 mmol, 20 mol%) and 51µL 
(0.50 mmol) of benzaldehyde. Purification by flash chromatography (7% ethyl 
acetate in hexane) gave 80 mg (84%) of the title compound.  Separation of the enantiomers by 
chiral HPLC (Daicel Chiracel™ OD-H column, flow rate 0.5 mL/min, 10% iPrOH, 90% hexane, 
Tr 11.1 (3R, 4R) and 14.1 (3S, 4S) min) provided the enantiomeric ratio: (3R, 4R): (3S, 4S)  = 
98:2 (96% ee).  [α]D +89.2 (c 1.50, CH3Cl3); IR (thin film):  2960, 1809, 1454, 1368, 1120, 881 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.42-7.39 (m, 5H), 5.60 (d, J = 6.4 Hz, 1H), 3.60 (dd, J = 
11.4, 6.4 Hz, 1H), 1.82 (m, 1H), 1.07 (d, J = 6.6 Hz, 3H), 0.53 (d, J = 6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 171.1, 134.6, 128.9, 128.4, 126.7, 75.5, 62.5, 25.2, 20.2, 19.9; HRMS (EI) m/z 
calcd for (M+) C12H14O2: 190.0994; found: 190.0987.  
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3.0  CINCHONA ALKALOID-CATALYZED AAC 
3.1 DEVELOPMENT OF LEWIS-BASE CATALYZED AAC 
The 2nd generation Al-triamine complex works very well for alkyl-substituted ketenes and 
structurally diverse aldehydes AAC reactions, affording synthetically very useful building block 
disubstituted β-lactones in high yields and excellent enantioselectivities, however, this Al-
triamine catalyst system does not work for α-branched aldehydes and the Al-triamine catalyst is 
not very easily accessible. Considering the limitations of Al-triamine catalyzed AAC reactions 
and based on the Wynberg’s pioneering investigations on cinchona alkaloids-catalyzed ketene-
chloral cycloaddition (eq 17),9  
O
HH
H CCl3
O O
O
CCl3
+
2 mol% 1
98% ee
N
HN
OH
1
OMe
(17)
 
we attempted to develop asymmetric Lewis base-catalyzed acid chloride-aldehyde 
cyclocondensation (AAC) reactions applicable to a range of structurally diverse aldehydes. 
Extending the Wynberg ketene-aldehyde cycloadditions to structurally diverse aldehydes would 
afford access to more versatile enantioenriched β-lactones.  
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Alkaloids catalyze ketene-aldehyde addition via nucleophilic addition to ketene, 
generating the acyl ammonium enolate 53 responsible for mediating C-C bond construction 
(Figure 22). The specificity of Wynberg’s original cycloaddition for highly electrophilic 
aldehydes (e.g. chloral) suggested that chiral acyl ammonium enolates 53 possess relatively 
limited nucleophilicity. We conceived of two potential ways to solve the limitation of the 
Wynberg’s protocol: (1) increase nucleophilicity of the acyl ammonium enolate or (2) increase 
electrophilicity of the aldehyde. In our previous Al-triamine catalyzed AAC reactions, we 
utilized chiral Lewis acids to activate aldehydes. We speculated that addition of Lewis acid to 
Wynberg’s system would greatly increase the electrophilicity of the aldehydes by lowering the 
energy of the LUMO orbital of aldehyde after forming RCHO-Lewis acid complex. Furthermore, 
a possible closed transition state 54 would provide entropic activation to facilitate β-lactone 
formation.  
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Figure 22. Postulated mechanism for alkaloid-catalyzed AAC reaction 
 
 51 
3.2 PRELIMINARY EVALUATION OF REACTION CONDITIONS FOR 
ALKALOID-CATALYZED AAC 
Preliminary reaction development focused on identifying a cinchona alkaloid-Lewis acid 
combination that would allow in situ ketene generation to be integrated with the catalyzed 
ketene-aldehyde cycloadditions. However, there are three practical problems associated with 
Lewis acid/alkaloid-catalyzed AAC reactions (Figure 23): (1) enolization and aldol reaction of 
aliphatic aldehydes in the presence of Lewis acid and base; (2) Lewis base-catalyzed ketene 
dimerization;11 (3) strong Lewis acids and alkaloids forming irreversible complexes,42 these 
irreversible complexes cannot act as catalysts to complete the catalytic cycle, therefore we need 
to find suitable Lewis acid that can form reversible complexes with alkaloids. 
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Figure 23. Competing reaction pathways in Lewis-base-catalyzed AAC reactions 
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In 1990, Grieco reported that 5M solutions of lithium perchlorate in diethyl ether (LPDE) 
can accelerate the Diels-Alder reaction dramatically.43 It has also been found that the [2+2] 
cycloaddition involving nonactivated ketenes is facilitated by using 5M solution of LPDE.44 Due 
to the success of using lithium perchlorate as Lewis acid activating aldehydes in these previous 
examples, and we speculated relatively weak Lewis acid LiClO4 forming reversible complexes 
with cinchona alkaloids (Figure 24), LiClO4 and commercially available quinidine had been 
examined as a co-catalyst system for acetyl chloride and hydrocinnamaldehyde cycloaddition.  
NN
N
MM'
weak Lewis acidstrong Lewis acid
M'
M
 
Figure 24. Complexation of Lewis acids and cinchona alkaloids 
 
In situ ketene generation by combining N, N-diisopropylethylamine and acid halide was 
developed and applied successfully in the Lewis acid-catalyzed asymmetric ketene-aldehyde 
cycloaddition previously in our group.28 We required that this convenient method for generating 
different ketenes be applied for alkaloid-catalyzed AAC reactions. Since dichloromethane is a 
good polar solvent for ketene generation and lithium perchlorate is soluble in diethyl ether, we 
use diethyl ether and dichloromethane mixed solvent for these alkaloids-catalyzed AAC 
reactions. In our initial study of alkaloid-catalyzed AAC reactions, 5 mol% of quinidine and 15 
mol% of LiClO4 were used as co-catalyst for hydrocinnaldehyde, a representative unactivated 
aldehyde, and acid chloride cycloaddition. The reaction was run at −25 °C and the ketene was 
generated over 30 min by slow addition of acid chloride to the reaction mixture. After the work 
up, we were pleased to find the desired cyclocondensation product was formed in 56% 
conversion and 62% ee (Table 7, entry a). Background AAC reactions between the ketene and 
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hydrocinnamaldehyde did not occur without using quinidine or lithium perchlorate (Table 7, 
entries b and c). These observations suggested that LiClO4 and quinidine were good Lewis 
acid/Lewis base combination for AAC reactions. Applying 30 mol % LiClO4 and 10 mol % O-
trimethylsilyl quinine (TMS-QN) instead of in situ generated quinine propionate as catalyst to 
the cycloaddition of in situ generated methylketene with hydrocinnamaldehyde, gave the desired 
β-lactone in moderate conversion and excellent enantioselectivity (Table 7, entry d), this 
indicated that the trimethylsilyl protected quinidine gave much higher enantioselectivity than the 
quinidine propionate.   
 
Table 7. Initial observations for alkaloid-catalyzed AAC reactions 
H Ph
O
Cl
O
alkaloid iPr2NEt+
O
O
CH2CH2Ph
R
R
+ +
temp (°C)
+
CH2Cl2/Et2O
1.0 mmol 2.0 eq 2.5 eq
alkaloid (mol%) % conversionaentry
a
b
c
d
−25
−25
−78
15
0
30
0
0
60
LiClO4
−25 15 56
LiClO4(mol%)
H
H
H
Me
% eeb
quinidine (5)
quinidine (0)
quinidine (5)
TMS-QN (10)
62
99
R
-
-
a Conversion determined by 1H NMR of crude product mixture. b Enantiomer ratio assayed by chiral HPLC.  
 
After finding that LiClO4 is an efficient co-catalyst for cinchona alkaloids catalyzed acyl-
chloride aldehyde cyclocondensations, we screened various commercially available Lewis acids 
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in order to identify other effective Lewis acids. A standard test reaction consisted of: 
hydrocinnamaldehyde (1.0 mmol) as the electrophile, propionyl chloride (2.0 mmol) as the 
ketene source, N, N-diisopropylethylamine (2.5 mmol) as the base, dichloromethane and diethyl 
ether as the mixed solvent and TMS-QN (0.10 mmol) as the catalyst, under a N2 atmosphere at –
78 oC (eq 18). The reaction mixture was stirred for 15 h at –78 °C.  After work up, the crude 
product mixture was used to determine the aldehyde conversion by 1H NMR, the relative 
integration ratio of the characteristic 1H NMR resonance of starting aldehydes and resulting 
products was used to determine the reaction conversion and β-lactone ketene dimer ratio. The 
characteristic 1H NMR resonance of the starting aldehyde and the resulting products used for 
analysis were chosen as depicted in eq 18. 
 
H Ph
O
Cl
O
10 mol% TMS-QN
10-30 mol% Lewis acid
iPr2NEt, −78 °C
+
O
O
CH2CH2Ph
Me
Me
+
O
O
Me
Me
H
H
 δ 9.84 ppm
H H
 δ 3.76, 4.57 ppm  δ 3.97, 4.75 ppm
(18)
 
 
Unfortunately, various Lewis acids (Sc(OTf)3, Y(OTf)3, La(OTf)3, Sn(OTf)2, Zn(OTf)2, 
Mg(OTf)2, Mg(ClO4)2, MgBr2, SmCl3, AlCl3,  Me2AlCl, SiCl4, BF3·OEt) gave no desired 
product β-lctone in this standard test reaction. We speculated that these relatively strong Lewis 
acids either form irreversible complexes with the alkaloid or speed the decomposition of 
aldehydes by self-aldol reaction. Less Lewis acidic species MgCl2 in THF/CH2Cl2 (MgCl2 is 
much more soluble in THF than Et2O) gave promising results, however the diastereoselectivity 
of the reaction is only about 4-5: 1 (eq 19). 
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H R
O
Cl
O
TMS-QN
iPr2NEt, −40 °C+
O
O
R
Me
Me
10 mol%
+ +
CH2Cl2/THF
MgCl2
0.5 eq2 eq
100% conversion
 dr = 5.5 : 1
 97% ee
100% conversion
 dr = 4 : 1
 99% ee
(19)
R = Ph R = CH2CH2Ph
 
3.3 REACTION OPTIMIZATION 
To optimize these AAC reactions, we systematically investigated Lewis acid stoichiometry, 
solvent complexation and Lewis base reactivity. Given the results up to this point, lithium 
perchlorate appeared to be an effective Lewis acid for alkaloid-catalyzed AAC reaction. The 
stoichiometry of LiClO4 emerged as a crucial variable that could be conveniently modulated in 
order to maximize reaction efficiency depending on the aldehyde structure. For sterically 
hindered aldehydes (e.g. cyclohexanecarboxaldehyde) and aromatic aldehydes, 2 equiv of 
LiClO4 were required to activate the aldehydes, while for sterically less hindered aliphatic 
aldehydes (e.g. hydrocinnamaldehyde), 0.5 equiv of LiClO4 were required for activating 
aldehydes.  
We then investigated the solvent effect on cinchona alkaloid/LiClO4 system-catalyzed 
AAC reactions. Experimental data (Table 8) indicated that small amounts of Et2O were 
necessary to ensure solubility of the LiClO4 at low temperature given its insolubility in 
dichloromethane (entry a vs b-f). However, too much diethyl ether decreases the reaction 
conversion (entry g vs b-f) by competitive coordination with lithium. Based on the reaction 
conversion, we choose Et2O/CH2Cl2 (V/V = 1: 2) as reaction solvent in later studies. 
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Table 8. Solvent effect on TMS-QN catalyzed AAC reaction 
H Ph
O
Cl
O
TMS-QN iPr2NEt+
O
O
CH2CH2Ph
Me
Me
+ +
−78 °C
+
CH2Cl2/Et2O
1.0 mmol 2.0 eq 0.1 eq 0.3 eq 2.5 eq
Et2O (mL) CH2Cl2 (mL) % conversion
aentry
a
b
c
d
e
f
0.2
0.4
0.6
1.2
1.8
2.4
2.8
2.6
2.4
1.8
1.2
0.6
85
77
93
77
49
5
LiClO4
g
0 3.0 0
a Conversion determined by 1H NMR of crude product mixture.
45a
 
 
The next study conducted for optimization was focused on improving the reactivity of the 
Lewis base catalyst. Catalyst candidates for AAC reactions were drawn from easily accessed 
cinchona alkaloid derivatives differing in the C9 oxygen substitution (Table 9). Investigation of 
AAC efficiency as a function of the catalyst revealed that the O-trimethylsilyl alkaloid 3 afforded 
optimum reaction yields and enantioselectivities (Table 9, entry e). In the presence of 10 mol% 
O-trimethylsilyl quinine 3, 50 mol% LiClO4, cyclocondensation between methyl ketene and 
hydrocinnamaldehyde gave the desired β-lactone in high conversion and enantioselectivity (entry 
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e). Interestingly, the AAC reaction catalyzed by O-trimethylsilyl cinchonine 57 only went to 
30% conversion (entry c), the methoxy group at quinoline played an important but not yet 
understood role in these cycloaddition. The quinidine benzoate 56 and O-trimethylsilyl 
cinchonine 55 gave very similar results (entry a and b). 
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Table 9. Effect of alkaloids on the methyl ketene-hydrocinnamaldehyde cycloaddition 
H Ph
O
Cl
O
alkaloid
iPr2NEt, −78 °C
+
O
O
CH2CH2Ph
Me
Me
10 mol%
+ +
CH2Cl2/Et2O
% conversionaentry
a
b
c
d
e
30
30
50
50 3
82
30
59
98
99
99
99
30 87 99
LiClO4 (mol%) alkaloid % eeb, c
N
N
H
H
N
OR
OMe
OR'
N
OMe
R = H
R = TMS
R' = TMS
R' = Bz
N
H
OTMS
N
55
56
57
58
3
LiClO4
56
57
58
ND
55
45a
c Ent-45a provided using 55, 56 and 57 as catalyst.
a Conversion determined by 1H NMR of crude product mixture. b Enantiomer ratio assayed by chiral HPLC.
(3R, 4S)
 
Based on these investigations, slow addition of acid chloride (2 equiv over 1-4 h to 
minimize ketene dimerization) to a CH2Cl2/Et2O (2:1) solution containing TMS-QN 3 (10 mol 
%), LiClO4 (for benzyloxyacetaldehyde 30 mol%, hydrocinnamaldehyde 50 mol%, aromatic 
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aldehydes and sterically hindered aldehydes 200 mol%) and iPr2NEt (2.5 equiv) provided the 
optimized conditions for AAC reactions employing a variety of aldehydes.45  
After identifying the optimal asymmetric AAC reaction condition, we then explored 
reaction scope as a function of aldehyde structure for the alkaloid-catalyzed asymmetric AAC 
reactions. These investigations indicated that TMS-QN/LiClO4 or TMS-QD/LiClO4 catalyst 
system render a variety of structurally diverse aldehydes as suitable substrates for the AAC 
reaction (Table 10). Straight chain, β-branched, and alkoxy-substituted aliphatic aldehydes 
(entries a-g), a variety of substituted aromatic aldehydes (entries h-k), afforded the β-lactones 
with uniformly high yield and enantioselectivity (84-99% ee). Conjugated enals and very 
electron-rich aromatic aldehydes such as p-anisaldehyde are not effective substrates for the 
alkaloid-catalyzed asymmetric cycloaddition. 
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Table 10. TMS-QN/TMS-QD catalyzed AAC reactions* 
H R2
O
Cl
O 10 mol%TMS-QN 3 O
O
R2
R1
R1CH2Cl2/Et2O
% eea syn:antib,centry
a
b
c
d
e
f
Me
Me
Me
Me cC6H11
92
84
>99
99
99
97
-
-
98:2
88:12
95:5
>98:2g
cC6H11 94 -
iPr2NEt, LiClO4
+
10 mol%TMS-QD 55
iPr2NEt, LiClO4
CH2Cl2/Et2O
O
O
R2R1
% yieldd
h
i
j
Me
Me
Me
Ph
oC6H4Cl
oC6H4CH3
pC6H4CH3
>99
>99
>99
>99
98:2
98:2
>98:2
98:2k
Me
80
70
84
68
72
74
85
78
80
76
68
R1 R2
H
H
CH2CH(CH3)2
H
59ent-59
catalyst
55
55
55
3
3
3
3
3
3
3
3
CH2CH2Ph
CH2OBn
CH2CH2Ph
CH2OBn
 
a Enantiomeric ratios determined by chiral HPLC or GLC. b Diastereomeric ratios determined by 1H NMR 
of crude product mixtures. c Relative and absolute stereochemical assignments based on prior literature precedent; 
see 3.7 for detail. Absolute stereochemistry of compound 59 shown here. d Yields for diastereomerically pure 
materials. * Investigation performed in collaboration with Dr. Cheng Zhu.  
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Although these alkaloid-catalyzed AAC reactions are superficially related to the Al(III)-
catalyzed variants previously developed, the alkaloid-LiClO4 system offers several notable 
advantages. In reactions involving acetyl chloride-derived ketene, even sterically hindered 
aldehydes such as cyclohexanecarboxaldehyde served as effective substrates providing the β-
lactone in 94% ee (Table 10, entry a). Similar α-branched aldehydes are unreactive under Al(III) 
catalyst conditions. Methylketene is also an effective AAC reaction partner. In fact, 
enantioselectivity in reactions employing propionyl chloride-derived methylketene is 
significantly higher than the simple ketene cyclocondensation (Table 10, entry d vs b, e vs c). A 
variety of aldehydes reacted with propionyl chloride affording 3,4-cis disubstituted β-lactones 
with near perfect enantio- and diastereoselectivities (Table 10).  
 
3.4 MAGNESIUM CHLORIDE/ALKALOID-CATALYZED AAC FOR 
ETHYLKETENE 
The LiClO4/TMS-QN system works well for ketene and methyl ketene AAC reactions. However, 
only small amounts of desired β-lactones were formed when the optimized conditions were 
applied to the butyryl chloride-derived ethyl ketene AAC reaction with ethyl ketene dimer being 
the major side product (eq 20 and 21). 
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H Ph
O
Cl
O
+
O
O
CH2CH2Ph
Et
Et−78 °C
CH2Cl2/Et2O
20% conversion
H
O
Cl
O
+
O
O
Et
Et
trace
TMS-QN, LiClO4
iPr2NEt
−78 °C
CH2Cl2/Et2O
TMS-QN, LiClO4iPr2NEt
+
O
O
Et
Et
O
O
Et
Et
+
(20)
(21)
 
It was clear that we needed to improve the TMS-QN/LiClO4 system for less reactive substituted 
ketenes. From previous results, MgCl2 was shown to be a more reactive Lewis acid than LiClO4 
for the AAC reactions. We revisited this Lewis acid as a potential solution for unreactive ketene 
systems. Magnesium dichloride was found to allow for full conversion in the ethyl ketene-
benzaldehyde cycloaddtion, though the diastereoselectivity is low (3.8:1, eq 22). For aliphatic 
aldehydes, under the MgCl2/TMS-QN reaction conditions, the aldehyde was consumed, giving 
trace amount of desired β-lactones (eq 23). 
H Ph
O
Cl
O
TMS-QN
iPr2NEt, −25 °C
+
O
O
Ph
Et
Et
10 mol%
+ +
CH2Cl2/THF
MgCl2
1.0 eq2 eq
100% conversion
dr = 3.8 : 1
89% ee
H CH2CH2Ph
O
Cl
O
TMS-QN
iPr2NEt, −40 °C
+ O
O
CH2CH2Ph
Et
Et
10 mol%
+ +
CH2Cl2/THFMgCl2
0.5 eq2 eq
trace
(22)
(23)
 
 
We speculated that altering the coordination between alkaloids and MgCl2 might change the 
reactivity of catalyst system, so dimeric-quinine such as (DHQ)2AQN (60) and MgCl2 were 
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utilized to catalyze the substituted ketene AAC (Table 11). This system gave better conversions 
for aliphatic aldehydes compared to TMS-QN/MgCl2 system; however, the diastereoselectivity 
was still low for aromatic aldehydes (Table 11, entry b and d). So, the diastereoselectivity of 
AAC reaction catalyzed by MgCl2/alkaloid system was not as good as LiClO4/alkaloid system, 
although the reactivity of the MgCl2/alkaloid system is a little better than the LiClO4/alkaloid 
system, future studies needed to find better alkaloid for MgCl2. 
 
Table 11. (DHQ)2AQN/MgCl2 catalyzed AAC reaction 
H R'
O
Cl
O
iPr2NEt, −40 °C
+
O
O
R
R
R'
10 mol%
+ +
CH2Cl2/THF
MgCl2
1.0 eq2 eq
% conversionaentry
a
b
c
d
Me
Et
Et
85
75
85
Me 100 99
R' % eec
Ph
CH2CH2Ph
Ph
95
CH2CH2Ph
syn:antib
95 : 5
5 : 1
10 : 1
3 : 1
OO
N
OMe
N
MeO
OO
N
Et
ND
ND
R
N
Et
60
 a Conversion determined by 1H NMR of crude product mixture. b Diastereomer ratios determined 
   by 1H NMR of crude product mixtures. c Enantiomer ratios assayed by chiral HPLC.
(DHQ)2AQN
(DHQ)2AQN
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3.5 LITHIUM IODIDE/O-METHYL QUININE-CATALYZED AAC FOR 
ETHYLKETENE 
 
It has been reported that concentrated lithium perchlorate in diethyl ether solution can be 
potentially explosive.46 In order to avoid this potential hazard, we systematically investigated 
other lithium salts to find a more convenient Lewis acid co-catalyst for our AAC reactions. In the 
presence of one equiv of lithium salt and 10 mol% TMS-QN, we tested the reactivity of various 
lithium salts for the cycloaddition of cyclohexanecarboxaldehyde with methyl ketene in 2: 1 
CH2Cl2/Et2O (Table 12). These investigations revealed several lithium salts were active Lewis 
acids for the AAC (entry a-e) with lithium trifluoromethanesulfonimide and lithium iodide being 
more efficient Lewis acids than LiClO4 for the AAC reactions (entry d, e vs c). One added 
advantage of LiI in the AAC reaction is its increased solubility in diethyl ether as compared to 
LiClO4. Based on these investigations, for sterically hindered aldehydes and α-branched 
aldehydes, lithium iodide was selected as the Lewis acid co-catalyst in the alkaloid-catalyzed 
AAC reactions. For reactive aldehydes and easily enolizable aldehydes, litium perchlorate was 
still used as the optimal Lewis acid. 
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Table 12. Evalution of lithium salts by the methyl ketene-cyclohexanecarboxaldehyde cycloaddition 
H
O
Cl
O
TMS-QN
iPr2NEt, −78 °C
+
O
O
Me
Me
10 mol%
+ +
CH2Cl2/Et2O
entry
a
b
c
d
e 50
g
h
i
0
0
f 0
LiX
30
35
45
0
25
1 equiv
% conversionaX entry % conversionaX
OTfPF6
ClO4
I
Br
OCOCF3
BF4
SbF6
jb
kb
lb 100
100
100
ClO4
I
b 2 eq of lithium salts were used.a Conversion determined by 1H NMR of crude product mixtures.
NTf2
NTf2
(3R, 4S)
 
  
In order to solve the reactivity problem observed for lithium-alkaloid system catalyzed 
ethyl ketene AAC reaction, we attempted to increase the nucleophilicity of acyl ammonium 
enolate by modifying the structure of the alkaloid. Based on the premise that less sterically 
hindering protecting groups on the quinine would possibly increase the reactivity of the alkaloid, 
several sterically different protected quinine were synthesized to investigate the reactivity. Using 
LiI as Lewis acid and 8:1 CH2Cl2/Et2O (small amounts of Et2O was used to dissolve LiI) as 
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solvent, we used methylketene-hydrocinnamaldehyde cycloaddition to test the reactivities of 
several different alkaloids (Table 13). From these results, we concluded that bulky protection 
groups decrease the reactivity of alkaloids (entry e, g, vs a), the olefin functional group on the 
quinuclidine ring has little effect on reactivity (entry a vs f), the Me-QN 61 and TMS-QN gave 
similar results for methyl ketene-hydrocinnamaldehyde cycloaddition (entry a vs b).  
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Table 13. Effect of alkaloids on methyl ketene-hydrocinnamaldehyde cycloaddition 
H Ph
O
Cl
O
alkaloid
iPr2NEt, −78 °C
+
O
O
CH2CH2Ph
Me
Me
10 mol%
+ +
CH2Cl2/Et2O
% conversionaentry
a
b
c
d
f
50
50
50
50
75
65
70
70 97c
50 100 99
LiI (mol%) alkaloid % eeb
NH
N
OR
OMe
R = Me
R = MOM
61
LiI
62
63
64
ND
61
R = Bn 63
R = Piv 64
NH
N
OR
OMe
R = TMS 65
N
66
e
50 100 99
66
ND
ND
62
R = TMS 3
g
50 3 100 99
65
H
O
N
OMe
45a
 a Conversion determined by 1H NMR of crude product mixture. b Enantiomer ratios assayed by chiral HPLC.
 c Ent-45a provided using 66 as catalyst.
(3R, 4S)
 
We further compared the reactivity of O-methylated quinine 61 and O-trimethylsilyl quinidine 
55 in side by side ethyl ketene AAC reactions, as shown in Table 14, we found that using Me-
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QN as a catalyst gave higher aldehyde conversion than TMS-QD in these reactions (entry a vs b 
and c vs d). 
 
Table 14. Comparison of Me-QN and TMS-QD on the ethyl ketene AAC reaction 
H R
O
Cl
O
alkaloid
iPr2NEt, −78 °C
+
O
O
R
Et
Et10 mol%
+ +
CH2Cl2/Et2O
% conversionbentry
a
b
c
d
300
300
300
70
100
80
300 100 99
LiI (mol%) alkaloida % eec
NH
N
OMe
OMe
LiI
99
61
ND
ND
N
HN
OMe
OTMS
61 55
55
61
55
R
pC6H4F
pC6H4F
oC6H4Cl
oC6H4Cl
 a  61 and 55 provided different enantiomers, 61 gave (3R, 4R) enantiomer.  b Conversion determined 
by 1H NMR of crude product mixtures. c Enantiomer ratios assayed by chiral HPLC.
 
 
The newly discovered LiI/Me-QN system worked well for the cyclocondensation of 
aromatic aldehydes (Table 15 entry c-f and h). Although preliminary results look promising, 
further improvements are still needed for the cycloaddition involving aliphatic aldehydes (entry a, 
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b and g), since these reactions did not go to completion by using 1 equiv of LiI, if we increased 
the amount of LiI, aliphatic aldehydes started to be consumed without producing desired β-
lactones, while we can use 3 equiv of LiI for non-enolizable aldehydes to achieve good 
conversion and yield. 
 
Table 15. LiI/Me-QN system catalyzed ethyl ketene AAC reactions  
H R2
O
Cl
O 10 mol% Me-QN O
O
R2
R1
R1CH2Cl2/Et2O
% eea syn:antibentry
a
g
Et
nPr
Et cC6H11b
iPr2NEt, LiI
+
% yieldc
c
d
e
f
Et
Et
Et
nPr
Ph
pC6H4F
oC6H4Cl
oC6H4CH3
Ph
>99
>99
>99
>99
>99
98:2
98:2
98:2
98:2
98:2h
Et 84
75
83
70
70
R1 R2
67
30
30
40
ND
ND
ND
94:6
94:6
95:5
 a Enantiomer ratios assayed by chiral HPLC, absolute stereochemistry of 67 shown here. b Diastereomer 
ratios determined by 1H NMR of crude product mixtures. c Isolated yield for diastereomerically pure materials.
CH2CH2Ph
CH2CH2Ph
 
In summary, the cinchona alkaloid-Lewis acid catalyzed AAC reaction dramatically 
expands the scope of Wynberg’s original cycloaddition between ketene and chloral. By 
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modulating the protecting group on the alkaloid and by careful selection of a Lewis acid and 
solvent, a broad spectrum of β-lactones can be expediently assembled. The cinchona alkaloid-
Lewis acid catalyzed AAC reaction is a mechanistically distinct process that serves as a 
complimentary system to the aluminium-triamine-catalyzed AAC reaction variant. Together, 
these two subsets of AAC tolerate a vast array of molecular diversity. Selection of the AAC 
variant can provide a desired β-lactone in good yields with high enantioselectivities. 
 
3.6 EXPERIMENTALS 
General procedure B: TMS-QN/LiClO4 catalyzed asymmetric ketene-aldehyde 
cycloadditions:  To a solution of TMS-QD/TMS-QN (0.10 mmol) and LiClO4 (0.30-3.0 mmol, 
weighed in glovebox) in 1.0 mL of diethyl ether at ambient temperature was slowly added 2.0 
mL of CH2Cl2. The resulting mixture was cooled to −78 °C (several reactions at –40 °C) and 0.44 
mL of N, N-diisopropylethylamine (2.5 mmol) was added, then aldehyde (1.0 mmol) was added 
dropwise followed by the addition of 2.0 mmol of acid chloride in 0.5 mL CH2Cl2 over 1-4 h by 
syringe pump ( the tip of syringe was put into the reaction mixture). The reaction mixture was 
stirred for 14-16 h at –78 °C (or –40 °C).  The reaction was quenched at –78 °C (or –40 °C) by 
adding 10 mL of Et2O and the resulting mixture was filtered through silica gel eluting with 3 x 
20 mL of Et2O.  The filtrate was concentrated in vacuo and the crude product mixture was 
purified by flash chromatography. 
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 (S)-4-Cyclohexyloxetan-2-one (ent-59a):28 General procedure B was 
followed employing 40 mg of TMS-QD (0.10 mmol, 10 mol%), 212 mg LiClO4 
(2.0 mmol, 200 mol%) and 120 µL of cyclohexanecarboxaldehyde (1.0 mmol). 
Reaction was run at –40 °C.  Purification by flash chromatography (15% diethyl ether in pentane) 
gave 129 mg (84%) of the title compound as white crystalline solid. Separation of enantiomers 
by chiral GLC [Chiraldex™ G-TA column 20 m x 0.25 mm, flow rate 0.5 mL/min, method: 100 
°C for 10 min, ramp @ 15.0 °C/min to 130 °C for 8.0 min, ramp @ 15.0 °C/min to 160 °C for 
10.0 min, Tr: 24.5 min (4S), 26.2 min (4R)] provided the enantiomeric ratio (4S):(4R) = 97.2:2.8 
(94% ee).  [α]D +19.8 (c 1.48, CHCl3). 
O
O
ent-59a
 
 
 (R)-4-Phenethyloxetan-2-one (ent-59b):28 General procedure B was 
followed employing 40 mg of TMS-QD (0.10 mmol, 10 mol%), 53 mg LiClO4 
(0.50 mmol, 50 mol%) and 132 µL of hydrocinnamaldehyde (1.0 mmol). The 
reaction mixture was stirred at –78 °C for 7 h.  Purification by flash chromatography (25% 
diethyl ether in pentane) gave 141 mg (80%) of the title compound as colorless oil. Separation of 
the enantiomers by chiral HPLC [Daicel Chiracel™ OD-H column, flow rate 1.0 mL/min, 10% 
iPrOH, 90% hexane, Tr 15.5 min (S) and 17.3 min (R)] provided the enantiomeric ratio: (R):(S) = 
96:4 (92% ee). [α]D +37.8 (c 2.40, CHCl3). 
O
O
Ph
ent-59b
 (R)-4-(Benzyloxy)methyl)oxetan-2-one (59c):28 General procedure B 
was followed employing 40 mg of TMS-QN (0.10 mmol, 10 mol%), 32 mg 
LiClO4 (0.3 mmol, 30 mol%) and 140 µL of benzyloxyacetaldehyde (1.0 mmol). 
Purification by flash chromatography (25% ethyl acetate in hexane) gave 134 mg (70%) of the 
O
O
OBn
59c
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title compound as colorless oil. Separation of the enantiomers by chiral HPLC [Daicel 
Chiracel™ OD-H column, flow rate 0.9 mL/min, 15% iPrOH, 85% hexane, Tr 13.9  min (R) and 
24.8 min (S)] provided the enantiomer ratio: (R):(S) = 92:8 (84% ee).  [α]D –13.9 (c 1.80, CHCl3). 
 
 (3R, 4S)-3-Methyl-4-phenethyloxetan-2-one (59d): General 
procedure B was followed employing 40 mg of TMS-QN (0.10 mmol, 10 
mol%), 53 mg LiClO4 (0.5 mmol, 50 mol%) and 132 µL of 
hydrocinnamaldehyde (1.0 mmol). Purification by flash chromatography (10% ethyl acetate in 
hexane) gave 161 mg (84%) of the title compound as colorless oil. Separation of enantiomers by 
Chiral HPLC [Daicel ChiracelTM OD-H column, flow rate 1.0 mL/min, 5% iPrOH, 95% hexane 
Tr: 12.9 min (3S, 4R), 14.0 min (3R, 4S)] provided only one enantiomer (3R, 4S) (≥99% ee).  
[α]D –47.2 (c 2.04, CHCl3). Spectra data as reported on page 42. 
O
Me CH2CH2Ph
O
59d
 
 (3R, 4R)-4-(Benzyloxy)methyl)-3-methyloxetan-2-one (59e):29 
General procedure B was followed employing 40 mg of TMS-QN (0.10 mmol, 
10 mol%), 32 mg LiClO4 (0.3 mmol, 30 mol%) and 140 µL of 
benzyloxyacetaldehyde (1.0 mmol). Purification by flash chromatography (20% ethyl acetate in 
hexane) gave 140 mg (68%) of the title compound as colorless oil. Separation of the enantiomers 
by chiral HPLC [Daicel Chiracel™ OD-H column, flow rate 1.0 mL/min, 10% iPrOH, 90% 
hexane, Tr 13.4 min (3R, 4R) , 31.4 min (3S, 4S)] provided the enantiomeric ratio: (3R, 4R):(3S, 
4S) ≥ 99.5:0.5 (≥99% ee).  [α]D –7.60 (c 1.58, CHCl3). 
O
O
OBn
Me
59e
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 (3R, 4S)-4-Isobutyl-3-methyloxetan-2-one (59f): General procedure 
B was followed employing 1.0 g of TMS-QN (2.5 mmol, 10 mol%), 5.3 g 
LiClO4 (50.0 mmol, 200 mol%) and 2.68 mL of isovaleraldehyde (25.0 
mmol). Purification by flash chromatography (9% diethyl ether in pentane) gave 2.55 g (72%) of 
the title compound as colorless oil. Separation of enantiomers by chiral GLC [Chiraldex™ G-TA 
column 20 m x 0.25 mm, flow rate 0.6 mL/min, method: 80 °C for 5.0 min, ramp @ 5.0 °C/min 
to 100 °C for 10.0 min, ramp @ 5.0 °C/min to 130 °C for 5.0 min, Tr: 23.9 min (3R, 4S) and 25.0 
min (3S, 4R)] provided the enantiomeric ratio (3R, 4S): (3S, 4R) = 99.7:0.3 (99% ee).  [α]D –41.8 
(c 1.88, CHCl3). IR (thin film): 1824, 1465, 1124 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.67 (ddd, 
J = 9.7, 6.5, 3.8 Hz, 1H), 3.77 (qd, J = 7.8, 6.5 Hz, 1H), 1.82 (m, 1H), 1.71 (ddd, J = 14.3, 9.7, 
6.0 Hz, 1H), 1.51 (ddd, J = 14.3, 7.6, 3.8 Hz, 1H), 1.29 (d, J = 7.8 Hz, 3H), 1.01 (d, J = 6.6 Hz, 
3H), 0.99 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.7, 74.2, 47.4, 38.5, 25.2, 22.8, 
22.0, 8.1; HRMS (EI) m/z calcd for (M+) C8H14O2: 142.0994; found: 142.0988.  
O
O
Me Me
Me
59f
 
 (3S, 4R)-4-Cyclohexyl-3-methyloxetan-2-one (ent-59g): General 
procedure B was followed employing 40 mg of TMS-QD (0.10 mmol, 10 
mol%), 212 mg LiClO4 (2.0 mmol, 200 mol%) and 120 µL of 
cyclohexanecarboxaldehyde (1.0 mmol). Reaction was run at –40 °C. Purification by flash 
chromatography (15% diethyl ether in pentane) gave 124 mg (74%) of the title compound as 
white crystalline solid. Separation of enantiomers by chiral GLC [Chiraldex™ G-TA column 20 
m x 0.25 mm, flow rate 0.5 mL/min, method: 100 °C for 10 min, ramp @ 15.0 °C/min to 130 °C 
for 8.0 min, ramp @ 15.0 °C/min to 160 °C for 15.0 min, Tr: 26.8 min (3S, 4R), 27.7 min (3R, 
4S)] provided the enantiomer ratio (3S, 4R): (3R, 4S) = 98.3: 1.7 (97% ee).  [α]D –13.4 (c 1.45, 
O
O
Me
ent-59g
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CHCl3). IR (thin film): 2932, 2854, 1825, 1132 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.18 (dd, J 
= 10.6, 6.3 Hz, 1H), 3.72 (qd, J = 7.8, 6.3 Hz, 1H), 2.01-1.92 (m, 1H), 1.82-1.52 (m, 5H), 1.34 (d, 
J = 7.8 Hz, 3H), 1.32-1.19 (m, 3H), 1.07-0.88 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 172.9, 79.0, 
46.8, 37.7, 28.9, 28.1, 26.0, 25.0 (2C), 8.4; HRMS (EI) m/z calcd for (M+) C10H16O2: 168.1150; 
found: 168.1158.  
 
 (3R, 4R)-3-Methyl-4-phenyloxetan-2-one (59h): General procedure B 
was followed employing 40 mg of TMS-QN (0.10 mmol, 10 mol%), 212 mg 
LiClO4 (2.0 mmol, 200 mol%) and 102 µL of benzaldehyde (1.0 mmol). 
Purification by flash chromatography (10% ethyl acetate in hexane) gave 126 mg (78%) of the 
title compound as colorless oil. Separation of the enantiomers by chiral HPLC [Daicel 
Chiracel™ OD-H column, flow rate 1.0 mL/min, 3% iPrOH, 97% hexane, Tr 10.8 min (3R, 4R), 
11.7 min (3S, 4S)] provided only one enantiomer (≥99% ee).  [α]D +139 (c 1.79, CHCl3). Spectra 
data as reported on page 43. 
O
Ph
O
Me
59h
 
 (3S, 4S)-4-(2-Chlorophenyl)-3-methyloxetan-2-one (ent-59i): 
General procedure B was followed employing 40 mg of TMS-QD (0.10 mmol, 
10 mol%), 212 mg LiClO4 (2.0 mmol, 200 mol%) and 113 µL of 2-
chlorobenzaldehyde (1.0 mmol).  Purification by flash chromatography (10% diethyl ether in 
pentane) gave 158 mg (80%) of the title compound as colorless oil. Separation of enantiomers by 
chiral HPLC [Daicel Chiracel™ OD-H column, flow rate 0.6 mL/min, 2% iPrOH, 98% hexane, 
Tr 13.4 min (3R, 4R), 14.1 min (3S, 4S)] provided only one enantiomer (≥99% ee).  [α]D –201 (c 
1.68, CHCl3); IR (thin film): 2979, 1827, 1472, 1444, 1289, 1055, 946, 880, 755 cm-1; 1H NMR 
O
O
Me
Cl
ent-59i
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(300 MHz, CDCl3) δ 7.55-7.52 (m, 1H), 7.43-7.31 (m, 3H), 5.86 (d, J = 6.3 Hz, 1H), 4.16 (qd, J 
= 7.7, 6.3 Hz, 1H), 0.98 (d, J = 7.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.5, 133.0, 131.2, 
129.6, 129.3, 127.2, 126.9, 73.3, 50.3, 9.1; HRMS (EI) m/z calcd for (M+) C10H9ClO2: 196.0291; 
found: 196.0299.  
 
 (3R, 4R)-3-Methyl-4-o-tolyloxetan-2-one (59j): General procedure B 
was followed employing 40 mg of TMS-QN (0.10 mmol, 10 mol %), 212 mg 
LiClO4 (2.0 mmol, 200 mol%) and 116 µL of 2-methylbenzaldehyde (1.0 
mmol).  Reaction was run at –40 °C. Purification by flash chromatography (10% ethyl acetate in 
hexane) gave 134 mg (76%) of the title compound as white crystalline solid. Separation of 
enantiomers by chiral HPLC [Daicel Chiracel™ OD-H column, flow rate 0.5 mL/min, 4% iPrOH, 
96% hexane, Tr 18.1 min (3R, 4R), 19.1 min (3S, 4S)] provided only one enantiomer (≥99% ee).  
[α]D +201 (c 1.49, CHCl3); IR (thin film): 2978, 1829, 1493, 1260 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.48-7.45 (m, 1H), 7.31-7.20 (m, 3H), 5.78 (d, J = 6.3 Hz, 1H), 4.08 (qd, J = 7.7, 6.3 
Hz, 1H), 2.22 (s, 3H), 0.91 (d, J = 7.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.9, 133.8, 
132.9, 130.2, 128.2, 126.3, 124.9, 73.7, 49.5, 18.7, 9.2; HRMS (EI) m/z calcd for (M+) C11H12O2: 
176.0837; found: 176.0831.  
O
O
Me
Me
59j
 
 (3R, 4R)- 3-Methyl-4-p-tolyloxetan-2-one (59k): General 
procedure B was followed employing 40 mg of TMS-QN (0.10 mmol, 10 
mol %), 212 mg LiClO4 (2.0 mmol, 200 mol %) and 118 µL of 4-
methylbenzaldehyde (1.0 mmol).  Reaction was run at –40 °C. Purification by flash 
chromatography (hexanes: ethyl acetate: Et3N = 10:1: 0.1) gave 120 mg (68%) of the title 
O
O
Me
Me59k
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compound as white crystal. Separation of enantiomers by chiral HPLC [Daicel Chiracel™ OD-H 
column, flow rate 1.0 mL/min, 3% iPrOH, 97% hexane, Tr 8.1 min (3R, 4R), 9.0 min (3S, 4S)] 
provided only one enantiomer (≥99% ee).  [α]D +118 (c 1.46, CHCl3); IR (thin film): 3023, 1826, 
1216, 940, 756 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.27-7.11 (m, 4H), 5.63 (d, J = 6.3 Hz, 1H), 
4.03 (qd, J = 7.7, 6.3 Hz, 1H), 2.38 (s, 3H), 0.95 (d, J = 7.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 172.3, 138.2, 131.4, 129.1, 125.5, 75.2, 49.8, 20.9, 9.3; HRMS (EI) m/z calcd for (M+) 
C11H12O2: 176.0837; found: 176.0834.  
 
6-Methoxy-4-[methoxy-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-
yl)methyl]quinoline (61):50 250 mg NaH (6.47 mmol, 1.05eq, 60% 
suspended in oil) was washed twice with 10 mL of pentane and suspended 
in 10 mL of THF. The suspension was cooled to 0 °C and a solution of 2.0 g 
of quinine (6.17 mmol) in 18 mL THF was added dropwise. The reaction mixture was stirred at 0 
°C for 1 h and then ambient temperature for 6 h. The reaction mixture was recooled to 0 °C and 
403 uL of methyl iodide (6.47 mmol, 1.05 eq) was added dropwise and stirred at 0 °C for 1 h and 
then ambient temperature for 14 h. The resulting mixture was filtered through silica gel eluting 
with 2 x 100 ml of Et2O.  The filtrate was concentrated in vacuo and the crude product mixture 
was purified by flash chromatography (2% methanol in ethyl acetate) and recrystallization 
(CH2Cl2/ethyl acetate), giving 810 mg (39%) of title compound as crystalline solid. [α]D –83.6 (c 
1.51, CHCl3); IR (KBr Plate): 1735, 1619, 1506, 1474, 1429, 1239, 1227 cm-1; 1H NMR (300 
MHz, CDCl3) δ 11.43 (br, 1H), 8.79 (d, J = 4.5 Hz, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.50 (d, J = 2.6 
Hz, 1H), 7.46 (d, J = 4.4 Hz, 1H), 7.44 (dd, J = 9.2, 2.6 Hz, 1H), 6.48 (br, 1H), 5.59 (ddd, J = 
17.1, 10.2, 6.6 Hz, 1H), 5.11 (t, J = 1.3 Hz, 1H), 5.06 (dd, J = 7.1, 1.1 Hz, 1H), 4.25-4.19 (m, 
NH
OMe
N
OMe
61
 77 
1H), 4.18 (s, 3H), 3.53-3.39 (m, 2H), 3.51 (s, 3H), 3.29-3.16 (m, 2H), 2.78 (br, 1H), 2.23-2.14 
(m, 3H), 1.98-1.88 (m, 1H), 1.54-1.45 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 159.0, 146.9, 
144.6, 139.7, 136.8, 131.8, 126.6, 123.1, 118.2, 117.4, 100.3, 75.7, 59.6, 58.8, 56.9, 54.5, 44.1, 
36.4, 26.7, 23.9, 19.1; HRMS (ESI) calcd for C21H27 N2O2 (M++H): 339.2073; found: 339.2079.  
Later, by switching base from NaH to KH, much higher yield was obtained. Here is the 
procedure: 247 mg KH (1.85 mmol, 1.20 eq, 30% suspended in oil) was washed three times with 
5 mL pentane and suspended in 5 mL of THF. The suspension was cooled to 0 °C and stirred for 
10 min. Then a solution of 0.5 g of quinine (1.54 mmol) in 4 mL THF was added dropwise. The 
reaction mixture was stirred at 0 °C for 30 min and then 50 °C for 30 min. The reaction mixture 
was cooled down to ambient temperature and 101 uL of methyl iodide (1.62 mmol, 1.05 eq) was 
added dropwise and stirred at ambient temperature for 1 h. The resulting mixture was recooled 
down to 0 °C and quenched with water. The resulting mixture was extracted by ethyl acetate (3 x 
15 mL). The organic layer was washed by brine and dried over Na2SO4 and concentrated in 
vacuo. The crude product mixture was purified by flash chromatography (2% methanol in ethyl 
acetate), giving 490 mg (94%) of title compound as crystalline solid. 
 
General procedure C: Me-QN/LiI-catalyzed asymmetric ketene-aldehyde 
cycloadditions:  To a solution of Me-QN (0.10 mmol) and LiI (1.0-3.5 mmol, weighed in 
glovebox) in 0.25 mL of diethyl ether at ambient temperature was slowly added 2.0 mL of 
CH2Cl2. The resulting mixture was cooled to −78 °C and 0.44 mL of N, N-diisopropylethylamine 
(2.5 mmol) was added, and then aldehyde (1.0 mmol) was added dropwise, then a solution of 
acid chloride (2mmol) in 0.5 mL CH2Cl2 was added over 1-4 h by syringe pump (the tip of 
syringe was put into the reaction mixture). The reaction mixture was stirred for 14-16 h at −78 °C.  
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The reaction was quenched at −78 °C by adding 10 mL of Et2O and the resulting mixture was 
filtered through silica gel eluting with 3 x 20 ml of Et2O.  The filtrate was concentrated in vacuo 
and the crude product mixture was purified by flash chromatography. 
 
 (3R, 4S)-3-Ethyl-4-phenethyloxetan-2-one (67a): General 
procedure C was followed employing 20 mg of Me-QN (0.06 mmol, 10 
mol%), 67 mg LiI (0.50 mmol, 100 mol%) and 66 µL of 
hydrocinnamaldehyde (0.50 mmol). Purification by flash chromatography (9% ethyl acetate in 
hexane) gave 31 mg (30%) of the title compound as colorless oil (reaction conversion 65% was 
determined by 1H NMR of crude product mixtures). Spectra data as reported on page 44. 
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 (3S, 4R)-4-Cyclohexyl-3-ethyloxetan-2-one (67b): General procedure 
C was followed employing 34 mg of Me-QN (0.10 mmol, 10 mol%), 402 mg 
LiI (3.0 mmol, 300 mol%) and 120 µL of cyclohexanecarboxaldehyde (1.0 
mmol). Purification by flash chromatography (14% diethyl ether in pentane) gave 55 mg (30%) 
of the title compound as white crystalline solid (reaction conversion 50% was determined by 1H 
NMR of crude product mixtures). 1H NMR (300 MHz, CDCl3) δ 4.16 (dd, J = 10.2, 6.2 Hz, 1H), 
3.53 (dt, J = 10.7, 5.9 Hz, 1H), 1.98-1.65 (m, 8H), 1.35-1.22 (m, 3H), 1.14 (t, J = 7.4 Hz, 3H), 
1.10-0.88 (m, 2H); HRMS (EI) calcd for (M+-CO2) C10H18: 138.1409; found: 138.1406.  
O
O
Et
67b
 
 
 (3R, 4R)-3-Ethyl-4-phenyloxetan-2-one (67c): General procedure C was 
followed employing 34 mg of Me-QN (0.10 mmol, 10 mol%), 402 mg LiI (3.0 
O
Ph
O
Et
67c
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mmol, 300 mol%) and 102 µL of benzaldehyde (1.0 mmol). Purification by flash 
chromatography (6% ethyl acetate in hexane) gave 148 mg (84%) of the title compound as 
colorless oil. Separation of the enantiomers by chiral HPLC [Daicel Chiracel™ OD-H column, 
flow rate 0.5 mL/min, 10% iPrOH, 90% hexane, Tr 13.3 min (3R, 4R), 16.1 min (3S, 4S)] 
provided only one enantiomer (≥99% ee).  [α]D +134 (c 2.27, CHCl3). Spectra data as reported 
on page 46. 
 
 (3R, 4R)-3-Ethyl-4-(4-fluorophenyl)oxetan-2-one (67d): General 
procedure C was followed employing 34 mg of Me-QN (0.10 mmol, 10 
mol%), 402 mg LiI (3.0 mmol, 300 mol%) and 108 µL of 4-
fluorobenzaldehyde (1.0 mmol).  Purification by flash chromatography (9% ethyl acetate in 
hexane) gave 146 mg (75%) of the title compound as colorless oil. Separation of enantiomers by 
chiral HPLC [Daicel Chiracel™ OD-H column, flow rate 1.0 mL/min, 5% iPrOH, 95% hexane, 
Tr 7.7 min (3R, 4R), 8.5 min (3S, 4S)] provided only one enantiomer (≥99% ee).  [α]D +122 (c 
2.01, CHCl3); IR (thin film): 2979, 2938, 1827, 1601, 1144, 1112 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.47-7.44 (m, 2H), 7.30-7.27 (m, 2H), 5.77 (d, J = 6.4 Hz, 1H), 3.99 (td, J = 8.3, 6.4 
Hz, 1H), 1.68-1.58 (m, 1H), 1.46-1.36 (m, 1H), 1.00 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 171.3, 162.7 (d, J = 246.0 Hz), 130.5, 127.6 (d, J = 8.3 Hz), 115.5 (d, J = 21.6 Hz), 
74.5, 56.9, 18.5, 11.1; HRMS (EI) m/z calcd for (M+) C11H11FO2: 194.0743; found: 194.0739.  
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 (3R, 4R)-4-(2-Chlorophenyl)-3-ethyloxetan-2-one (67e): General 
procedure C was followed employing 34 mg of Me-QN (0.10 mmol, 10 mol%), 
402 mg LiI (3.0 mmol, 300 mol%) and 113 µL of 2-chlorobenzaldehyde (1.0 
O
O
Et
Cl
67e
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mmol).  Purification by flash chromatography (4% diethyl ether in pentane) gave 174 mg (83%) 
of the title compound as colorless oil. Separation of enantiomers by chiral HPLC [Daicel 
Chiracel™ OD-H column, flow rate 1.0 mL/min, 2% iPrOH, 98% hexane, Tr 6.9 min (3R, 4R), 
7.8 min (3S, 4S)] provided only one enantiomer (≥99% ee).  [α]D +221 (c 2.30, CHCl3); IR (thin 
film): 2971, 2938, 1832, 1473, 1444, 1145, 942, 897 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.57-
7.51 (m, 1H), 7.42-7.30 (m, 3H), 5.87 (d, J = 6.3 Hz, 1H), 3.96 (ddd, J = 8.9, 7.6, 6.3 Hz, 1H), 
1.42-1.34 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 170.8, 133.0, 131.2, 
129.5, 129.2, 127.0, 126.8, 72.6, 56.6, 18.5, 11.1; HRMS (EI) m/z calcd for (M+) C11H11ClO2: 
210.0448; found: 210.0458.  
 
 (3R, 4R)-3-Ethyl-4-o-tolyloxetan-2-one (67f): General procedure C 
was followed employing 34 mg of Me-QN (0.10 mmol, 10 mol%), 452 mg LiI 
(3.4 mmol, 340 mol%) and 116 µL of 2-methylbenzaldehyde (1.0 mmol).  
Purification by flash chromatography (5% ethyl acetate in hexane) gave 133 mg (70%) of the 
title compound as colorless oil. Separation of enantiomers by chiral HPLC [Daicel Chiracel™ 
OD-H column, flow rate 0.5 mL/min, 4% iPrOH, 96% hexane, Tr 14.9 min (3R, 4R), 17.8 min 
(3S, 4S)] provided only one enantiomer (≥99% ee).  [α]D +210 (c 1.98, CHCl3); IR (thin film): 
2971, 2938, 1825, 1462, 1148, 939, 891 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.54-7.51 (m, 1H), 
7.38-7.33 (m, 2H), 7.30-7.27 (m, 1H), 5.85 (d, J = 6.3 Hz, 1H), 3.95 (dt, J = 9.8, 6.4 Hz, 1H), 
2.33 (s, 3H), 1.37-1.23 (m, 1H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.3, 
133.9, 133.1, 130.1, 128.2, 126.2, 125.1, 73.2, 56.3, 18.7, 18.6, 11.2; HRMS (EI) m/z calcd for 
(M+) C12H14O2: 190.0994; found: 190.0990.  
O
O
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 (3R, 4S)- 4-Phenethyl-3-propyloxetan-2-one (67g): General 
procedure C was followed employing 20 mg of Me-QN (0.06 mmol, 10 
mol%), 67 mg LiI (0.50 mmol, 100 mol%) and 66 µL of 
hydrocinnamaldehyde (0.50 mmol). Purification by flash chromatography (6% ethyl acetate in 
hexane) gave 44 mg (40%) of the title compound as colorless oil (reaction conversion 80% was 
determined by 1H NMR of crude product mixtures). Spectra data as reported on page 46. 
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 (3R, 4R)-4-Phenyl-3-propyloxetan-2-one (67h): General procedure C 
was followed employing 34 mg of Me-QN (0.10 mmol, 10 mol%), 470 mg LiI 
(3.5 mmol, 350 mol%) and 102 µL of benzaldehyde (1.0 mmol). Purification by 
flash chromatography (5% ethyl acetate in hexane) gave 133 mg (70%) of the title compound as 
colorless oil. Separation of the enantiomers by chiral HPLC [Daicel Chiracel™ OD-H column, 
flow rate 0.5 mL/min, 10% iPrOH, 90% hexane, Tr 11.7 min (3R, 4R), 13.6 min (3S, 4S)] 
provided only one enantiomer (≥99% ee).  [α]D +117 (c 1.80, CHCl3). Spectra data as reported 
on page 47. 
O
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3.7 STEREOCHEMICAL PROOFS FOR β-LACTONES 
The absolute configuration of β-lactones ent-59g was established by conversion to the 
corresponding methyl ester 68 using the published procedure (La(OtBu)3, MeOH)47  and 
correlating the ester’s specific rotations to those of authentic samples of known configuration: 68 
[α]D23 = +5.2 (2S, 3R) (c 1.64, CHCl3) [lit [α]D23 = –5.5 (2R, 3S) (c 0.3, CHCl3).48  The 
configuration of lactone 59h was established similarly by conversion to corresponding ethyl ester 
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69 according to the literature procedure (La(OtBu)3, EtOH) 47 and correlating the ester’s specific 
rotations to those of authentic samples of known configuration: 69 [α]D23 = +20.6 (2R, 3R) (c 
1.07, CHCl3) [lit [α]D23 = –22.0 (2S, 3S) (c 0.87, CHCl3).49  
                                                                                                                                                  
Scheme 2. Absolute stereochemistry 
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4.0  ENANTIOSELECTIVE TOTAL SYNTHESIS OF (―)-PIRONETIN 
4.1 BACKGROUND 
4.1.1 Isolation and Biological Activity 
Pironetin or PA-48153C (Figure 25) is an unsaturated δ-lactone derivative that was isolated in 
1993 independently by two research groups from the fermentation broths of Streptomyces 
prunicolor PA-48153 51 and Streptomyces sp. NK 10958.52,53 Pironetin shows potent 
immunosuppressive and plant growth regulator activity. More importantly, it has recently been 
identified as a strong antitumor agent, that inhibts the tubulin assembly by its ability to bind 
covalently to the α-subunit of tubulin at Lys-352, this is the first compound that covalently binds 
to the α-subunit of tubulin and inhibits the interaction of tubulin heterodimers.54 Structure 
elucidation and relative as well as absolutely stereochemical assignments for pironetin were 
achieved by spectral methods, X-ray crystallographic analysis, and further confirmed by total 
synthesis.55  Based on the potential value of pironetin as a lead compound for cancer therapy and 
as a demonstration of our AAC methodology, we targeted a catalytic asymmetric total synthesis 
of the natural product that would be amenable to scale-up and derivatization.   
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Figure 25. (–)-Pironetin 
4.1.2 Previous Total Synthesis of (–)-Pironetin 
To date, eight total syntheses of (–)-pironetin have been reported by eight different synthetic 
groups.  The first total synthesis of pironetin was reported by Kawada56 in 1995 starting from 
methyl-4,6-O-benzylidene-α-glucopyranoside 70 and (S)-methyl-3-hydroxyl-2-methylpropionate 
71 (Figure 26). The key steps in this synthesis were achieved by trans-diaxial ring opening of 
epoxy mesylate 72 to introduce the ethyl group,57 Wittig reaction of aldehyde 73 with a 
phosphorous ylide 74 derived from epoxide 75,  which was made from the  methyl propionate 71. 
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Figure 26. Retrosynthesis of (–)-Pironetin: Kawada Approach 
  
Gurjar58,59 published his synthesis of pironetin that involves the aldol reaction between 
aldehyde 76 and 4-benzyl-3-butyryl-2-oxazolidinone 77 (Figure 27).  (Z)-Double bond in the 
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pyranone was achieved by modified Horner-Wadsworth-Emmons reaction.60 The preparation of 
aldehyde 76 was involved a regio-selective reduction of epoxide 78 with Red-Al. Synthesis of 
epoxide 78 from epoxide 79 was achieved by this sequence: Me2CuLi ring opening of epoxide 
79, protection of primary alcohol as TBS ether, methylation of secondary alcohol, deprotection 
of TBS ether, oxidation, olefination, DIBAL reduction and asymmetric Sharpless epoxidation. 
The similar sequence was used for converting of alcohol 80 to epoxide 79.   
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Figure 27. Retrosynthesis of (–)-Pironetin: Gurjar Approach 
 
In his 1997 publication, Chida61 disclosed his synthesis of pironetin by addition of 
dithiane anion derived from 81 to the epoxide 82 (Figure 28). The key steps involved in the 
formation of dithiane 81 from alcohol 83 were glycol cleavage and Still-Gennari olefination.62 
Alcohol 83 was obtained from L-malic acid in 6 steps. The epoxide 82 which has four 
contiguous stereocenters was constructed stereoselectively from L-quebrachitol. The key step 
involved here is trans-diaxial opening of epoxide 84 by trimethylaluminium.  
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Figure 28. Retrosynthesis of (–)-Pironetin: Chida Approach  
 
Published in 1998, Kitahara’s63,64 synthetic approach to pironetin also involved a 
nucloephilic addition of dathiane anion derived from 85 to epoxide 86 (Figure 29).  Dithiane 85 
was synthesized from a chiral building block 5-hydroxy-bicyclo[4.1.0]heptan-2-one 87, and 
epoxide 86 was prepared from the benzylate 88, which was made from epoxy alcohol 89.  
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Figure 29. Retrosynthesis of (–)-Pironetin: Kitahara Approach 
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In 2001, Keck65 reported a convergent total synthesis of pironetin. Key step included a 
highly selective BF3 promoted Mukaiyama aldol reaction between silyl enol ether 90 and 
aldehyde 91, which was obtained by a diastereoselective TiCl4 mediated addition of 
crotylstannane 92 to aldehyde 93 66 (Figure 30). Silyl enol ether 90 was obtained by using 
asymmetric alkylation protocol developed by Meyers67 from chiral auxiliary 94.   
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Figure 30. Retrosynthesis of (–)-Pironetin: Keck Approach 
 
More recently 2003, Dias68,69 reported the asymmetric synthesis of pronetin by using of 
three very efficient Evans oxazolidinone-mediated syn-aldol condensations,70 a high-yield 
coupling between lithium acetylide ethylenediamine71 complex and tosylate 97 and a selective 
reduction to establish C12-C13 (E) double bond (Figure 31). 
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Figure 31. Retrosynthesis of (–)-Pironetin: Dias Approach  
 
The most recent total synthesis of (−)-pironetin was published by Enders in 2007.72 The 
α,β-unsaturated-δ-lactone fragement was installed by ring-closing metathesis of triene 99, which 
was synthesized by coupling between the ketone 101 and aldehyde 102 by using a Mukaiyama-
aldol reaction. The stereogenic centers of 101 and 102 were generated by employing the 
SAMP/RAMP (SAMP = (S)-1-amino-2-methoxymethylpyrrolidine, RAMP = (R)-1-amino-2-
methoxymethyl-pyrrolidine) hydrazone methodology (Figure 32). 
 
O
Me
OMe
Me
OMe
Me
OH
1
57
12
O
Me
OMe
Me
OMe
Me
OAc
57
12
OTBS
Me
Me
Me Me
OH
57
12
O
Me
Me
Me
12
O
OTBS
Me
O
57
+
99
100101 102  
Figure 32. Retrosynthesis of (–)-Pironetin: Enders Approach 
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4.2 RETROSYNTHETIC ANALYSIS OF (―)-PIRONETIN 
 
Our retrosynthetic analysis of pironetin is based on the novel approach of creating all 
stereocenters using our AAC methodologies (Figure 33). We envisioned that the α,β-unsaturated 
δ-lactone moiety in pironetin could be installed via a ring expansion of β-lactone 103. The C12-
C13 propenyl unit could be made via an allylic cuprate addition to tosylate 104 followed by 
olefin isomerization. Four contiguous syn, anti, syn stereocenters in the tosylate 104 will be 
made from masked dipropionate β-lactone 105 which will be made from β-lactone 106. The β-
lactone 106 will be synthesized by [2+2] cycloaddition of 3-(4-methoxybenzyloxy)-
propionaldehyde 107 and in situ generated methyl ketene.   
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Figure 33. Retrosynthetic analysis of (−)-Pironetin 
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4.3 SYNTHESIS OF (―)-PIRONETIN 
The synthesis of (–)-pironetin began from 3-(4-methoxybenzyloxy)-propionaldehyde 107 which 
was prepared according to the published procedure.73,74 Lactone 106 was prepared in 70% yield 
(99% ee) from aldehyde 107 under standard alkaloid-catalyzed AAC conditions (LiClO4, 
EtCOCl, iPr2NEt, CH2Cl2/Et2O, –78 °C) employing 10 mol % of the TMS-QD (Scheme 3). Ring 
opening of the enantioenriched β-lactone 106 by N,O-dimethylhydroxyl amine75 followed by 
triethylsilyl (TES) protection of secondary alcohol afforded the β-silyloxy amide 109 in 97% 
yield over 2 steps. Amide 109 was then reduced with iBu2AlH to α-chiral aldehyde 110 in 96% 
yield. 
 
Scheme 3. Synthesis of α-methyl β-triethylsiloxy chiral aldehyde 
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Aldehyde 110 was then used as the coupling partner in a double diastereoselective AAC 
reaction (Table 16).  The first test reaction consisted of 2.0 equiv of LiI and 10 mol% of TMS-
QN, 2.5 equiv of iPr2NEt, 2.0 equiv of propionyl chloride and at –40 °C,  under these conditions, 
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aldehyde 110 underwent facile [2+2] cycloaddition with in situ generated methyl ketene to afford 
β-lactone 111 in 62% yield as single diastereomer (1H NMR of crude reaction mixture); however, 
reaction did not proceed to full conversion and a small amount of α, β-unsaturated aldehyde was 
formed via β-elimination. By changing the reaction temperature to –78 °C and increasing the LiI 
to 3 equiv, the [2+2] cycloaddition proceeded to full conversion and produced syn, anti, syn β-
lactone 111 in 87% yield as a single diastereomer. 
 
Table 16. Effect of LiI stoichiometry on the AAC reaction 
a Isolated yields of purified products.  b Reaction was performed using  10 mol% TMS-QN, 2.5     
   equiv of iPr2NEt and 2.0 equiv of propionyl chloride.
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3.0 equiv LiI
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 Using the mechanism we proposed for achiral aldehyde AAC reaction, we have 
interpreted this AAC reaction involving chiral aldehyde electrophiles using the well-established 
models that accurately predict and rationalize the stereochemical outcome of analogous aldol 
additions.76 Due to the steric bulk of the alkaloid, the activated acyl ammonium enolate derived 
from methyl ketene and alkaloid is a Z-isomer.11 With the nucleophilic addition of Z-enolate to 
an α-substituted aldehyde, anti-Felkin-Anh induction is generally adopted to avoid the syn-
pentane non-bonding interaction involved in the Felkin-Anh model.76 So transition state A for 
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the double diastereoselective AAC reaction in Figure 34 would be expected to be lower energy 
than transition state B, thus the β-lactone 111 was formed in high yield and excellent 
diastereoselctivity.  
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Figure 34. Postulated transition state for AAC reaction 
  
Having successfully established the four contiguous stereogenic centers in pironetin, the 
next phase of our synthesis focused on installing the terminal C12-C13 propenyl unit.  Reduction 
of β-lactone 111 by iBu2AlH generated 1,3-diol 112 in 59-70% yield. Selective tosylation of 
primary hydroxyl group provided tosylate 113 in 70% yield.77 In the presence of 2,6-di-tert-
butyl-4-methyl-pyridine, methylation of secondary alcohol by methyl triflate78 produced the 
methyl ether 114 in low yield with the concomitant deprotection of TES ether (Scheme 4). 
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Scheme 4. Synthesis of protected tetraol 
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Since the TES protection group found to be labile under reaction conditions, we 
examined more robust protection group tert-butyldimethylsilyl (TBS). The synthesis of α-methyl 
β-tert-butyldimethylsiloxyl chiral aldehyde 116 was straightforward. Ring opening of highly 
enantioenriched β-lactone 106 by in situ generated N,O-dimethylhydroxyl amine-aluminium salt 
followed by TBS protection of secondary alcohol afforded the β-silyloxy amide 115 in 97% yield 
over 2 steps. Amide 115 was reduced to α-chiral aldehyde 116 on treatment with iBu2AlH in 
96% yield (Scheme 5). 
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Scheme 5. Synthesis of α-methyl β-tert-butyl-dimethylsiloxy chiral aldehyde 
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This more steric bulky aldehyde 116 was then employed as the coupling partner in the double 
diastereoselective AAC reaction (Table 17). Subjecting aldehyde 116 to the aboved mentioned 
optimal AAC reaction conditions for TES-protected aldehyde 110  (3.0 equiv of LiI, 10 mol% 
TMS-QN, 2.5 equiv of iPr2NEt, and 2.0 equiv of propionyl chloride at –40 °C), however, under 
these conditions, the reaction only proceeded to 60% conversion and 30% yield.  Again, by 
adjusting the reaction condition to –78 °C and 5 equiv of LiI, the [2+2] cycloaddition proceeded 
to completion and the desired β-lactone 117 was formed in 95% yield as single diastereomer (1H 
NMR of crude reaction mixture). 
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Table 17. Effect of β-protection group on AAC reaction 
a Isolated yields of purified products.  b Reaction was performed using  10 mol% TMS-QN, 
2.5 equiv of iPr2NEt and 2.0 equiv of propionyl chloride.
Lewis Acid
3.0 equiv LiI
5.0 equiv LiI
entry
a
b
OTBS
Me
OPMB
OTBS
Me
OPMB
O
Me
O
LiI, TMS-QN,  iPr2NEt
Et2O/CH2Cl2
H
O
Cl
Me
O
+
Temp (°C) Yield (%)
−40
−78
30
95
dr
>95:5
>95:5
116 117
 
 
Compare to the TES-protected β-lactone 111, the yield for iBu2AlH reduction of TBS-
protected β-lactone 116 and the following tosylation of primary alcohol became much higher, the 
tosylate 118 was formed in 81% yield over 2 steps (Scheme 6). Then the methylation of 
secondary alcohol 118 was investigated,79 under the optimal conditions (6 equiv of proton 
sponge and Meerwein’s salt), the protected tetraol 119 was produced in 82% yield (Scheme 6).   
 
Scheme 6. Synthesis of new protected tetraol 
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With the protected tetraol 119, several in situ generated allylic cuprates were screened to 
establish the optimal reaction conditions for effecting the introduction of the terminal olefin 
(Table 18).  Treatment of tosylate with excess amount of in situ generated cuprates was 
envisioned to result in nucleophilic attack of cuprates to tosylate to form terminal olefin 120.80 
Cuprates derived from copper cyanide and copper iodide provided the desired olefin product 120, 
but in modest yields (50-62%, entry a, b). The cuprate derived from 5 equiv of copper bromide 
and 10 equiv of allyl magnesium bromide afforded the product 120 in 85% yield (entry c).  
 
Table 18. Effect of copper salts on the substitution reaction 
a Isolated yields of purified products.  b Reaction was performed  (−20 to 0 °C)
3.0 equiv CuI
5.0 equiv CuBr
entry
b
c
OTBS
Me
OPMB
CuX, Et2O
Yield (%)
6 equiv
10 equiv
60-62
85
OMe
Me
TsO
MgBr OTBS
Me
OPMB
OMe
Me
CuX
3.0 equiv CuCNa 6 equiv 50
MgBr
119 120
 
 
Then by using iridium-catalyzed olefin isomerization developed by the Nelson group,81 
this terminal olefin 120 was regioselectively and quantitatively converted to internal olefin 121 
catalyzed by in situ generated iridium cation from 1 mol% [Ir(COE)2Cl]2, 6 mol% PCy3 and 2 
mol% NaBPh4 (eq 24). 
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Me
OMe OTBS
Me
OPMB
Me
OMe OTBS
Me
OPMB
PCy3, NaBPh4
[Ir(COE)2Cl]2
99%
CH2Cl2/CH3COCH3
rt
Me
(24)
120 121
 
Deprotection of PMB ether 121 by DDQ82 formed the primary alcohol 122 in 81% yield which 
was converted to the aldehyde 123 by Swern oxidation in 88% yield (eq 25).  
 
Me
OMe OTBS
Me Me
OMe
CHO
OTBS
Me
DDQ
81% 88%
CH2Cl2/PH 7
DMSO, (COCl)2
Et3N, CH2Cl2
0 °C
Me
Me
OMe OTBS
Me
OH
Me Me
(25)
122 123121
OPMB
 
 
Having obtained the chiral aldehyde 123, the AAC reaction for this aldehyde 123 was examined 
to set up the last two stereocenters. First, the standard alkaloid-catalyzed AAC reaction condition 
(10 mol% of TMS-QD, 1.0 equiv of LiI, 2.5 equiv of iPr2NEt and 2 equiv of butyryl chloride) 
was employed for the chiral aldehyde 123 and in situ generated ethyl ketene [2+2] cycloaddition 
(eq 26), however, there was no β-lactone 124 formation, the starting aldehyde was almost 
untouched and the major side product is ethyl ketene dimer.  
LiI, TMS-QD,  iPr2NEt
Et2O/CH2Cl2
Cl
Et
O
+
Me
OMe
CHO
OTBS
Me
Me
Me
OMe OTBS
Me
Me
O
Et
O
(26)
123 124  
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Since the alkaloid/LiI system did not catalyzed the [2+2] cycloaddition between aldehyde 123 
and ethyl ketene, the 2nd generation Al-catalyzed AAC reaction conditions was tried for the [2+2] 
cyclocondensation between aldehyde 123 and ethyl ketene. We were pleased to find that the 
chiral aldehyde 123 was converted to β-lactone 124 in 25% yield under the 2nd generation Al-
triamine catalyzed AAC reaction condition (20 mol% Al-triamine, nPrCOBr, iPr2NEt, BTF, –25 
°C (Table 19). The yield of β-lactone could be increased to 65% by increasing the catalyst 
loading to 50 mol%, and the diastereoselectivity is excellent (>90% de, 1H NMR of crude 
reaction mixture). 
Table 19. Ethyl ketene AAC reaction 
a Isolated yields of purified products.  b Reaction 
was performed using  2.5 equiv of iPr2NEt and 
2.0 equiv of butyral bromide.
 Al (mol%)
20
50
entry
a
b
Al-catalyst,  iPr2NEt
Br
Et
O
Yield (%)
25
65
dr
>95:5
+
Me
OMe
CHO
OTBS
Me
Me
Me
OMe OTBS
Me
Me
O
Et
O
N
N
N
SO2CF3O2S
iPr iPr
CF3
Al(III) Catalyst
F3C
CF3
Al
Me
BTF, −25 °C
123 124
>95:5
 
 
Having set up all stereocenters for pironetin, only the extension of β-lactone 124 to α,β-
unsaturated-δ-lactone 128 was necessary to complete the total synthesis. We proposed following 
procedure to achieve this transformation (β-lactone to α,β-unsaturated-δ-lactone, Figure 35). 
Ring-opening of the β-lactone by in situ generated ester enloate would produce β-keto ester, 
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which would exit as the mixture of β-keto ester and its tautomer enol ester, reduction of β-keto 
ester would give β-hydro ester, then under acidic conditions, β-hydro ester would be expected to 
undergo lactonization and dehydration, forming the α,β-unsaturated-δ-lactone. 
O
R2
O
R1
OR
O- M+
Me OR
O
+ ORR1
OO
R2
OH
O
O
R2
R1
Enolization
ORR1
OOH
R2
OH
Ring-opening
Reduction
OH
O
O
R2
R1
LactonizationDehydration
 
Figure 35. Synthesis of α, β-unsaturated δ-lactone from β-lactone 
 
Then this proposed route for synthesizing of α,β-unsaturated-δ-lactone from β-lactone 
was applied to our synthesis (Scheme 8). Ring opening of β-lactone 124 by in situ generated tert-
butyl acetate magnesium enolate gave β-keto ester 125 in 66% yield.  Sodium borohydride 
reduction of β-keto ester 125 gave the β-hydro ester 126 in 75% yield. TFA mediated 
deprotection of tert-butyl ester and TBS ether, lactonization forming β-hydroxy σ-lactone 127 in 
80% yield, after dehydration of the β-hydroxy σ-lactone 127, pironetin 128 was obtained in 84% 
yield. The β-hydroester 126 can also be directly transformed to (–)-pironetin 128 in 75% yield by 
treated with TsOH at 100 °C, deprotection of tert-butyl group, TBS group, lactonization and 
dehydration occurred in the last step. 
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Scheme 7. Complete the synthesis of pironetin 
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In summary, catalytic asymmetric synthesis of β-lactones methodologies have been 
successfully applied to the total synthesis of the potent antitumor agent (–)-pironetin. The route 
encompassed 16 steps and afforded pironetin in 5.9% overall yield from the inexpensive and 
readily available starting material 3-(4-methoxybenzyloxy)-propionaldehyde 107. Asymmetric 
AAC reactions were responsible for directly establishing all the stereogenic centers in (–)-
pironetin. Highlights of the synthesis include an efficient iridium-catalyzed olefin isomerization 
and a facile transformation of β-lactone to α,β-unsaturated δ-lactone. 
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4.4 SYNTHESIS OF α,β-UNSATURATED δ-LACTONES FROM β-LACTONES 
Enantioenriched α,β-unsaturated δ-lactones are key structural subunit of widely occurring natural 
products, the synthesis of which have generated considerable interest. During the synthesis of 
pironetin, a facile transformation of β-lactone to α,β-unsaturated δ-lactone was developed to 
complete the synthesis. This method was then used for a variety of simple β-lactones to generate 
a small δ-lactone library. Ring-opening of β-lactones by in situ generated ester enloate formed 
the β-keto esters 129, which were then reduced by NaBH4 to form β-hydroxy esters 130 (Scheme 
7).  
 
Scheme 8. Synthesis of β-hydroxy-ester 
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Then depend on the property of the R1 group (aromatic or aliphatic), two different procedures 
were employed to convert these β-hydroxy esters 130 to α,β-unsaturated δ-lactones. When the 
R1 is aromatic group, 2 step-procedure was used: 1. Trifluoroacetic acid mediated deprotection 
of tert-butyl ester and lactonization; 2. TsOH catalyzed dehydration (eq 27).  
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OO
R2
R1 OH
O
O
R2
R1
TFA TsOH
toluene
100 °C0 °C
R
R1 = Aromatic
R
OtBuR1
OOH
R2
OH
R
(27)
130  
When the R1 is aliphatic group, 1 step-procedure can be used: TsOH catalyzed deprotection of 
tert-butyl ester, lactonization and dehydration directly forming δ-lactone (eq 28).83  When R1 is 
aromatic group, we had to use 2 step-procedure, because if we use 1 step-procedure, under TsOH 
and high temperature, the δ benzylic position in 130 is very easy to form benzyl cation, thus the 
δ-chiral center is epimerized.  
R1 = Aliphatic
O
O
R2
R1
TsOH
toluene
100 °C
R
OtBuR1
OOH
R2
OH
R
(28)
130  
 
After identifying the optimal reaction procedures, we then explored reaction scope as a 
function of β-lactones structure for β-lactone to δ-lactone transformation. Table 20 listed some 
specific examples. Ring opening of the β-lactones derived from aliphatic aldehydes (chain or α-
branched) by different tert-butyl ester derived lithium enolate formed different β-keto esters 
(131-134) in moderate to excellent yield (51-92%). Then by using the 2 step proceures I 
mentioned above, these different β-keto esters was converted to α, β unsaturated δ-lactones 
(135-138) in good yield (50-68%).  
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Table 20. α, β-unsaturated δ-lactones from aliphatic aldehyde derived β-lactones  
O
O
Ph
Me
O
O
Ph
Me
Ph
O
O
Me
O
O
Ph
Me
Me
Me
O
Me
O
OtBu
OO
Me
OH
β-lactone β-keto ester  (% yield) δ-lactone (% yield over 2 steps)
Ph
Ph
OtBu
OO
Me
OHPh
Me
92% 68%
74% 58%
O
Me
O
OtBu
OO
Me
OH
Me
71% 53%
OtBu
OO
Me
OHPh
Ph
51% 50%
131 135
132 136
133 137
134 138
 
 
 
Table 21 listed some examples for benzyladehyde derived β-lactones. Again by using the 3 steps 
proceure I mentioned above, these β-lactones were converted to β-keto esters (139-141) in good 
yield (70-83%), and then to α, β-unsaturated δ-lactones (142-144) in 53-64% yield.  
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Table 21. α, β-unsaturated δ-lactones from aromatic aldehyde  derived β-lactones  
O
Me
O
OtBu
OO
Me
OH
β-lactone β-keto ester  (% yield) δ-lactone (% yield over 3 steps)
OtBu
OO
Et
OH
72%
83%
OtBu
OO
Et
OH
Me 70%
O
O
Ph
Me
O
O
Ph
Et
O
O
Ph
Et
Me
O
Et
O
64%
53%
59%139
140
141
142
143
144
 
 
In summary, an efficient method for transforming of β-lactones to α,β-unsaturated δ-lactones 
was developed,  a series of syntnetic useful building block  α,β-unsaturated δ-lactones has been 
easily synthesized in moderate yield. 
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 4.5 EXPERIMENTALS 
 
 
(3S, 4R)-4-[2-(4-Methoxy-benzyloxy)ethyl]-3-methyloxetan-2-one 106: 
To a solution of TMS-QD (0.926 g, 2.32 mmol) and LiClO4 (0.737 g, 
6.95 mmol) in 23 mL of diethyl ether was added 46 mL of CH2Cl2 and the 
reaction mixture was cooled to −78 °C. To the resulting mixture was added N, N-
diisopropylethylamine (10.0 mL, 57.9 mmol) followed by 3-(4-methoxy-benzyloxy)-
propionaldehyde 107 (4.49 g, 23.2 mmol). A solution of propionyl chloride (4.0 mL, 46.4 mmol) 
in 6.0 mL of CH2Cl2 was then added over 1 h by syringe pump. The reaction mixture was stirred 
for 18 h then was quenched at the −78 °C by adding 100 mL of Et2O and 100 mL saturated 
aqueous NH4Cl solution. The mixture was extracted by Et2O (3 x 100 mL). The organic layer 
was washed by brine and dried over Na2SO4 and concentrated in vacuo. The crude product 
mixture was purified by flash chromatography (15% ethyl acetate in hexane) gave 4.06 g (70%) 
of the title compound as a colorless oil (syn: anti = 89: 11). Separation of enantiomers by Chiral 
HPLC [Daicel ChiracelTM OD-H column, flow rate 1.0 mL/min, 10% iPrOH, 90% hexane, Tr: 
13.3 min (3R, 4S), 18.7 min (3S, 4R)] provided the only one enantiomer (3S, 4R) (99% ee).  [α]D 
+38.8 (c 1.81, CHCl3); IR (thin film):  1817, 1613, 1514, 1248cm-1; 1H NMR (300 MHz, CDCl3) 
δ 7.26 (d, J = 8.6 Hz, 2H),  6.89 (d, J = 8.7 Hz, 2H), 4.79 (ddd, J = 8.2, 6.5, 5.2 Hz, 1H), 4.46 (s, 
2H),  3.82 (s, 3H), 3.77(dq, J = 7.7, 6.5 Hz, 1H), 3.67-3.56 (m, 2H), 2.05-1.96 (m, 2H), 1.28 (d, J 
O
O
CH2CH2OPMBMe
106
 106 
= 7.8 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 172.1, 158.8, 129.7, 128.8, 113.3, 72.5, 72.3, 65.2, 
54.7, 46.8, 30.0, 7.7; HRMS (EI) m/z calcd for (M+) C14H18O4: 250.1205; found: 250.1203. 
 
               (2S, 3R)-3-Hydroxy-5-(4-methoxy-benzyloxy)-2-methyl-
pentanoic acid methoxy-methyl-amide 145: To a suspension of N, 
O-Dimethyl-hydroxylamine hydrochloride (2.26 g, 23.2 mmol) in 
40 mL of CH2Cl2 at 0 °C was added dimethylaluminium chloride (23.2 mL, 1.0 M solution in 
hexanes, 23.2 mmol) dropwise. The resulting mixture was warmed to ambient temperature and 
stirred for 2 h, then cooled to  −25 °C and a solution of 106 (2.90 g, 11.6 mmol) in 30 mL 
CH2Cl2 was added dropwise. The reaction mixture was stirred 2h then was quenched at the −25 
°C by adding 50 mL of aqueous Rochelle solution. The mixture was extracted by CH2Cl2 (3 x 
100 mL). The organic layer was washed by brine and dried over Na2SO4 and concentrated in 
vacuo. The crude product was used without purification. [α]D +10.1 (c 1.92, CHCl3); IR (thin 
film): 3459 (br), 1655, 1248cm-1; 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H), 6.87 (d, 
J = 8.7 Hz, 2H), 4.45 (s, 2H), 4.05 (dt, J = 9.1, 3.7 Hz, 1H), 3.93 (s, 1H), 3.81 ( s, 3H), 3.67 (s, 
3H), 3.67-3.63 (m, 2H), 3.19 (s, 3H), 2.92 (br, 1H), 1.89-1.78 (m, 1H), 1.73-1.63 (m, 1H), 1.20 
(d, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 177.1, 158.8, 130.0, 128.8, 113.3, 72.4, 70.1, 
67.6, 61.1, 54.8, 39.3, 33.7, 31.5, 11.1; HRMS (EI) m/z calcd for (M+) C16H25NO5: 311.1733; 
found: 311.1733. 
OPMBN
O
Me
OH
MeO
Me
145
 
           (2S, 3R)-3-(tert-Butyl-dimethyl-silanyloxy)-5-(4-methoxy-
benzyloxy)-2-methyl-pentanoic acid methoxy-methyl-amide 115:  
To a solution of 145 (11.6 mmol crude product from last step) in 35 
OPMBN
O
Me
OTBS
MeO
Me
115
 107 
mL of DMF at ambient temperature was added imidazole (1.71 g, 25.1 mmol) followed by 
TBSCl (3.15 g, 20.9 mmol) and DMAP (142 mg, 1.16 mmol).  The reaction mixture was stirred 
for 20 h then was quenched by adding 100 mL saturated aqueous NH4Cl solution. The mixture 
was extracted by CH2Cl2 (3 x 150 mL). The organic layer was washed by brine and dried over 
Na2SO4 and concentrated in vacuo. The crude product mixture was purified by flash 
chromatography (10% ethyl acetate in hexane) gave 4.80 g (97% over 2 steps) of the title 
compound as a colorless oil.  [α]D +0.30 (c 1.76, CHCl3); IR (thin film): 1661, 1514, 1250,  837, 
776cm-1; 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.41 (s, 
2H), 4.03 (dt, J = 7.9, 4.9 Hz, 1H), 3.81 (s, 3H), 3.61 (s, 3H), 3.58-3.49 (m, 2H), 3.15 (s, 3H), 
3.04-2.96 (m, 1H), 1.86-1.80 (m, 2H), 1.14 (d, J = 6.9, 3H), 0.89 (s, 9H), 0.062 (s, 3H), 0.050 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 176.1, 159.1, 130.6, 129.2, 113.6, 72.4, 71.3, 66.2, 61.1, 55.2, 
41.2, 35.4, 32.1, 25.9, 18.0, 14.3, –4.4, –4.5; HRMS (ESI) m/z calcd for (M++Na) 
C22H39NO5SiNa: 448.2495; found: 448.2452.  
 
        (2S, 3R)-3-(tert-Butyl-dimethyl-silanyloxy)-5-(4-methoxy-
benzyloxy)-2-methyl-pentanal 116: To a solution of 115 (4.45 g, 10.45 
mmol) in 50 mL of THF at −50 °C was added DIBAL-H (13.0 mL, 1.0 M 
in hexanes, 13.0 mmol) over 30 min by syringe pump. The reaction mixture was stirred for 30 
min then was quenched by adding 100 mL aqueous Rochelle solution. The mixture was extracted 
by Et2O (3 x 100 mL). The organic layer was washed by brine and dried over Na2SO4 and 
concentrated in vacuo. The crude product mixture was purified by flash chromatography (11% 
ethyl acetate in hexane) gave 3.68 g (96%) of the title compound as a colorless oil. [α]D +47.7 (c 
1.46, CHCl3); IR (thin film): 1726, 1613, 1514, 1250, 837, 776cm-1; 1H NMR (300 MHz, CDCl3) 
OPMBH
O
Me
OTBS
116
 108 
δ 9.78 (s, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 4.45 (d, J = 11.5 Hz, 1H), 4.39 
(d, J = 11.5 Hz, 1H), 4.31 (ddd, J = 7.2, 5.7, 3.7 Hz, 1H), 3.82 (s, 3H), 3.49 (t, J = 5.7 Hz, 2H), 
2.53-2.44 (m, 1H), 1.82-1.77 (m, 2H), 1. 06 (d, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.072 (s, 3H), 
0.047 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 204.3, 159.0, 130.1, 129.0, 113.5, 72.4, 69.0, 65.9, 
54.8, 51.3, 34.4, 25.5, 17.7, 7.5, –4.7, –4.9; HRMS (ESI) m/z calcd for (M++Na) C20H34O4SiNa:  
389.2124; found: 389.2114.  
 
4-(2-(tert-Butyl-dimethyl-silanyloxy)-4-(4-methoxy-
benzyloxy)-1-methylbutyl)-3-methyl-oxetan-2-one 117: To a 
suspension of TMS-QN (397 mg, 0.99 mmol) and LiI (6.64 g, 49.59 
mmol) in 4.5 mL of diethyl ether was added 40.0 mL of CH2Cl2 and the reaction mixture was 
cooled to −78 °C. To the resulting mixture was added N, N-diisopropylethylamine (4.3 mL, 24.9 
mmol) followed by a solution of 116 (3.43 g, 9.92 mmol) in 8.0 mL CH2Cl2. A solution of 
propionyl chloride (1.73 mL, 20.0 mmol) in 6.0 mL CH2Cl2 was then added over 3 h by syringe 
pump. After the addition of propionyl chloride the reaction mixture was quenched at the −78 °C 
by adding 100 mL of Et2O and 100 mL saturated aqueous NH4Cl solution. The mixture was 
extracted by Et2O (3 x 100 mL). The organic layer was washed by brine and dried over Na2SO4 
and concentrated in vacuo. The crude product mixture was purified by flash chromatography 
(9% ethyl acetate in hexane) gave 3.60 g (91%) of the title compound as a single diastereomer. 
[α]D –20.3 (c 2.28, CHCl3); IR (thin film): 1824, 1613, 1250cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.25 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.47 (d, J = 11.6 Hz, 1H), 4.41 (dd, J = 11.1, 
6.3 Hz, 1H), 4.36 (d, J = 11.4 Hz, 1H), 4.10 (t, J = 6.2 Hz, 1H), 3.82 (s, 3H), 3.75 (m, 1H), 3.43 
(t, J = 6.4 Hz, 2H), 1.88-1.78 (m, 3H), 1.26 (d, J = 7.7 Hz, 3H), 0.89 (s, 9H), 0.81 (d, J = 6.7 Hz, 
OPMB
Me
OTBSO
Me
O
117
 109 
3H), 0.065 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 172.6, 159.0, 130.2, 129.1, 113.7, 75.9, 72.5, 
67.5, 66.4, 55.1, 46.3, 37.0, 35.0, 25.8, 18.0, 8.2, 7.3, –4.5, –5.0; HRMS (EI) m/z calcd for (M+–
tBu) C19H29O5Si: 365.1784; found: 365.1786.  
  
(2S,3R,4R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-7-(4-
methoxy-benzyloxy)-2,4-dimethyl-heptane-1,3-diol 146: To a 
solution of 117 (3.60 g, 8.52 mmol) in 60 mL of THF at −50 °C 
was added DIBAL-H (25.6 mL, 1.0 M in hexanes, 25.6 mmol) over 30 min by syringe pump. 
The reaction mixture was stirred for 10 min then was quenched by adding 50 mL of Et2O and 50 
mL aqueous Rochelle solution. The mixture was extracted by Et2O (3 x 100 mL). The organic 
layer was washed by brine and dried over Na2SO4 and concentrated in vacuo. The crude product 
was used without purification. [α]D +33.0 (c 1.99, CHCl3); IR (thin film): 3465 (br), 1514, 1250, 
837, 778cm-1; 1H NMR (300 MHz, CDCl3) δ 7.26, (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 
4.46 ( d, J = 11.5 Hz, 1H), 4.40 (d, J = 11.4 Hz, 1H), 4.00-3.96 (m, 1H), 3.94 (dd, J = 10.3, 2.0 
Hz, 1H), 3.82 (s, 3H), 3.80 (dd, J = 10.5, 3.6 Hz, 1H), 3.68 (dd, J = 10.6, 5.4 Hz, 1H), 3.60-3.48 
(m, 2H), 1.94-1.83 (m, 3H), 1.66-1.63 (m, 1H), 0.96 (d, J = 7.0 Hz, 3H), 0.90 (s, 9H), 0.75 (d, J = 
7.1 Hz, 3H), 0.133 (s, 3H), 0.074 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.1, 130.4, 129.2, 
113.7, 76.0, 74.9, 72.5, 67.8, 66.6, 55.2, 39.7, 36.2, 31.1, 25.6, 17.8, 13.4, 8.3, –4.5, –5.1; HRMS 
(ESI) m/z calcd for (M++Na) C23H42O5SiNa:  449.2699; found: 446.2668. 
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(2S,3R,4R,5R)-Toluene-4-sulfonic acid 5-(tert-
butyldimethyl-silanyloxy)-3-hydroxy-7-(4-methoxy-
benzyloxy)-2,4-dimethyl-heptyl ester 118: To a solution of 146 
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(1.81 g, 4.24 mmol) in 40 mL of CH2Cl2 at ambient temperature was added pyridine (840 mg, 
10.61 mmol) followed by DMAP (104 mg, 0.85 mmol) and TsCl (1.21 g, 6.37 mmol).  The 
reaction mixture was stirred for 22 h then was quenched by adding 40 mL CH2Cl2 and 50 mL 
saturated aqueous NH4Cl solution. The mixture was extracted by CH2Cl2 (3 x 80 mL). The 
organic layer was washed by brine and dried over Na2SO4 and concentrated in vacuo. The crude 
product mixture was purified by flash chromatography (7% ethyl acetate in hexane) gave 2.05 g 
(83% over 2 steps) of the title compound as a colorless oil. [α]D +18.6 (c 1.86, CHCl3); IR (thin 
film): 3469 (br), 1613, 1514, 1361, 1249, 964, 838cm-1; 1H NMR (300 MHz, CDCl3) δ 7.80 (d, J 
= 8.3 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 4.45 (d, 
J = 11.5 Hz, 1H), 4.39 (d, J = 11.5 Hz, 1H), 4.12 (d, J = 7.3 Hz, 1H), 4.09 (d, J = 7.2 Hz, 1H), 
3.98-3.91 (m, 2H), 3.82 (s, 3H), 3.70 (dd, J = 10.2, 1.7 Hz, 1H), 3.56-3.47 (m, 2H), 2.44 (s, 3H), 
1.92-1.70 (m, 4H), 0.87 (s, 9H), 0.84 (d, J = 6.8 Hz, 3H), 0.69 (d, J = 7.1 Hz, 3H), 0.094 (s, 3H), 
0.057 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.0, 144.3, 133.2, 130.3, 129.6, 129.1, 127.7, 
113.6, 74.6, 73.5, 72.4, 71.7, 66.4, 55.1, 39.3, 35.2, 31.0, 25.6, 21.4, 17.7, 13.0, 8.1, –4.6, –5.2; 
HRMS (ESI) m/z calcd for (M++Na) C30H48O7SSiNa: 603.2788; found: 603.2778.  
 
(2S,3R,4R,5R)-Toluene-4-sulfonic acid 5-(tert-
butyldimethyl-silanyloxy)-3-methoxy-7-(4-methoxy-
benzyloxy)-2,4-dimethyl-heptyl ester 119: To a solution of 118 
(2.09 g, 3.60 mmol) in 40 mL of CH2Cl2 at ambient temperature was added Proton Sponge (3.20 
g, 21.6 mmol) followed by Me3OBF4 (4.626 g, 21.6 mmol). The reaction mixture was stirred for 
8 h (prevention from light by covered flask with aluminum foil) then was quenched by adding 
100 mL of CH2Cl2 and 150 mL of saturated aqueous NH4Cl solution. The mixture was extracted 
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by CH2Cl2 (3 x 100 mL). The organic layer was washed by brine and dried over Na2SO4 and 
concentrated in vacuo. The crude product mixture was purified by flash chromatography (8% 
ethyl acetate in hexane) gave 1.73 g (81%) of the title compound as a colorless oil. [α]D –0.67 (c 
1.79, CHCl3); IR (thin film): 1514, 1365, 1249, 1189, 1178, 835cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 
8.7 Hz, 2H), 4.44 (d, J = 11.6 Hz, 1H), 4.38 (d, J = 11.6 Hz, 1H), 4.09-4.04 (m, 2H), 4.02-3.94 
(m, 1H), 3.81 (s, 3H), 3.41 (td, J = 6.8, 1.0 Hz, 2H), 3.33 (s, 3H), 3.26 (dd, J = 9.4, 1.7 Hz, 1H), 
2.46 (s, 3H), 2.02-1.95 (m, 1H), 1.86-1.75 (m, 2H), 1.56-1.50 (m, 1H), 0.87 (s, 9H), 0.77 (d, J = 
6.8 Hz, 3H), 0.67 (d, J = 6.9 Hz, 3H), 0.068 (s, 3H), 0.062 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
158.7, 144.3, 133.0, 130.2, 129.4, 128.6, 127.5, 113.3, 80.0, 72.3, 72.2, 69.0, 66.5, 60.3, 54.7, 
39.8, 35.4, 34.7, 25.7, 21.1, 17.9, 9.0, 8.8, –3.7, –4.6; HRMS (EI) m/z calcd for (M+–tBu) 
C27H41O7SSi: 537.2342; found: 537.2316.  
 
(3R,4R,5R,6S)-tert-Butyl-(3-methoxy-1-(2-(4-
methoxy-benzyloxy)-ethyl)-2,4-dimethyloct-7-enyloxy)-
dimethyl-silane 120: To a suspension of CuBr (825 mg, 5.75 
mmol) in 2.5 mL of Et2O at −20 °C was added allylmagnesium bromide (11.5 mL, 1.0 M in Et2O, 
11.5 mmol) dropwise and the reaction mixture was stirred for 30 min. To the resulting mixture 
was added a solution of 119 (683 mg, 1.15 mmol) in 4.0 mL Et2O. The reaction mixture was 
stirred 10 min at −20 °C, then warmed to ambient temperature and stirred for 4.5 h. The reaction 
mixture was quenched by adding 20 mL of saturated aqueous NH4Cl solution. The mixture was 
extracted by Et2O (3 x 40 mL). The organic layer was washed by brine and dried over Na2SO4 
and concentrated in vacuo. The crude product mixture was purified by flash chromatography 
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(6% ethyl acetate in hexane) gave 454 mg (85%) of the title compound as an oil.  [α]D –12.4 (c 
1.65, CHCl3); IR (thin film): 1640, 1614, 1514, 1249, 1097, 835cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.27 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.83 (ddt, 17.0, 10.2, 6.7 Hz, 1H), 
5.0 (m, 2H), 4.45 (d, J = 11.5 Hz, 1H), 4.40 (d, J = 11.5 Hz, 1H), 4.13 (td, J = 6.9, 1.4 Hz, 1H), 
3.81 (s, 3H), 3.47 (s, 3H), 3.43 (td, J = 6.8, 1.7 Hz, 2H), 3.13 (dd, J = 9.4, 1.7 Hz, 1H), 2.23-2.02 
(m, 2H), 1.89-1.82 (m, 2H), 1.69-1.40 (m, 4H), 0.89 (s, 9H), 0.83 (d, J = 6.7 Hz, 3H), 0.73 (d, J = 
6.9 Hz, 3H), 0.091 (s, 3H), 0.083 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.0, 139.0, 130.6, 
129.1, 114.3, 113.7, 84.7, 72.6, 69.3, 67.2, 60.8, 55.2, 40.7, 35.9, 34.4, 32.0, 26.0, 18.3, 12.8, 9.5, 
–3.4, –4.3; HRMS (EI) m/z calcd for (M+) C27H48O4Si: 464.3322; found: 464.3304.  
 
(3R,4R,5R,6S)-tert-Butyl-(3-methoxy-1-(2-(4-
methoxy-benzyloxy)-ethyl)-2,4-dimethyl-oct-6-enyloxy)-
dimethyl-silane 121: To a solution of NaBPh4 (7.7 mg, 
0.0225 mmol) in 0.2 mL of CH3COCH3 at ambient temperature was added a solution of 
[(cC8H14)2IrCl]2 (10.2 mg, 0.0113 mmol) and PCy3(19.0 mg, 0.0678 mmol) in 10.8 mL  of 
CH2Cl2. The reaction mixture was stirred for 5 min, then this catalyst solution was added to 120 
(550 mg, 1.185 mmol). The reaction mixture was stirred for 3 h then was filtered through silica 
gel eluting with 120 ml of Et2O. The filtrate was concentrated in vacuo and the crude product 
mixture was purified by flash chromatography (6% ethyl acetate in hexane) gave 539 mg (98%) 
of the title compound as a colorless oil. [α]D –8.5 (c 1.02, CHCl3); IR (thin film): 1614, 1249, 
1097, 835cm-1; 1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 
5.51-5.36 (m, 2H), 4.45 (d, J = 11.6 Hz, 1H), 4.40 (d, J = 11.6 Hz, 1H), 4.12 (t, J = 6.2 Hz, 1H), 
3.81 (s, 3H), 3.48 (s, 3H), 3.43 (td, J = 7.7, 2.4 Hz, 2H), 3.18 (dd, J = 9.4, 1.6 Hz, 1H), 2.15 (m, 
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1H), 2.01 (m,1H), 1.87 (dd, J = 6.8, 2.2 Hz, 1H), 1.82 (dd, J = 7.3, 3.6 Hz, 1H),  1.67 (d, J = 5.0 
Hz, 3H), 1.58 (br, 1H), 1.54-1.46 (m, 1H), 0.89 (s, 9H), 0.81 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.9 
Hz, 3H), 0.079 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 158.9, 130.5, 128.9, 126.0, 113.5, 83.6, 
72.4, 69.3, 67.0, 60.6, 54.9, 40.7, 38.2, 35.9, 35.5, 25.9, 18.2, 17.8, 12.7, 9.4, –3.5, –4.5; HRMS 
(EI) m/z calcd for (M+) C27H48O4Si: 464.3322; found: 464.3345.  
 
(3R,4R,5R,6S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-
methoxy-4,6-dimethyl-dec-8-en-1-ol 122: To a solution of 
DDQ (282 mg, 1.24 mmol) in 2.2 mL of CH2Cl2 and 0.45 mL of 
PH 7 buffer  at 0 °C was added a solution of 121 (486 mg, 1.05 mmol) in 7.0 mL of CH2Cl2. The 
resulting mixture was stirred for 40 min and then quenched by adding 10 mL of H2O. The 
mixture was extracted by Et2O (3 x 40 mL). The organic layer was washed by brine and dried 
over Na2SO4 and concentrated in vacuo. The crude product mixture was purified by flash 
chromatography (gradient 6% 10% 20% ethyl acetate in hexane) gave 291 mg (81%) of 
the title compound as a oil. [α]D –9.3 (c 1.40, CHCl3); IR (thin film): 3401(br), 1253, 1077, 835, 
774cm-1; 1H NMR (300 MHz, CDCl3) δ 5.51-5.35 (m, 2H), 4.15-4.10 (m, 1H), 3.69 (td, J = 6.5, 
1.4 Hz, 2H), 3.49 (s, 3H), 3.16 (dd, J = 9.2, 1.8 Hz, 1H), 2.15 (m, 1H), 2.01 (m, 1H), 1.84-1.76 
(m, 2H), 1.67 (d, J = 5.3 Hz, 3H), 1.64-1.59 (m, 2H), 0.91 (s, 9H), 0.83 (d, J = 6.8 Hz, 3H), 0.77 
(d, J = 7.0 Hz, 3H), 0.113 (s, 3H), 0.107 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 130.3, 126.3, 
84.2, 69.2, 60.8, 59.4, 40.2, 38.5, 38.2, 35.5, 25.9, 18.2, 17.9, 12.6, 9.6, –3.4, –4.4; HRMS (EI) 
m/z calcd for (M+–tBu) C15H31O3Si: 287.2042; found: 287.2050.  
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(3R,4R,5R,6S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-
methoxy-4,6-dimethyl-dec-8-enal 123: To a solution of DMSO 
(139 uL, 1.96 mmol) in 5.0 mL of CH2Cl2 at −78 °C was added 
(COCl)2 (490 uL, 2 M in CH2Cl2, 0.98 mmol) dropwise. The reaction mixture was stirred for 40 
min before adding a solution of 122 (270 mg, 0.785 mmol) in 2.5 mL of CH2Cl2. The resulting 
mixture was stirred for 30 min then Et3N (548 uL, 3.92 mmol) was added dropwise, the reaction 
mixture was stirred for another 30 min then warmed to ambient temperature and quenched by 
adding 10 mL of saturated aqueous NH4Cl solution. The mixture was extracted by CH2Cl2 (3 x 
40 mL). The organic layer was washed by brine and dried over Na2SO4 and concentrated in 
vacuo. The crude product mixture was purified by flash chromatography (6% ethyl acetate in 
hexane) gave 235 mg (88%) of the title compound as an oil.  [α]D –6.2 (c 1.62, CHCl3); IR (thin 
film): 2718, 1728, 1472, 1134, 1089, 836, 775cm-1; 1H NMR (300 MHz, CDCl3) δ 9.79 (t, J = 
2.4 Hz, 1H), 5.53-5.35 (m, 2H), 4.63 (td, J = 6.2, 1.8 Hz, 1H), 3.50 (s, 3H), 3.17 (dd, J = 9.2, 1.8 
Hz, 1H), 2.67 (ddd, J = 16.1, 6.2, 2.5 Hz, 1H), 2.55 (ddd, J = 16.1, 6.2, 2.3 Hz, 1H), 2.15 (m, 1H), 
2.05 (m, 1H), 1.76-1.66 (m, 1H), 1.67 (d, J = 4.9 Hz, 3H), 1.60-1.50 (m, 1H), 0.89 (s, 9H), 0.82 
(d, J = 6.9 Hz, 3H), 0.80 (d, J = 7.0 Hz, 3H), 0.13 (s, 3H), 0. 07 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 201.1, 130.3, 126.3, 83.9, 66.9, 60.6, 50.8, 42.6, 38.2, 35.5, 25.8, 18.2, 17.9, 12.8, 10.1, 
–3.8, –4.5; HRMS (EI) m/z calcd for (M+) C19H38O3Si: 342.2590; found: 342.2584. 
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4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-
3,5-dimethyl-non-7-enyl]-3-ethyl-oxetan-2-one 124: To a 
solution of Triamine ligand (169.5 mg, 0.25 mmol) in 2.0 ml 
of BTF at ambient temperature was slowly added a solution of AlMe3 (0.125 ml, 2.0 M in hexane, 
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0.25 mmol).  After stirring for 2 h, the resulting catalyst solution was cooled to −25 °C and N, N-
diisopropylethylamine (0.173 mL, 1.0 mmol) and butyryl bromide (0.212 mL, 2.0 mmol) were 
added consecutively.  The resulting heterogeneous mixture was stirred 20 min at −25 °C 
whereupon 123 (170 mg, 0.50 mmol) in 1.0 mL of BTF was added dropwise and the reaction 
was stirred 21 h at −25 °C.  The reaction was quenched at −25 °C by adding 10 ml of a 3% Et3N-
Et2O solution (v/v) and the resulting mixture was filtered through silica gel eluting with 60 ml of 
Et2O.  The filtrate was concentrated in vacuo and the crude product mixture was purified by flash 
chromatography (gradient 4% 6% ethyl acetate in hexane) gave 135 mg (65%) of the title 
compound.  [α]D +20.2 (c 1.06, CHCl3); IR (thin film):  1828, 1462, 1254, 836, 775cm-1; 1H 
NMR (300 MHz, CDCl3) δ 5.53-5.35 (m, 2H), 4.64 (dt, J = 6.5, 6.5 Hz, 1H), 4.20 (td, J = 6.9, 1.1 
Hz, 1H), 3.57(dt, J = 9.1, 7.4 Hz, 1H), 3.48 (s, 3H), 3.16 (dd, J = 9.5, 1.5 Hz, 1H), 2.15 (m, 1H), 
2.02 (m, 1H), 1.89 (t, J = 6.5 Hz, 2H), 1.85-1.79 (m, 1H), 1.74-1.66 (m, 1H), 1.67 (d, J = 4.7 Hz, 
3H), 1.62-1.60 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H), 0.91 (s, 9H), 0.82 (d, J = 6.8 Hz, 3H), 0.76 (d, J 
= 6.9 Hz, 3H), 0.11 (s, 3H), 0.10 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 172.0, 130.4, 126.4, 83.8, 
72.6, 69.2, 60.8, 54.2, 41.6, 38.3, 36.6, 35.6, 25.9, 18.3, 18.0, 17.6, 12.7, 12.1, 9.9, –3.7, –3.9; 
HRMS (EI) m/z calcd for (M+–tBu) C19H35O4Si: 355.2305; found: 355.2311.  
 
(4S,5R,7R,8R,9R,10S)-7-(tert-Butyl-
dimethyl-silanyloxy)-4-ethyl-5-hydroxy-9-
methoxy-8,10-dimethyl-3-oxo-tetradec-12-enoic 
acid tert-butyl ester 125: To a solution of KHMDS (1.14 mL, 0.5 M in toluene, 0.57 mmol) in 
1.0 mL of THF at −78 °C was added tert-butyl acetate (66.2 mg, 0.57 mmol). The reaction 
mixture was stirred for 1h.  Then this enolate solution was transferred to a suspension of 
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MgBr2·OEt2 (147 mg, 0.57 mmol) in 1.0 mL of THF. The resulting mixture was stirred for 
another 1h. Then 124 (47 mg, 0.114 mmol) was added to this mixture and stirred for 30 min. The 
reaction mixture was quenched by adding 10 mL of saturated aqueous NH4Cl solution. The 
mixture was extracted by Et2O (3 x 30 mL). The organic layer was washed by brine and dried 
over Na2SO4 and concentrated in vacuo. The crude product mixture was purified by flash 
chromatography (15% ethyl acetate in hexanes) gave 40 mg (66%) of the title compound and its 
tautomer as inseperatable mixture. IR (thin film): 3467 (br), 1733, 1709cm-1; 1H NMR (300 MHz, 
CDCl3) δ 5.50-5.33 (m, 2H), 4.14-4.10 (m, 1H), 4.04 (q, J = 4.9 Hz, 1H), 3.48 (d, J = 1.6 Hz, 2H), 
3.44 (s, 3H), 3.06 (dd, J = 8.2, 1.9 Hz, 1H), 2.75 (dt, J = 8.9, 4.3 Hz, 1H), 2.16-2.07 (m, 1H), 
2.02-1.93 (m, 1H), 1.88-1.73 (m, 3H), 1.67 (d, J = 5.2 Hz, 3H), 1.63-1.58 (m, 4H), 1.47 (s, 9H), 
0.92 (t, J = 7.4 Hz, 3H), 0.90 (s, 9H), 0.85 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H), 0.11 (s, 
3H), 0.10 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 206.6, 166.5, 130.2, 126.5, 84.7, 81.7, 71.6, 
69.3, 60.2, 59.0, 52.0, 40.7, 39.2, 38.6, 35.5, 28.3, 28.0, 26.0, 19.8, 17.9, 13.4, 12.2, 11.5, –3.8, –
4.3; HRMS (EI) m/z calcd for (M+) C29H56O6Si: 528.3846; found: 528.3842.  
 
(4S,5R,7R,8R,9R,10S)-7-(tert-Butyl-
dimethyl-silanyloxy)-4-ethyl-3,5-dihydroxy-9-
methoxy-8,10-dimethyl-tetradec-12-enoic acid 
tert-butyl ester 126: To a solution of 125 (27 mg, 0.05 mmol) in 1.0 mL of EtOH at 0 °C was 
added NaBH4 (6 mg, 0.16 mmol). The resulting mixture was stirred for 40 min and then 
quenched by adding 50 uL acetic acid. The mixture was extracted by ethyl acetate (3 x 30 mL). 
The organic layer was washed by brine and dried over Na2SO4 and concentrated in vacuo. The 
crude product used without purification. 
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  (–)-Pironetin 128: A solution of 126 (15 mg crude 
product from last step) and TsOH·H2O (5 mg) in 1.0 mL of 
toluene was heated at 110 °C for 30 min. The mixture was then 
cooled down to ambient temperature and diluted by adding 50 
mL of ethyl acetate. The resulting mixture was washed with 10 mL of aqueous NaHCO3 solution 
and brine consecutively; the organic layer was dried over Na2SO4 and concentrated in vacuo. 
The crude product mixture was purified by flash chromatography (40% ethyl acetate in hexanes) 
gave 4.6 mg (56% over two steps) of the title compound as a white solid.  [α]D –135 (c 0.35, 
CHCl3) {lit.53 [α]D –144 (c 0.50, CHCl3) 1H NMR (300 MHz, CDCl3) δ 7.02 (dd, J = 9.8, 6.0 Hz, 
1H), 6.03 (d, J = 9.8 Hz, 1H), 5.51-5.32 (m, 2H), 4.74 (m, 1H), 4.21 (brd, 1H), 3.48 (s, 3H), 3.45 
(d, J = 2.3 Hz, 1H), 2.99 (dd, J = 6.1, 4.4 Hz, 1H), 2.33-2.25 (m, 1H), 2.13-2.06 (m, 1H), 1.92-
1.84 (m, 2H), 1.81-1.76 (m, 1H), 1.74-1.65 (m, 3H), 1.67(d, J = 5.3 Hz, 3H), 1.58-1.46 (m, 1H), 
1.01 (d, J = 7.1 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 164.6, 150.6, 128.8, 126.9, 120.9, 91.1, 77.8, 67.5, 61.5, 39.1, 39.0, 37.3, 36.7, 36.2, 
20.8, 17.9, 15.2, 12.2, 11.0; HRMS (EI) m/z calcd for (M+−H2O) C19H30O3: 306.2195; found: 
306.2185.  
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General Procedure D for Ring Opening of β-lactone by Lithium Enolate: To a 
solution of iPr2NH (0.35 mL, 2.50 mmol) in 1.0 mL of THF at −78 °C was added nBuLi (1.56 
mL, 2.50 mmol), the resulting solution was stirred for 5 min. Then tert-butyl ester (2.50 mmol) 
was added to this solution and stirred for 45 min. Then a solution of β-lactone (0.5 mmol in 1.0 
mL THF) was added to this enolate mixture and stirred for 1-2 h. The reaction mixture was 
quenched by adding 20 mL of saturated aqueous NH4Cl solution. The mixture was extracted by 
Et2O (3 x 30 mL). The organic layer was washed by brine and dried over Na2SO4 and 
concentrated in vacuo. The crude product mixture was purified by flash chromatography gave β-
keto ester (major) and its tautomer (minor) as an inseperatable mixture. The 1H NMR and 13C 
NMR data were reported for major isomer. 
 
5-Hydroxy-4-methyl-3-oxo-7-phenyl-heptanoic acid 
tert-butyl ester 131: The General procedure D was followed  
employing 95 mg of β-lactone (0.50 mmol) and 338 µL (2.50 
mmol) of tert-butyl acetate.  Purification by flash chromatography (16% ethyl acetate in hexane) 
gave 130 mg (85%) of the title compound. IR (thin film):  3467, 1732, 1708 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.30-7.20 (m, 5H),  4.02 (dt, J = 6.5, 2.9 Hz, 1H), 3.47 (d, J = 15.4 Hz, 1H), 3.46 
(d, J = 15.4 Hz, 1H), 2.86 (ddd, J = 14.8, 9.4, 5.0 Hz, 1H), 2.75-2.60 (m, 2H), 1.92-1.81 (m, 1H), 
1.68-1.59 (m, 1H), 1.46 (s, 9H),  1.17 (d, J = 7.2 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 207.8, 
166.4, 141.6, 128.4, 128.3, 125.8, 82.1, 70.1, 50.9, 49.4, 35.7, 32.2, 27.9, 9.5; HRMS (EI) m/z 
calcd for (M+) C18H26O4: 306.1831; found:306.1829. 
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5-Hydroxy-4-methyl-3-oxo-5-phenyl-pentanoic acid tert-
butyl ester 139: The General procedure D was followed  
employing 80 mg of β-lactone (0.494 mmol) and 334 µL (2.469 mmol) 
of tert-butyl acetate.  Purification by flash chromatography (16% ethyl acetate in hexane) gave 
100 mg (72%) of the title compound. IR (thin film):  3497, 1732, 1708 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.43-7.34 (m, 5H),  5.21 (dd, J = 3.1, 3.0 Hz, 1H), 3.47 (d, J = 15.6 Hz, 1H), 3.46 (d, J 
= 15.6 Hz, 1H), 3.07 (d, J = 3.0 Hz, 1H), 3.06 (qd, J = 7.1, 3.8 Hz, 1H), 1.55 (s, 9H),  1.17 (d, J = 
7.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 207.7, 166.3, 141.4, 128.3, 127.4, 125.8, 82.2, 72.9, 
52.9, 49.7, 27.9, 9.8; HRMS (EI) m/z calcd for (M+) C16H22O4: 278.1518; found:278.1524. 
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-(Hydroxy-phenyl-methyl)-3-oxo-hexanoic acid tert-butyl 
ester 
a
 5-Hydroxy-2,4-dimethyl-3-oxo-7-phenyl-heptanoic 
acid tert-
4
140: The General procedure D was followed  
employing 176 mg of β-lactone (1.0 mmol) and 700 µL (2.5 mmol) of 
tion by flash chromatography (14% ethyl acetate in hexane) gave 242 
mg (83%) of the title compound. IR (thin film):  3468, 1732, 1708 cm
OH
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OtBu
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140
tert-butyl acetate.  Purific
-1; 1H NMR (300 MHz, 
CDCl3) δ 7.44-7.28 (m, 5H),  4.97 (dd, J = 5.5, 2.8 Hz, 1H), 3.29 (d, J = 15.5 Hz, 1H), 3.20 (d, J 
= 15.5 Hz, 1H), 3.13-3.11 (m, 1H), 2.99 (ddd, J = 9.5, 5.6, 4.1Hz, 1H), 1.90-1.79 (m, 1H), 1.74-
1.66 (m, 1H), 1.51 (s, 9H),  0.91 (t, J = 7.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 206.8, 166.1, 
141.7, 128.3, 127.6, 126.0, 81.8, 73.6, 60.5, 51.7, 27.8, 19.8, 11.9. 
 
OH
t
O O
Me
O Bu
Me
132
butyl ester 132: The General procedure D was 
followed employing 95 mg of β-lactone (0.50 mmol) and 377 µL 
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(2.50 mmol) of tert-butyl propionate.  Purification by flash chromatography (16% ethyl acetate 
in hexane) gave 111 mg (70%) of the title compound as 1: 1 diastereomer mixture. IR (thin film):  
3524, 1737, 1708 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-7.23 (m, 10H),  4.04 (dt, J = 9.0, 3.4 
Hz, 1H), 3.95 (dt, J = 9.3, 3.4 Hz, 1H), 3.67 (q, J = 7.1 Hz, 1H), 3.65 (q, J = 7.1 Hz, 1H), 2.96-
2.80 (m, 4H), 2.76-2.66 (m, 2H), 1.99-1.83 (m, 2H), 1.74-1.62 (m, 2H), 1.49 (s, 9H), 1.44 (s, 9H), 
1.33 (d, J = 7.1 Hz, 3H), 1.32 (d, J = 7.1 Hz, 3H), 1.23 (d, J = 7.1 Hz, 3H), 1.21 (d, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 211.6, 210.9, 169.3, 169.2, 141.7, 141.6, 128.4, 128.33 (2C), 
128.28, 125.83, 125.76, 82.0, 81.8, 70.6, 69.9, 53.1, 52.2, 49.9 (2C), 35.7 (2C), 32.3, 32.2, 27.8, 
27.7, 12.8, 12.5, 10.1, 9.8; HRMS (EI) m/z calcd for [M+-tBu] C15H20O4: 264.1362; 
found:264.1350. 
 
5-Cyclohexyl-5-hydroxy-2,4-dimethyl-3-oxo-pentanoic acid 
tert-butyl ester 134: The General procedure D was followed  
employing 84 mg of β-lactone (0.50 mmol) and 377 µL (2.50 mmol) 
of tert-butyl propionate.  Purification by flash chromatography (11% ethyl acetate in hexane) 
gave 105 mg (71%) of the title compound as 1: 1 diastereomer mixture.  IR (thin film):  3534, 
1739, 1708 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.68-3.52 (m, 4H),  3.01-2.91 (m, 2H), 2.10 (t, J 
= 1.4, Hz, 2H), 1.74 (m, 4H), 1.69 (m, 2H), 1.56 (m, 2H), 1.45 (s, 18H), 1.29 (d, J = 7.1 Hz, 3 H), 
1.28 (d, J = 7.1 Hz, 3 H), 1.22 (m, 4H), 1.12 (d, J = 7.0 Hz, 3 H), 1.11 (d, J = 7.2 Hz, 3 H), 0.95 
(m, 6H); 13C NMR (75 MHz, CDCl3) δ 212.0, 211.0, 169.4, 169.3, 82.0, 81.8, 75.1, 74.6, 52.5, 
52.0, 46.6, 46.4, 40.2, 39.6, 29.6, 29.3, 28.9, 28.8, 26.24, 26.19, 25.94, 25.90, 25.72, 25.69, 12.8, 
12.7, 9.0, 8.9; HRMS (EI) m/z calcd for (M+) C17H30O4: 298.2144; found:298.2136. 
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4-(Hydroxy-phenyl-methyl)-2-methyl-3-oxo-hexanoic acid 
tert-butyl ester 141: The General procedure D was followed  
employing 88 mg of β-lactone (0.50 mmol) and 377 µL (2.50 mmol) 
of tert-butyl propionate.  Purification by flash chromatography (11% ethyl acetate in hexane) 
gave 92 mg (69%) of the title compound. IR (thin film):  3501, 1736, 1707 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.40-7.35 (m, 5H),  4.92 (dd, J = 6.3, 2.8 Hz, 1H), 3.30 (q, J = 7.0 Hz, 1H), 3.15 
(ddd, J = 10.0, 6.3, 3.9 Hz, 1H), 2.80 (d, J = 2.9 Hz, 1H), 1.98-1.85 (m, 1H), 1.76-1.66 (m, 1H), 
1.51 (s, 9H),  1.04 (d, J = 7.0 Hz, 3 H), 0.93 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
208.7, 169.0, 142.0, 128.3, 127.7, 126.2, 81.7, 74.0, 59.9, 54.8, 27.9, 20.2, 12.1, 11.7; HRMS 
(ESI) m/z calcd for (M++Na) C18H26O4Na: 329.1729; found:329.1703. 
OH
Et
OtBu
O O
Me
141
  
 2-Benzyl-5-hydroxy-4-methyl-3-oxo-7-phenyl-
heptanoic acid tert-butyl ester 133: The General procedure D 
was followed employing 145 mg of β-lactone (0.76 mmol) and 
470 mg (2.28 mmol) of 3-Phenyl-propionic acid tert-butyl ester.  Purification by flash 
chromatography (9% ethyl acetate in hexane) gave 155 mg (51%) of the title compound as 1: 1 
diastereomer mixture. IR (thin film):  3466, 1738, 1708 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.38-7.14 (m, 20H),  4.00-3.93 (m, 1H), 3.92-3.86 (m, 2H), 3.65-3.59 (m, 1H), 3.20-3.06 (m, 4H), 
2.87-2.78 (m, 2H), 2.74-2.59 (m, 3H), 2.56-2.46 (m, 2H), 2.17 (d, J = 3.0 Hz, 1H), 1.88-1.76 (m, 
1H), 1.74-1.62 (m, 2H), 1.41 (s, 9H), 1.36 (s, 9H), 1.10 (d, J = 7.1 Hz, 3H), 0.85 (d, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 210.1, 209.7, 167.8 (2C), 141.7, 141.6, 138.3, 138.2, 128.9 
(2C), 128.5 (2C), 128.3 (4C), 126.63, 126.57, 125.84, 125.80, 82.5, 82.2, 69.9, 69.8, 60.6, 60.3, 
OH
Me
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51.3, 50.9, 35.7, 35.4, 34.3, 33.9, 32.19, 32.15, 27.80, 27.75, 9.3, 8.7; HRMS (ESI) m/z calcd for 
(M++Na) C25H32O4Na: 419.2198; found:419.2192. 
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General Procedure E for Preparation of δ-lactone (R = Aliphatic group): To a 
solution of β-keto ester (1.85 mmol) in 9 mL of EtOH at 0 °C was added NaBH4 (70 mg, 1.85 
mmol). The resulting mixture was stirred for 40 min and then quenched by slowly adding acetic 
acid until no gas evolution. The mixture was extracted by ethyl acetate (3 x 40 mL). The organic 
layer was washed by brine and dried over Na2SO4 and concentrated in vacuo. The crude product 
used without purification. A solution of β-hydro ester (crude product from NaBH4 reduction) and 
TsOH·H2O (175.6 mg, 0.923 mmol) in 15 mL of toluene was heated at 110 °C for 45 min. The 
mixture was then cooled down to ambient temperature and diluted by adding 100 mL of ethyl 
acetate. The resulting mixture was washed with 20 mL of aqueous NaHCO3 solution and brine 
consecutively; the organic layer was dried over Na2SO4 and concentrated in vacuo. The crude 
product mixture was purified by flash chromatography gave δ-lactone as single diasteromer 
(based on 1H NMR of crude product mixture). 
 
5-Methyl-6-phenethyl-5,6-dihydro-pyran-2-one 135: The general 
procedure E was followed employing 55 mg of β-keto ester (0.18 mmol) 
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and 6.8 mg (0.18 mmol) of NaBH4 and 17 mg (0.09 mmol) of TsOH·H2O.  Purification by flash 
chromatography (25% ethyl acetate in hexane) gave 23 mg (58% over 2 steps) of the title 
compound. IR (thin film):  1721 cm-1; [α]D +155 (c 0.63, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
7.34-7.21 (m, 5H), 6.94 (dd, J = 9.7, 6.1 Hz, 1H), 5.97 (dd, J = 9.7, 0.8 Hz, 1H), 4.41 (dt, J = 9.3, 
3.9 Hz, 1H), 2.93 (ddd, J = 14.2, 9.5, 5.3 Hz, 1H), 2.73 (ddd, J = 13.8, 9.1, 7.2 Hz, 1H), 2.41-
2.31 (m, 1H), 2.22-2.10 (m, 1H), 1.87-1.75 (m, 1H), 1.06 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 164.6, 151.5, 140.9, 128.50, 128.45, 126.1, 119.9, 79.0, 33.2, 32.2, 31.3, 11.3; HRMS 
(EI) m/z calcd for (M+) C14H16O2: 216.1150; found: 216.1154.  
 
3,5-Dimethyl-6-phenethyl-5,6-dihydro-pyran-2-one 136: The 
general procedure E was followed employing 34 mg of β-keto ester 
(0.106mmol) and 5.0 mg (0.13 mmol) of NaBH4 for 1st step and 16 mg 
crude β-hydro ester (0.05 mmol) and 9.5 mg (0.10 mmol) of 
TsOH·H2O for 2nd step.  Purification by flash chromatography (16% ethyl acetate in hexane) 
gave 13 mg (55% over 2 steps) of the title compound. IR (thin film):  1716 cm-1; [α]D +53.6 (c 
1.08, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.34-7.20 (m, 5H), 6.64 (dq, J = 6.3, 1.5 Hz, 1H), 
4.38 (dt, J = 8.9, 3.9 Hz, 1H), 2.92 (ddd, J = 14.6, 9.1, 5.0 Hz, 1H), 2.72 (ddd, J = 13.9, 9.3, 7.1 
Hz, 1H), 2.34-2.26 (m, 1H), 2.20-2.08 (m, 1H), 1.91 (dd, J = 1.4, 1.0 Hz, 3H), 1.83-1.74 (m, 1H), 
1.02 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.1, 145.6, 141.1, 128.51, 128.47, 
127.1, 126.1, 79.1, 33.25, 32.59, 31.4, 16.9, 11.5; HRMS (EI) m/z calcd for (M+) C15H18O2: 
230.1307; found: 230.1314.  
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6-Cyclohexyl-3,5-dimethyl-5,6-dihydro-pyran-2-one 138: The 
general procedure E was followed employing 65 mg of β-keto ester 
(0.218mmol) and 8.3 mg (0.218 mmol) of NaBH4 and 20 mg (0.105 mmol) 
of TsOH·H2O.  Purification by flash chromatography (9% ethyl acetate in 
hexane) gave 24 mg (53% over 2 steps) of the title compound. IR (thin film):  1742 cm-1; [α]D 
+169 (c 1.77, CHCl3); 1H NMR (300 MHz, CDCl3) δ 6.67 (dq, J = 6.6, 1.4 Hz, 1H), 3.97 (dd, J = 
10.0, 3.0 Hz, 1H), 2.42-2.37 (m, 1H), 2.34-2.26 (m, 1H), 1.91 (dd, J = 1.1, 1.0 Hz, 3H), 1.78-
1.59 (m, 5H), 1.33-1.19 (m, 4H), 0.99 (d, J = 7.0 Hz, 3H), 0.93-0.88 (m, 1H); 13C NMR (75 MHz, 
CDCl3) δ 166.4, 145.8, 127.1, 84.2, 38.1, 30.3, 29.5, 27.9, 26.3, 25.6, 25.3, 16.8, 11.0; HRMS 
(EI) m/z calcd for (M+) C13H20O2: 208.1463; found: 208.1454.  
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3-Benzyl-5-methyl-6-phenethyl-5,6-dihydro-pyran-2-
one 137: The general procedure E was followed employing 71 
mg of β-keto ester (0.18 mmol) and 6.8 mg (0.18 mmol) of 
NaBH4 for 1st step and 17.1 mg (0.09 mmol) of TsOH·H2O for 
2nd step.  Purification by flash chromatography (14% ethyl acetate in hexane) gave 27 mg (50% 
over 2 steps) of the title compound. IR (thin film):  1716, 1495, 1454 cm-1;  [α]D −66.6 (c 0.98, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.33-7.18 (m, 5H),  6.42 (dt, J = 6.3, 1.1 Hz, 1H), 4.36 
(dt, J = 9.1, 3.9 Hz, 1H), 3.66 (d, J = 15.9 Hz, 1H), 3.58 (d, J = 15.9 Hz, 1H), 2.90 (ddd, J = 14.7, 
9.8, 5.3 Hz, 1H), 2.69 (ddd, J = 13.9, 9.4, 6.9 Hz, 1H), 2.36-2.25 (m, 1H), 1.83-1.71 (m, 1H), 
1.00 (d, J = 7.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 165.5, 146.1,  141.0, 138.3, 131.2, 129.2, 
128.5 (2C), 128.4, 126.4, 126.1, 78.9, 36.4, 33.2, 32.6, 31.4, 11.4; HRMS (ESI) m/z calcd for 
(M++Na) C21H22O2Na: 329.1517; found:329.1511. 
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General Procedure F for Preparation of δ-lactone (R = Ph): To a solution of β-keto 
ester (0.15 M in EtOH) at 0 °C was added NaBH4 (1.0 eq). The resulting mixture was stirred for 
40 min and then quenched by slowly adding acetic acid until no gas evolution. The mixture was 
extracted by ethyl acetate (3 x 30 mL). The organic layer was washed by brine and dried over 
Na2SO4 and concentrated in vacuo. The crude product was dissolved in methylene chloride and 
anisole (0.1M, 5: 1 CH2Cl2: anisole) and the solution was cooled down to 0 °C and TFA (2 
mL/mmol diol) was added dropwise, then the resulting mixture was stirred at 0 °C for 2 h. The 
mixture was concentrated in vacuo. Then the crude mixture and TsOH·H2O (0.5 eq) in toluene 
(about 0.1 M) was heated at 110 °C for 30 min. The mixture was then cooled down to ambient 
temperature and diluted by adding 50 mL of ethyl acetate. The resulting mixture was washed 
with 10 mL of aqueous NaHCO3 solution and brine consecutively; the organic layer was dried 
over Na2SO4 and concentrated in vacuo. The crude product mixture was purified by flash 
chromatography gave δ-lactone (dr based on crude 1H NMR). 
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5-Methyl-6-phenyl-5,6-dihydro-pyran-2-one 142: The general 
procedure F was followed employing 17.7 mg of β-keto ester (0.0632 mmol) and 
3.0 mg (0.0793 mmol) of NaBH4 for 1st step and 0.12 mL TFA for 2nd step and 
6.0 mg (0.0316 mmol) of TsOH·H2O for 3rd step.  Purification by flash 
chromatography (16% ethyl acetate in hexane) gave 7 mg (59% over 3 steps) of the title 
compound (8:1 dr). IR (thin film):  1728 cm-1;  [α]D +471 (c 0.41, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 7.45-7.33 (m, 5H),  7.11 (dd, J = 9.6, 6.2 Hz, 1H), 6.10 (d, J = 9.7 Hz, 1H), 5.61 (d, J = 
3.5 Hz, 1H), 2.68-2.63 (m, 1H), 0.83 (d, J = 7.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 164.4, 
151.7,  137.0, 128.5, 127.9, 125.5, 120.1, 81.0, 34.8, 11.8; HRMS (EI) m/z calcd for (M+) 
C12H12O2: 188.0837; found:188.0845. 
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5-Ethyl-6-phenyl-5,6-dihydro-pyran-2-one 143: The general procedure 
F was followed employing 36 mg of β-keto ester (0.123 mmol) and 5.6 mg 
(0.148 mmol) of NaBH4 for 1st step and 0.24 mL TFA for 2nd step and 11.7 mg 
(0.062 mmol) of TsOH·H2O for 3rd step.  Purification by flash chromatography 
(16% ethyl acetate in hexane) gave 16 mg (64% over 3 steps) of the title compound (9:1 dr). IR 
(thin film):  1732 cm-1;  [α]D −442 (c 0.90, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.41-7.30 (m, 
5H),  7.18 (dd, J = 9.8, 6.2 Hz, 1H), 6.16 (q, J = 9.8 Hz, 1H), 5.62 (d, J = 3.7 Hz, 1H), 2.56-2.48 
(m, 1H), 1.37-1.27 (m, 2H), 0.81 (t, J = 7.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 164.3, 150.8,  
136.9, 128.4, 127.9, 125.5, 120.8, 81.3, 41.0,  20.9, 10.9; HRMS (EI) m/z calcd for (M+) 
C13H14O2: 202.0994; found:202.0996. 
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5-Ethyl-3-methyl-6-phenyl-5,6-dihydro-pyran-2-one 144: The 
general procedure F was followed employing 70 mg of β-keto ester (0.229 
mmol) and 34.6 mg (0.915 mmol) of NaBH4, 62.4 mg ZnCl2 (0.456 mmol)  
for 1st step and 0.48 mL TFA for 2nd step and 21.8 mg (0.114 mmol) of 
TsOH·H2O for 3rd step.  Purification by flash chromatography (11% ethyl acetate in hexane) 
gave 25 mg (53% over 3 steps) of the title compound (>19:1 dr). IR (thin film):  1725 cm-1;  [α]D 
−343 (c 2.36, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.39-7.32 (m, 5H),  6.87 (dq, J = 6.3, 1.5 
Hz, 1H), 5.58 (d, J = 3.7 Hz, 1H), 2.47-2.42 (m, 1H), 2.02 (t, J = 1.2 Hz, 3H), 1.35-1.21 (m, 2H), 
0.78 (t, J = 7.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 165.8, 144.6,  137.1, 128.3, 127.9, 127.7, 
125.5, 81.3, 41.3,  20.8, 17.1, 11.0; HRMS (EI) m/z calcd for (M+) C14H16O2: 216.1150; 
found:216.1157. 
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General Procedure G for 1, 3 syn reduction of β-keto ester:84 A suspension of ZnCl2 
(0.4 mmol, 2 eq.) and NaBH4 (0.8 mmol, 4 eq) in 2 mL of ether was stirred at ambient 
temperature for 15 min, then the mixture was cooled down to 0 °C and a solution of β-keto ester 
(0.2 mmol) in 1.0 mL ether was added, the resulting mixture was stirred for 2 h before quenched 
by slowly adding 20 mL of saturated aqueous NH4Cl solution, The mixture was extracted by 
ether (3 x 30 mL). The organic layer was washed by brine and dried over Na2SO4 and 
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concentrated in vacuo. The crude product mixture was purified by flash chromatography gave 
diol (dr based on 1H NMR of crude product mixture). 
 
3-Hydroxy-4-(hydroxy-phenyl-methyl)-hexanoic acid tert-
butyl ester 147: The general procedure G was followed employing 29 
mg of β-keto ester (0.10 mmol) and 20.5 mg (0.15 mmol) of ZnCl2 
and 11.3 mg (0.30 mmol) of NaBH4.  Purification by flash chromatography (16% ethyl acetate in 
hexane) gave 19.5 mg (67%) of the title compound (8:1 dr). IR (thin film): 3427(br), 1720 cm-1;  
[α]D −26.3 (c 1.15, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.45-7.41 (m, 5H),  5.19 (s, 1H), 4.46 
(dq, J = 12.5, 2.6 Hz, 1H), 3.67 (d, J = 2.3 Hz, 1H), 3.36 (d, J = 2.0 Hz, 1H), 2.70 (dd, J = 16.5, 
10.0 Hz, 1H), 2.48 (dd, J = 16.5, 3.0 Hz, 1H), 1.67-1.60 (m, 2H), 1.56 (s, 9H), 0.74 (t, J = 7.5 Hz, 
3 H); 13C NMR (75 MHz, CDCl3) δ 172.8, 143.5, 128.1, 126.9, 125.6, 81.5, 71.9, 51.3(2C), 40.3,  
28.1, 14.7, 14.6; HRMS (EI) m/z calcd for (M+) C17H26O4: 294.1831; found:294.1844. 
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General Procedure H for cyclization of diol: The diol was dissolved in methylene 
chloride and anisole (0.1 M, 5: 1 CH2Cl2: anisole) and the solution was cooled down to 0 °C and 
TFA (2 mL/mmol diol) was added dropwise, then the resulting mixture was stirred at 0 °C for 2 
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h. The mixture was concentrated in vacuo and purified by flash chromatography gave β-
hydroxyl-δ-lactone (dr based on 1H NMR of crude product mixture). 
 
5-Ethyl-4-hydroxy-6-phenyl-tetrahydro-pyran-2-one 148: The 
general procedure H was followed employing 18.2 mg of diol (0.062 mmol) 
and 0.12 mL of TFA.  Purification by flash chromatography (50% ethyl 
acetate in hexane) gave 11.5 mg (84%) of the title compound (>9:1 dr). IR 
(thin film):  3434, 1716 cm-1;  [α]D −16.4 (c 0.84, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40-
7.30 (m, 5H),  5.97 (d, J = 2.8,  Hz, 1H), 4.37-4.32 (m, 1H), 2.92 (dd, J = 18.4, 5.4 Hz, 1H), 2.71 
(dd, J = 18.3, 3.0 Hz, 1H), 2.63 (br, 1H), 2.02-1.95 (m, 1H), 1.33-1.24 (m, 1H), 1.12-1.02 (m, 
1H), 0.76 (t, J = 7.5 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 170.6, 137.6,  128.4, 127.6, 125.4, 
78.7, 65.6, 47.1, 35.9, 17.4, 11.6; HRMS (EI) m/z calcd for (M+) C13H16O3: 220.1099; 
found:220.1099. 
O
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O
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4-Hydroxy-5-methyl-6-phenethyl-tetrahydro-pyran-2-one 
149: The general procedure H was followed employing 15.4 mg of diol 
(0.050 mmol) and 0.10 mL of TFA.  Purification by flash 
chromatography (55% ethyl acetate in hexane) gave 8.6 mg (74%) of 
the title compound (>9:1 dr). IR (thin film):  3433(br), 1714 cm-1;  [α]D +21.5 (c 0.75, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 7.33-7.19 (m, 5H),  4.74 (ddd, J = 9.5, 3.9, 2.9 Hz, 1H), 4.05 (dt, J = 
5.4, 3.4 Hz, 1H), 2.93 (ddd, J = 15.0, 10.2, 5.2 Hz, 1H), 2.83 (dd, J = 18.3, 5.4 Hz, 1H), 2.71 
(ddd, J = 13.8, 9.7, 6.7 Hz, 1H), 2.56 (dd, J = 18.2, 3.2 Hz, 1H), 2.15 (br, 1H), 2.13-2.03 (m, 1H), 
1.98-1.90 (m, 1H), 1.84-1.74 (m, 1H), 0.97 (d, J = 7.2 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 
O
Me
O
HO
149
 130 
170.3, 141.1, 128.5, 128.4, 126.1, 77.3, 68.7, 37.7, 35.9, 33.8, 31.8, 10.4; HRMS (ESI) m/z calcd 
for (M++Na) C14H18O3Na: 257.1154; found:257.1136. 
 
BuO
O
t
O
R
OH
Me
TMSCl
MeOH
O
O
Me
R
R = CH2CH2Ph,  Ph
MeO
 
General Procedure I for TMSCl mediated β-methoxy-δ-lactone formation:85 To a 
solution of β-keto ester (0.10 mmol) in 1.0 mL CH2Cl2 at –78 °C was slowly added MeOH (30 
eq) and TMSCl (4 eq) consecutively, The resulting mixture was warmed up to 0 °C and stirred 
for overnight (about 16 h), then the reaction mixture was quenched by slowly adding saturated 
aqueous NaHCO3 solution, the mixture was extracted by CH2Cl2 (3 x 30 mL). The organic layer 
was washed by brine and dried over Na2SO4 and concentrated in vacuo. The crude product 
mixture was purified by flash chromatography gave β-methoxy-δ-lactone.  
 
4-Methoxy-5-methyl-6-phenethyl-5,6-dihydro-pyran-2-one 
150: The general procedure I was followed employing 30.6 mg of β-
keto ester (0.10 mmol), 121 uL of MeOH (3.0 mmol) and 50.6 uL of 
TMSCl (0.40 mmol).  Purification by flash chromatography (20% 
ethyl acetate in hexane) gave 16 mg (65%) of the title compound. IR (thin film):  1713, 1622 cm-
1; [α]D −86.8 (c 0.49, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.39-7.27 (m, 5H), 5.15 (s, 1H), 
4.42 (dt, J = 9.2, 3.9 Hz, 1H), 3.80 (s, 3H), 2.99 (ddd, J = 14.4, 9.5, 5.4 Hz, 1H), 2.85-2.73 (m, 
1H), 2.36 (qd, J = 7.1, 3.2 Hz, 1H), 2.29-2.15 (m, 1H), 1.91-1.78 (m, 1H), 1.22 (d, J = 7.1 Hz, 
O
O
Me
MeO
150
 131 
3H); 13C NMR (75 MHz, CDCl3) δ 178.5, 167.2, 140.9, 128.52, 128.47, 126.1, 89.3, 77.2, 56.1, 
36.4, 32.8, 31.4, 10.8 ; HRMS (EI) m/z calcd for (M+) C15H18O3: 246.1256; found: 246.1255.  
 
4-Methoxy-5-methyl-6-phenyl-5,6-dihydro-pyran-2-one 151: 
The general procedure I was followed employing 42 mg of β-keto ester 
(0.151 mmol), 183 uL of MeOH (4.53 mmol) and 76.4 uL of TMSCl 
(0.604 mmol).  Purification by flash chromatography (33% ethyl acetate in 
hexane) gave 28 mg (85%) of the title compound. IR (thin film):  1713, 1624 cm-1; [α]D +331 (c 
0.96, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.43-7.27 (m, 5H), 5.56 (d, J = 3.4 Hz, 1H), 5.19 (s, 
1H), 3.79 (s, 3H), 2.58 (qd, J = 7.2, 3.4 Hz, 1H), 0.90 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 178.7, 166.8, 136.5, 128.4, 127.9, 125.6, 89.3, 79.5, 56.2, 38.6, 11.3; HRMS (ESI) m/z 
calcd for (M++Na) C13H14O3Na: 241.0841; found: 241.0850.  
O
Me
O
MeO
151
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